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Abstract  
Preterm labour is the most important cause of perinatal mortality. Our ability to prevent 
preterm labour has been hindered by poor understanding of the factors that initiate human 
parturition. cAMP is a second messenger which plays significant role in respiratory, 
cardiovascular, and reproductive systems. The role of cAMP-signalling pathway in the 
maintenance of pregnancy has been investigated.  
 
My results suggest that during pregnancy, high cAMP levels repress OTR via PKA-dependent 
pathway and this repression may contribute to myometrial quiescence. My results also 
suggest that as pregnancy advances, the activity of cAMP/PKA pathway declines and, in 
contrast, the levels of Epac1, rise. This pattern may be associated with an increase in OTR 
expression, which may contribute to uterine contractions.  
 
The ability of cAMP to repress inflammation in human myometrial cells was explored. My 
results show that cAMP repress the expression of inflammation related genes and pro-
inflammatory cytokines. These results suggest that high cAMP/PKA tone in pregnancy may 
exert an anti-inflammatory effect and a reduction of cAMP/PKA tone may contribute to the 
pro-inflammatory effects of labour. AKIP1 has been identified to act as a molecular switch, 
determining cAMP/PKA action towards NFκB activity in various cell types. To date, no study 
was done to investigate the role played by AKIP1 in myometrial cells. My results suggest 
that in myometrial cells, low AKIP1 levels, helps to promote the anti-inflammatory effects of 
cAMP/PKA. 
 
The ability of cAMP in enhancing myometrial response to progesterone was tested. The 
results suggest that cAMP enhanced progesterone responsive genes via PKA. Furthermore, 
the ability of progesterone to repress IL-1β-induced inflammation may be enhanced by 
cAMP. Knockdown studies using siRNA, suggest that cAMP acts via PKA to enhance the anti-
inflammatory action of progesterone. Overall, these data support a novel role for cAMP 
which may help in the prevention of preterm labour. (300 words) 
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1.1 Human parturition 
Labour is a complex physiological process involving fetal, placental, and maternal signals 
which consist of a sequence of events resulting in the expulsion of fetus from the uterus 
through the birth canal (1). It is characterised by the presence of synchronised and 
coordinated painful uterine contractions, which increase in frequency, duration and 
intensity leading to progressive cervical dilatation (1). The mean duration of human 
singleton pregnancy is 280 days (around 40 weeks) from the first day of the last normal 
menstrual period, with minor variations among ethnic groups (2). A term pregnancy is 
defined as the period from 259 to 293 days (37-42 weeks) after the first day of the last 
menstrual period. Preterm labour (defined as delivery between 24 - 37 weeks gestation) and 
post-term pregnancy (defined as pregnancy continuing beyond 42 weeks gestation) are both 
associated with a significant increase in perinatal morbidity and mortality (3). The 
mechanisms involved in the maintenance of human pregnancy and the initiation of 
parturition are highly complex and involve both maternal and fetal systems. Hormonal, 
immune, and neuronal pathways play a fundamental role participate in these highly 
orchestrated events, which culminate in the birth of the baby and, eventually, the 
resumption of a normal menstrual cycle (4). Over the years, several hypotheses have been 
proposed to explain the transition from myometrial quiescence during pregnancy to 
contractile state at the onset of labour; these are briefly described in the section below.  
 
Progesterone  withdrawal  
Progesterone is a steroid hormone which plays a critical role in the development of the 
endometrium, facilitating the process of implantation and, subsequently, supporting 
pregnancy by promoting myometrial relaxation (4). Csapo previously suggested that 
progesterone actively inhibits labour and that the process of parturition requires 
progesterone withdrawal (5). Indeed, in all mammals studied so far, including humans, 
parturition is induced by interventions that prevent progesterone action. In most species, 
the onset of parturition begins with a decline in progesterone levels in the maternal 
circulations at the end of pregnancy (6-10). For instance, the secretion of progesterone from 
ovine placental is reduced as term approaches. Rats, mice, rabbits, goats, and pigs 
experience luteal regression at term, causing a reduction in the levels of circulating 
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progesterone (11). However, in contrast to other species, in humans and higher primates 
labour starts when systemic progesterone levels are still high and increasing, prompting the 
suggestion that it is associated with a “functional progesterone withdrawal” whereby 
different cell types of the reproductive tract becomes less responsive to progesterone 
action (12-14). Several forms of progesterone receptor exist and relative changes in their 
levels may be responsible for the functional withdrawal of progesterone. These variants 
result from transcription of the single progesterone receptor gene at alternative start sites. 
Progesterone receptor B (PR-B) is the most common transcript, and mediates the actions of 
progesterone predominantly. Other shorter transcripts, including progesterone receptors A 
(PR-A) and C (PR-C), function as repressors of PR-B. The proportions of PR-A, PR-B, and PRC 
change with the onset of labour perhaps accounting for the functional withdrawal of 
progesterone action (13). 
 
Inflammation and the onset of labour 
There is evidence that human parturition, both preterm and term, is an inflammatory event, 
characterised by influx of inflammatory cells into the cervix, myometrium, chorioamniotic 
membranes and amniotic cavity, with a subsequent increase in pro-inflammatory cytokine 
production (15-18). These pro-inflammatory cytokines have been shown to increase 
prostaglandin synthesis, which leads to myometrial contraction, and thus the onset and 
progression of labour. The transcription factor nuclear factor kappa B (NFκB) is a key 
modulator of these pathways, exerting its role by promoting the expression of prostaglandin 
synthetic enzymes and of pro-inflammatory chemokines involved in labour (19).  
 
Uterine stretch  
To accommodate the growing fetus, placenta, and amniotic fluid during pregnancy, the 
uterine wall muscle is continuously growing by a combination of hyperplasia and 
hypertrophy. Data from animal studies showed that progesterone is responsible for 
promoting myometrial quiescence and preventing the stretch-induced increase in uterine 
wall tension (20-23). In the clinical context, however, excessive uterine stretch, as seen in 
multiple pregnancy, pregnancies complicated by polyhydramnios, and pregnancies in 
women with uterine anomalies, is associated with an increased risk of preterm labour (24-
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26). Intriguingly, although progesterone supplementation in high-risk singleton pregnancy 
can reduce the risk of preterm labour, it has minimal effect in reducing preterm labour in 
multiple pregnancy (27). Previous studies demonstrated that abortion in the second 
trimester and labour at term can be successfully induced by inflating a balloon to augment 
the distension of the gravid uterus (28, 29), despite high circulating levels of progesterone.  
This is in contrast to the situation in the rat, which seems tolerate uterine stretch as long as 
progesterone levels are maintained (21). These data imply that uterine stretch may render 
the human uterus resistant to the effects of progesterone, raising the possibility that uterine 
stretch may contribute to the mechanism of functional progesterone withdrawal before the 
onset of labour. This was examined by our group, who found no evidence that stretch of 
myometrial cells altered their response to progesterone, but in contrast to rat myometrial 
cells in culture, stretch-induced gene expression was not reduced in human myometrial cells 
(30). Previous study done in the group showed that mechanical stretch was associated with 
an increase in the expression of chemokine, and of cyclooxygenase-2 (COX-2), and 
interleukin- 8 (IL-8), in mitogen-activated protein kinases (MAPK) - dependent mechanism 
and oxytocin receptor (OTR) in a MAPK-independent mechanism (31-34). These data were 
consistent with evidence that stretch of rat myometrial strips is associated with 
extracellular-signal-regulated kinases (ERK) 1/2 activation and increased contractility, thus 
contributing to labour onset (35). 
 
Corticotropin-Releasing Hormone  
Others have demonstrated the association between levels of maternal plasma corticotropin-
releasing hormone (CRH), which is of placental origin, and the timing of birth (4, 36-40). 
Maternal plasma CRH levels increase exponentially as pregnancy progresses, peaking at the 
time of delivery. In women who deliver preterm, the exponential increase is rapid, whereas 
in women who deliver after the due date, the rise is slower (41, 42). These findings imply 
that a placental clock determines the timing of delivery (41). The human placenta produces 
a circulating binding protein for CRH (CRHBP). At the end of pregnancy, CRHBP levels fall, 
increasing the bioavailability of CRH (43, 44). Glucocorticoids stimulate the production of 
CRH by the placenta and increase the expression of the CRH gene further (45, 46). In turn, 
CRH stimulates the pituitary to produce ACTH, which drives the adrenal cortex to release 
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cortisol. It is suggested that these events permit a positive feed-forward system, which leads 
to the activation of inflammatory pathways in the amnion, leading to both cervical softening 
and increased myometrial contractions (47). 
 
 
Figure 1-1. Placental production of CRH from the maternal and fetal endocrine systems. 
The increase in placental synthesis of CRH stimulates the increase of ACTH and cortisol production in both 
mother and fetus. Subsequently, increased cortisol stimulates further production of CRH by generating a 
positive feed-forward loop, resulting in exponential rise in CRH synthesis. Besides aiding in lung maturation, 
and increasing surfactant and phospholipid production, the increase in fetal cortisol contributes to the 
activation of inflammatory pathways in the amnion, causing both cervical softening and myometrial activation. 
The myometrial activation generates the increase COX-2 production. This cascade of events, together with 
progesterone withdrawal and the consequent uterine stretching results in coordinate uterine contraction  (4). 
 
To date, the mechanisms responsible for the onset of human labour are still unclear. 
Parturition in human results from a complex and dynamic biochemical dialog that exists 
between the mother and the fetoplacental system (4). In short, the initiation of parturition 
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appears to involve two components: initial triggering factors and a succeeding cascade of 
events leading to myometrial contraction. As summarised in Figure 1-1, the combination of 
stretch action, increase in inflammatory factors, change in progesterone receptor isoforms 
contributing to functional withdrawal of progesterone action and an increase in placental 
CRH, which also leads to the increase in the inflammatory pathways, may be responsible for 
the onset and the progression of labour at term. A better understanding of the normal 
parturition pathway will allow potential sites at which a pathological event may act to 
precipitate preterm birth and, conversely, sites at which we can intervene to ensure the 
timely onset of labour to be identified. 
 
1.1.1. Term labour  
Physiologically, term labour marks the end of myometrial quiescence (48). There is some 
evidence to suggest that the fetus controls the timing of labour, however the final pathway 
for labour must exist within the uterus, as the myometrium contracts to expel the fetus and 
the cervix dilates to allow passage of the fetus. The process of human pregnancy and labour 
has been divided into four distinct physiologic phases (49-51): 
 
Phase 0: Quiescence. This phase is the longest phase, it covers most of pregnancy and is 
characterised by a state of functional myometrial quiescence, which is achieved primarily by 
progesterone. Other factors that are believed to play significant role in maintaining 
myometrial quiescence are prostacyclin (prostaglandin I-2), relaxin, parathyroid hormone-
related peptide, nitric oxide, CRH, calcitonin gene-related peptide, adrenomedullin, and 
vasoactive intestinal peptide. Although these factors play their function in different ways, 
they all finally lead to the increase of intracellular concentrations of cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which then inhibit 
intracellular calcium release thus causing a reduction in myosin light chain kinase activity 
and, therefore, myometrial contractility.  
 
The initiation of parturition has been described as the transition of the myometrium from 
quiescence (Phase 0) to activation (Phase 1) where the majority of mechanical and 
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biochemical changes take place, including maximal uterine stretch, and the increase of pro-
inflammatory cytokines, and prostaglandins (49). 
 
Phase 1: Activation. The uterus becomes more receptive towards action of uterotropins, 
such as oestrogen, and uterine function is activated by the action of mechanical stretch (50, 
52, 53). This phase is characterised predominantly by activation of specific ion channels, and 
the increased expression of a series of contraction-associated proteins (CAPs) and connexin-
43 (a key component of gap junctions), the oxytocin receptor (OTR) and prostaglandin F 
receptor.  An increase in gap junction formation between neighbouring myometrial cells 
leads to electrical synchrony within the myometrium which then allows an effective and 
rhythmic myometrial contraction to take place (Figure 1-2) (4).   
 
Phase 2: Stimulatory phase. Following activation, the uterus is prepared for stimulation by 
uterotonic agents, such as the stimulatory prostaglandins E2 and F2 alpha and oxytocin. 
 
 
Figure 1-2. The uterine smooth muscle cells (USMCs) during pregnancy and labour.  
A. During the quiescent phase of pregnancy, the USMCs have relatively low connectivity and low expression of 
contractile associated proteins. B. At the onset of labour, the uterine myometrium, which consists of the 
USMCs, is converted into contractile tissue with extensive physical connections. The physical connections 
occur through pores formed by multimers of connexion-43 gap junctions. In addition, the release of 
prostaglandin F2α and the increase in intracellular calcium concentrations contribute to the increase of these 
connections during labour. Through this extensive physical and biochemical connectivity, the depolarization 
within individual myocytes can be passed on to the neighbouring cells in order to form extensive waves of 
depolarization, and subsequently generate contraction over large area of the uterus. These result in the 
increase of myometrial contractility, progressive dilatation of the cervix and expulsion of the fetus. (4). 
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Phase 3: Involution.  This last phase which is mediated predominantly by oxytocin is when 
the gravid uterus to return to its pre-conception state. 
 
1.1.2. Preterm Labour 
Preterm labour arises when there is asynchrony between the labour process and fetal 
maturation. It occurs in about 8–10% of all pregnancies, and is the most important cause of 
perinatal death (2). Many premature babies are left with a lifelong disability severely 
limiting their future opportunities (54). The most recent economic evaluation suggests that 
the cost of premature birth to the UK is £2.946 billion/year and that delaying all preterm 
birth by just one week could potentially save £260 million/year (55, 56).  
In general, the cause of preterm labour fall into three categories: iatrogenic, where there is 
a complication of pregnancy such as preeclampsia or fetal distress that requires obstetric 
interventions, twin pregnancies, pregnancy complicated by polyhydramnios, uterine 
anomalies; premature rupture of the fetal membranes with or without infection; and, 
idiopathic preterm labour (57). However, the majority of premature labour is due to 
spontaneous preterm labour, making it the most important cause and, significantly, babies 
born after preterm labour have a worse prognosis due to the associated fetal inflammation 
(58). The exact mechanisms responsible for preterm labour are unknown, but it is thought 
that infection and inflammation play a crucial role in driving the process of preterm labour. 
In addition, it is well accepted that human parturition is an inflammatory process, initiated 
by influx of inflammatory cells into the myometrium and cervix, with a subsequent increase 
in pro-inflammatory cytokines and prostaglandin production, resulting in myometrial 
contraction and the onset of labour (15-17). 
Both term and preterm labour are described as having a common final pathway, however, 
the difference lies in the upstream pathways, some may be common to both term and 
preterm labour, but occurring earlier in pregnancy, others will be a part of a pathological 
process, such as infection, bleeding or excessive stretch (59). Therefore, the key to prevent 
preterm labour is to understand the causes and mechanisms involved and to elucidate the 
possible different pathways responsible for initiating the process. We will be able to not 
only design new treatment modalities to prevent preterm labour, but also use the optimal 
treatment for the cause of each case of preterm labour. 
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1.1.3. Current strategies for the prevention of preterm labour 
Preterm labour remains a global problem. Despite the advancement in obstetric medicine, 
the rate of preterm labour has increased by over 30% for the last 20 years, with over 50% of 
this increase being the result of multiple pregnancies (60). So far, our ability to successfully 
treat women whose pregnancies are complicated by preterm labour is hindered primarily by 
a lack of knowledge of the endocrine and biochemical factors that initiate human 
parturition. Other measures to prevent preterm labour, such as antibiotic therapy, bed rest 
and routine hospitalisation have proved to be ineffective (61-63).  
There are two key observations that may have recently changed in the management of 
spontaneous preterm labour. Firstly 60% of women at risk of early prematurity and 80% of 
women at risk of extreme prematurity due to spontaneous preterm labour to can be 
identified at 23 weeks by a combination of transvaginal cervical length assessment and 
elements of the obstetric history (64). Secondly, progesterone administration reduced the 
risk of spontaneous preterm labour in high-risk singleton pregnancies by up to 40%, (65-67) 
and although the ultimate evidence of benefit on perinatal outcome awaits the result of the 
Opptimum study, a study by Hassan et al. (68) showed that progesterone leads to an 
improvement in a composite score of perinatal outcome when used to treat women at high-
risk of preterm labour. Moreover, a recent meta-analysis has indicated that both 
progesterone treatment and cervical suture are independently as effective in reducing the 
risk of preterm labour less than 32 weeks of gestation in women with a short cervix and a 
previous obstetric history (69). These findings moved the therapeutic emphasis from 
tocolysis, the treatment of those presenting in spontaneous preterm labour, to the use of 
progesterone to prevent spontaneous preterm labour in high-risk women. However, despite 
many thousands of women now receiving progesterone to reduce the risk of spontaneous 
preterm labour, the molecular mechanisms which mediate the beneficial effects of 
progesterone still remains unclear. It is of paramount importance to understand how 
progesterone works as this may not only help us to design more effective treatments, but 
also to optimise the response to progesterone. 
Despite its efficacy in singleton pregnancies, progesterone does not reduce the risk of 
preterm labour in multiple pregnancies (27). On the contrary, a recent retrospective cohort 
study has published that progesterone given to women with twin pregnancy and short 
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cervix (<15mm) resulted in an increased risk of preterm labour (70). These observations 
emphasise the fact that a different pathways may be responsible for the onset of preterm 
labour in multiple pregnancies and that this pathway cannot be regulated by progesterone 
alone.  
As progesterone is only 40% effective in the prevention of high-risk singleton pregnancy (65-
67) and has no effect on multiple pregnancies (27), this led to part of the current project, 
which is to combine the effect of cAMP, a versatile second messenger and progesterone for 
the prevention of preterm labour.  
 
1.2. The role of inflammation 
 
1.2.1. Inflammation and pregnancy 
Inflammation is defined as a fundamental biological response by the body responds to 
harmful stimuli, such as pathogens (infectious nature) and/or damaged cells (non-infectious 
nature) (71). Inflammation consists of a complex protective immune response which 
involves immune cells, blood vessels, and molecular mediators whose purpose is to prevent 
the spread of micro-organisms, eliminate the initial cause of cell injury, remove necrotic 
cells and tissues damaged from the original insult and the inflammatory process, and 
subsequently to initiate tissue repair (72). Clinically, inflammation has been 
characteristically described by the presence of five cardinal signs: calor, dolor, rubor, tumor, 
and function laesa (which translates to heat, pain, redness, swelling, and impaired function), 
all of which reflect the effects of chemokines, cytokines, and other inflammatory mediators 
on local blood vessels and tissues (73). Inflammation, which is a part of the innate immunity, 
is closely regulated by the body; too little inflammation could lead to progressive tissue 
destruction by the harmful stimulus and compromise the survival of the organism; too much 
of inflammation, may lead to an abnormal host tissue response and excessive damage of 
normal tissue (74, 75).  
Indeed, in the reproductive tract, inflammation has been shown to play a crucial role in the 
rupture of an ovarian follicle, menstruation, the implantation of the blastocyst, and most 
importantly, in term and preterm parturition (76). In addition, adverse pregnancy outcomes, 
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such as spontaneous miscarriage, preeclampsia, intrauterine growth restriction and preterm 
labour, are usually caused by the disorder of cytokine networks (76). 
Although there are several pathological processes that can cause spontaneous preterm 
labour, inflammation is a common factor linking many of these mechanisms together. Since 
infection is a major cause of inflammation, intrauterine infection is one of the most common 
conditions leading to preterm labour and delivery (77-80). To date, inflammation is the only 
pathological process that has been recognised to have a firm causal link with preterm labour 
(59). Romero et al. (59, 73, 75) have summarised this causal relationship in both humans 
and animals: (1) intrauterine infection or administration of microbial products to pregnant 
animals can initiate preterm labour (81-83); (2) maternal sepsis which could be due to 
pneumonia, pyelonephritis, and malaria, are associated with preterm labour (84-86); (3) 
pregnant women who have intra-amniotic infection or intrauterine inflammation in the mid-
trimester are most likely to deliver prematurely (87-89); (4) antibiotic treatment of 
ascending intrauterine infections is able to prevent prematurity (90).  
As microorganisms reach the decidua, leukocytes, which are mostly consist of neutrophils 
and macrophages, are activated to trigger the inflammatory pathway in the uterus. The 
microorganisms may then cross the intact membranes into the amniotic cavity and in the 
process activate macrophages and other host cells before gaining access to the fetus to set 
off the systemic inflammatory response. This invasion of microorganisms is usually 
associated with the microbial proliferation and the production of bacterial products, such as 
lipopolysaccharides (LPS) (from cell wall of Gram-negative bacteria), peptidoglycans or 
lipoteichoic (from cell wall of Gram-positive bacteria), and endotoxin. These products which 
are recognised by the Toll-like receptors (TLR-4 recognises products from Gram-negative 
bacteria; TLR-2 identifies products from Gram-positive bacteria) and other receptors, are 
able to stimulate the release of inflammatory cytokines and chemokines, leading to 
increased production of prostaglandins and matrix-degrading enzymes, which consequently 
activate the cervical remodelling processes, fetal membranes weakening and rupture, and 
finally myometrial contractility (15, 18, 91).  
 
38 
 
1.2.2. Uterine cytokines and chemokines 
Cytokines are small proteins (5–20 kDa) signalling molecules produced by broad range of 
cells such as macrophages, B lymphocytes, T lymphocytes and mast cells, as well as 
endothelial cells, fibroblasts, and various stromal cells. They play fundamental role in 
regulating the body immune responses. Cytokines consists of chemokines, interferons, 
interleukins, lymphokines, tumour necrosis factor. Chemokine is a type of cytokine that is 
produced as a "chemo-attractant molecules" i.e to attract cells to sites of 
infection/inflammation (92-94). Chemokines, such as IL-8, RANTES and IP-10, move from 
regions of low concentration to high concentration, attract leukocytes to the site of 
inflammation and infiltrate tissues, thus consequently enhancing the inflammatory response 
(92, 94).  
There are four families of cytokines grouped according to their structure: the four-α-helix 
bundle family including Interleukin (IL)-2, Interferon (IFN)-γ, and IL-10; IL-1 family; IL-17 
family; and chemokines family such as IL-8, monocyte chemotactic protein-1 (MCP-1), and 
chemokine (C-C motif) ligand 5 (CCL5). Functionally, they can be classified according to their 
involvement in cell-mediated immunity and in humoral immune response. The former is 
regulated by T helper (Th) 1 cells where IL-1, IL-2, IL-6, IL-12, IL-15, IL-18, TNF-α, and IFN-γ,  
are mainly produced. The humoral immune response is regulated by Th2 cells, which are the 
source of IL-4, IL-5, IL-10, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-
CSF) (95).   
During early normal human pregnancy, Th2 initially exert the predominant role to protect 
the feto-maternal relationship, followed by a shift toward Th1 in the later stage of 
pregnancy. The balance of Th1 and Th2 cytokines can be altered abnormally by 
infection/inflammation processes which cause Th1 predominance, leading to the production 
of inflammatory cytokines as evidenced in spontaneous abortion, preeclampsia and preterm 
delivery (96). 
As uterine pro-inflammatory cytokines and chemokines play a major role in regulating both 
term and preterm parturition, several studies have focused on their individual function, 
such as IL-8 (97). IL-8 is one of the major mediators of the inflammatory response, 
responsible for the induction of chemotaxis, and directs the migration of cells, particularly 
neutrophil granulocytes, to sites of inflammation; it is released mainly by macrophages and 
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other cell types such as epithelial cells present in uterine tissues, including choriodecidua, 
placenta, cervix and myometrium (38, 98-100). Its expression increases in the uterus with 
advancing gestational age and can be induced by many stimuli, such as IL-1β, TNF-α and 
stretch (98, 101-103). There are two distinct promoter regions important for the regulation 
of IL-8 transcription. The distal promoter element composed of an AP-1 binding sequence 
and a proximal promoter region binds to C/EBP and NFκB.  These three transcription factors 
have been demonstrated to act in a synergistic manner in order to activate IL-8 expression 
(97).  
It is not surprising that infiltration of neutrophils into the myometrium is recognised as one 
of the major signs of inflammation associated with parturition. A leukocyte influx caused by 
IL-8 in the myometrium and lower uterine segment during labour (17, 104) is associated 
with cervical ripening and myometrial contractility.  Similar observations was also noted in 
when the application of IL-8 to the cervix of guinea pigs is sufficient to cause cervical 
ripening and can increase contractions (104). Moreover IL-8 mRNA expression increases in 
term labouring myometrium compared to term non-labouring myometrium. Finally in vitro 
experiments have demonstrated that factor associated with the initiation of labour such as 
IL-1β and stretch increase IL-8 expression in the myometrium (32, 103). 
On the contrary to other pro-inflammatory cytokines, IL-10 plays anti-inflammatory role to 
maintain pregnancy (105). This is supported by the evidence that IL-10 expression is 
significantly decreased in the placental tissues at both term and preterm labour (105); COX-
2 mRNA expression is reduced by IL-10 in cultured placental explants from preterm labour 
deliveries (105); IL-1β-induced uterine contractility is repressed by IL-10 and 
dexamethasone treatment in pregnant rhesus monkeys (106); and the administration of IL-
10 in pregnant rats prevents endotoxin-induced preterm birth (107). 
 
1.2.3. Prostaglandins in human parturition 
In human parturition, stimulatory prostaglandins (PGs) such as PGE2 and PGF2α play an 
important role in cervical ripening and uterine contractility (81, 108, 109). The evidence 
supporting their crucial roles in the initiation and progression of human parturition includes: 
(1) the concentrations of prostaglandins and their metabolites are found to be elevated in 
the amniotic fluid, intrauterine tissues, and maternal blood prior to and during labour (81, 
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110-112); (2) the administration of prostaglandins induces cervical ripening leading to 
pregnancy termination and labour (113, 114); (3) the inhibition of prostaglandin synthesis 
by both non-selective and selective COX-2 inhibitors prolongs pregnancy and delays labour, 
although it is associated with adverse maternal and fetal side effects (115-117); (4) calcium 
released from intracellular and extracellular stores by prostaglandins was thought to be a 
trigger for myometrial contractions (118, 119). However, the prostaglandin pathway 
modulation during human parturition is complex and not yet fully elucidated. 
Prostaglandins are 20-carbon chain fatty acids whose production starts when membrane 
phospholipids are cleaved by phospholipases to produce AA (120). The biosynthetic 
pathway of prostaglandin can be divided into three main stages (Fig. 1-3) (120): (1) 
hydrolysis of membrane phospholipids by phospholipase (PL) enzymes, such as PLA2, PLC 
and PLD, to generate free AA; (2) COX enzymes catalyse a reaction where molecular oxygen 
is inserted into free AA to form an unstable intermediate (PGG2), which is then immediately 
converted to PGH2; (3) conversion of PGH2 to PGE2, PGF2α, PGD2, PGI2 and thromboxane 
by specific synthase enzymes, which determines the cell-type-specific prostaglandin profile. 
 
 
41 
 
 
 
Figure 1-3. The synthesis and actions of prostaglandins. 
After the cells are activated by various inflammatory stimuli, arachidonic acid (AA), a 20-carbon unsaturated 
fatty acid, is released from plasma membrane by cytosolic phospholipase (cPLA2) and metabolised by the 
sequential actions of prostaglandin G/H synthase, or cyclooxygenase (COX), and respective synthases to the 
intermediate PGH2. In a specific cell-type, a heterogeneous family of PGH2 metabolising enzymes can form 
PGE2, PGD2, PGF2α, PGI2 (prostacyclin) and TxA2 (thromboxane). After being transported from the cell through 
a known prostaglandin transporter (PGT), these prostaglandins exert autocrine or paracrine actions on 
prostaglandin receptors EP1, EP2, EP3, EP4, DP1, DP2, FP, IP, TPα, and TPβ depending on the cell types. (120). 
 
The COX enzyme was first discovered by Vane in 1971 as the target of non-steroidal anti-
inflammatory drugs (NSAIDs) such as aspirin, through which they inhibit production of pro-
inflammatory prostaglandins (121). As stated above, the enzyme is bifunctional, possessing 
both a fatty-acid cyclooxygenase activity, which converts AA to PGG2, and a prostaglandin 
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hydroperoxidase activity that converts PGG2 to PGH2 by reducing the hydroperoxyl group to 
a hydroxyl (120). There are three isoforms in the COX enzyme family: COX-1, COX-2, and 
COX-3 (also known as prostaglandin G/H synthase (PGHS) -1, -2, and -3 respectively) (122). 
They are regulated by separate genes and controlled by different mechanisms, except that 
COX-3 is an mRNA-splicing isoforms from COX-1 gene (122). Although the function of COX-1 
and -2 appear identical, their expression is very different. COX-1 is constitutively expressed 
and acts as a housekeeping gene involved in tissue homeostasis, for example in the 
cytoprotection of the stomach and in platelet aggregation. COX-2 on the other hand, is an 
inducible enzyme and is expressed only in inflamed cells and is the major isoform involved in 
pathological processes (14, 123, 124). COX-2 has been is induced by a variety of pro-
inflammatory mediators including LPS, cytokines such as IL-1β and TNF-α and induced by 
transcription factors associated with inflammation, such as NFκB and AP-1 and CREB in a 
wide range of cell types. 
Unsurprisingly, given the significance of prostaglandins action, there is robust evidence that 
COX-2 is indeed an important regulator of parturition. Studies over the years have 
demonstrated the importance of COX-2 in the onset of human parturition: (1) COX-2 mRNA 
and protein levels, but not COX-1, increase in uterine tissues at term before and during 
labour (125-129); (2) The increase of PGE2 in human amnion with the onset of labour is 
associated with selective induction of COX-2 gene (130, 131); (3) a series of in vitro studies 
confirms that COX-2 expression can be induced in primary cultured cells of different 
gestational tissues (132-134); and COX-2 expression increases when amnion and myometrial 
are treated with known pro-labour factors such as IL-1β or mechanical stretch. 
As the results, the mechanisms involved in the transcriptional regulation of COX-2 gene and 
posttranslational modification of COX-2 protein have been an intriguing area to be 
investigated. Although COX-2 promoter has already been very well characterised, and 
known to contains several pro-inflammatory transcription factor binding sites such as NFκB, 
CCAAT-enhancer-binding protein (C/EBP), and AP-1 (135), the molecular mechanisms are 
still unclear due to the multifactorial nature of its regulation (136-140).  
Prostaglandin dehydrogenase (PGDH) is an enzyme that regulates prostaglandin metabolism 
by enhancing the irreversible conversion of PGE2 and PGF2α to their biological inactive forms 
(15-keto-derivatives). The amnion is the major source of prostaglandins, not surprisingly it 
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contains very low or no PGDH enzyme, which has been primarily localised to trophoblast 
cells of chorion (141). The chorion therefore becomes an important site for prostaglandin 
metabolism and interferes with the transfer of prostaglandins from the amnion to uterine 
tissue in order to control myometrium contraction. This suggests that myometrial 
contractility is driven by exposure to PGs, and it governed by the balance of COX-2 and 
PGDH in the chorion. Several studies have demonstrated that progesterone may prevent 
myometrial exposure to prostaglandins by stimulating PGDH and inhibiting COX-2 whereas 
oestrogen, CRH, cortisol and some immune cytokines play opposing roles by increasing 
active prostaglandins in the myometrium (52, 142-144).  
After prostaglandin biosynthesis and metabolism, prostaglandins are finally transported to 
the target cells where they exert their effects through specific G-protein coupled receptors 
(GPCR). Currently there are ten known prostaglandin receptors on various cell types. For 
examples, four PGE2 receptors have been identified: EP1, EP2, EP3 and EP4 while only one 
receptor, FP, has been detected for PGF2α. Among them, the EP1 and FP cause contraction 
by increasing intracellular calcium whereas EP4 are associated with relaxation by stimulating 
the production and increase of intracellular cAMP (145, 146). The EP3, however, can either 
mediate contraction or relaxation depending on the cohort of receptor isoforms expressed, 
which are generated by multiple alternatively spliced transcript variants (147). Similarly, EP2 
has been shown to have dual action on the myometrium. EP2 receptor working via Gαs 
cAMP maintains myometrial quiescence during term labour and via Gαq/11 to promote 
calcium signaling and myometrial contractility (148). Therefore, in order to fully understand 
the mechanisms of prostaglandin function and regulation in human parturition, a 
comprehensive characterisation of the prostaglandin expression in different gestational 
tissue is essential.  
 
1.2.4. Nuclear Factor Kappa B (NFκB) 
The transcription factor NFκB regulates genes involved in immune, inflammatory and anti-
apoptotic responses (149, 150). The mammalian NFκB family consists of five members: 
NFκB1 (p105/p50), NFκB2 (p100/p52), p65 (RelA), c-rel and RelB (Fig. 1-4) (19, 151). 
Structurally, these proteins all have a similar region, characterised by the presence of an N-
terminal Rel homology domain (RHD), which mediates dimerisation, DNA binding, nuclear 
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localisation and interaction with the inhibitors of kappa B (IκB) proteins (19, 151). 
In resting cells, the NFκB proteins are retained in the cytoplasm in an inactive form through 
association with IκB family proteins, the most prominent of which are IκBα, IκBβ, and IκBε. 
The promoter of the IκBα gene has an NFκB binding site. Therefore, following its 
degradation and liberation of p65, a rapid resynthesis of IκBα occurs, driven by NFκB, which 
then dissociates from the DNA-bound complexes and is re-bound in the cytoplasm (19). 
Stimulation with proinflammatory cytokines, activates the IκB kinase (IKK), a cytoplasmic 
kinase complex, and triggers the phosphorylation the IκB molecules, leading to their 
subsequent degradation through the ubiquitin–proteasome pathway. NFκB dimers then 
translocate to the nucleus where they can bind to κB to increase or decrease target genes 
expression. Only the p65, c-Rel and RelB NFκB subunits contain the C-terminal activation 
domain (TAD) necessary to trigger target gene expression. The most prototypical and 
abundant activated form of NFκB is the heterodimer p50/p65 combination, which is also 
most commonly associated with the regulation of inflammatory responses (151).  
Recently, a non-canonical pathway has been discovered, which initiates NFκB activation in 
response to a specific set of stimuli, such as B-cell activating factor (BAFF), lymphotoxin β 
(LTβ) and CD40 ligand (CD40L) (151, 152). In the canonical pathway, IκB degradation is 
primarily mediated by the IKKβ kinase, whereas in the non-canonical pathway, it depends 
on IKKα and specifically targets the p100 IκB family member, which favourably interacts 
with RelB in the cytoplasm (151). 
Although initiation of the IKK signal and subsequent degradation of IκBs provides the 
cytoplasmic switch for NFκB activation in both the canonical and non-canonical pathways, 
several additional regulatory mechanisms have developed to provide selectivity. One 
example includes, Rel subunits are subjected to multiple posttranslational modifications 
(such as, phosphorylation, acetylation, ubiquitinylation, sumoylation and nitrosylation), 
which then regulate the transactivating ability and stability of NFκB complexes, as well as 
their affinity to bind to particular promoters (153). NFκB-dependent gene expression is 
furthermore controlled by the interactions with other transcription factors and co-factors, 
and by the accessibility of the κB binding sites in a given promoter (154-156). 
Thus, if NFκB does play a role in the onset of labour, then the suppression of NFκB activity 
during pregnancy might be expected to promote the success of pregnancy. Indeed, it has 
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been reported by McCracken et al. that NFκB downregulation in T cells of pregnant women 
is essential for maintaining the cytokine profile necessary for a successful pregnancy (157). 
Moreover, King et al. suggested that suppression of NFκB activation in first trimester 
decidua contributes to the immunosuppressive mechanisms that occur during pregnancy 
(158). In the study of human parturition, there have been no associative genetic reports 
directly linking NFκB directly to labour onset. Nevertheless, the activation of NFκB as a result 
of alterations in the mechanisms that regulate NFκB may occur with labour and premature 
NFκB activation could play a part in the initiation of preterm labour.  
Accumulating evidence suggests that NFκB plays a major role in the pathophysiology of 
labour (159). Condon et al. reported that there is an increase in nuclear and cytosolic p65 
expression in fundal uterine segment myometrium in association with human labour (160). 
Moreover, the increased levels of nuclear NFκB at parturition have been demonstrated in 
the cervix (161) and the baseline NFκB DNA binding and transcriptional activity of a NFκB 
reporter are increased in amnion cells following spontaneous labour compared to non-
labouring amnion samples at term (162).  
However, it has also been proposed that activation of NFκB promotes increased myometrial 
contractility via direct and indirect pathways (163). NFκB can bind directly to the promoters 
of genes such as PGF2α receptor, Cx43, OTR, and COX-2 which then lead to the increase 
uterine contractility (164-167). NFκB can also impair the capacity of progesterone receptor 
(PR), and thus indirectly affect uterine quiescence (163). A recent clinical study showed that 
a specific NFκB antagonist was more effective than current treatments, by not only 
inhibiting preterm labour but also improving fetal outcomes (168). Thus, the identification 
of labour-specific NFκB signalling components and selective targeting of the NFκB pathway 
has the potential to discover new therapies for to treat preterm labour.  
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Figure 1-4. The NFκB signalling cascade.  
This diagram illustrates the canonical and non-canonical (alternative) pathways for NFκB activation. The 
canonical pathway is triggered by the presence of TLRs and proinflammatory cytokines such as TNFα and IL-1, 
leading to activation of RelA, and results in phosphorylation and activation of IKKβ, which then phosphorylates 
IκB, directing to its ubiquitination and proteasomal degradation. The degradation of IκB activates a signal of 
the NFκB p65 subunit, allowing the NFκB dimer to translocate to the nucleus, where it generates the 
transcription of its target genes. The non-canonical NFκB pathway is activated by extracellular stimuli involved 
in B-cell maturation and lymphoid organogenesis, such as D40L, LT β, BAFF, and RANKL. These pathways 
depend on IKKα, which is stimulated by the NFκB-inducing kinase (NIK). Active IKKα phosphorylates the p100 
IκB family protein, and once phosphorylated, p100 is partly degraded to p52 in the ubiquitin–proteasome 
pathway, therefore allowing p52-RelB NFκB dimer to translocate to the nucleus. Subsequently, the p52-RelB 
NFκB complex activates the transcription of NFκB target genes, which includes chemokines, cytokines and 
other genes involved in lymphocyte function (151). 
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1.2.5. Activator Protein 1 
The activator protein 1 (AP-1) family of transcription factors consists of the proteins 
belonging to the c-Fos, c-Jun, JunB, JunD, FRA-1, FRA-2, and Fos B (169). They bind to DNA 
and functions to regulate gene expression in response to a variety of stimuli, such as 
cytokines, growth factors, stress, and bacterial and viral infections. AP-1 in turn modulates 
varieties of cellular processes including differentiation, proliferation, and apoptosis (170).  
In a study aim to investigate the role of AP-1 in myometrium and parturition, oestrogen 
induced the expression of c-Fos, c-Jun and JunD and JunB (171), while progesterone reduces 
c-Fos, FRA-1 and FRA-2 and JunB mRNA levels in rat myometrium (172). Moreover, term 
labour was associated with an increase in c-Fos and JunB mRNA and protein expression in 
human myometrium (173). Contractile associated proteins such as OTR and connexion-43 
whose expression in the myometrium is key at the time of labour contains AP-1 binding sites 
in their promoter, therefore an increase in AP-1 expression in labour may induce the 
expression of these genes (174, 175). Furthermore, overexpression of c-Fos and c-Jun in 
myometrial cells activate connexin-43 promoter through AP-1 site (176). 
AP-1 interacts with other transcription factor and cross-coupling between AP-1 and NFκB 
proteins has been reported, which results in synergistic increase in the activity of both AP-1 
and NFκB sites (177).  
With regards to PR activity, AP-1 functions to up-regulate inflammatory response pathways 
and might impair PR activity, thus the balance between PR and pro-inflammatory 
transcription factors will, at least in part, determine the balance between uterine 
quiescence and contractility. In endometrial adenocarcinoma cells, AP-1 activity was 
stimulated by unliganded PR, which cannot translocate into the nucleus by itself, suggesting 
a potential interaction between PR and the Jun/Fos complex (178). In our previous study, 
we found that stretch of myometrial cells reduced the expression of PR-B, which is 
associated with activation of both C/EBPβ and AP-1 (30, 34). 
Earlier studies by Lamph et al. demonstrated the interaction between cAMP response 
element binding protein (CREB) and AP-1 (179).  They showed that CREB binds to the AP-1 
site that is present in the c-jun promoter and, phosphorylation by the catalytic subunit of 
cAMP dependent protein kinase A (PKA) activates this promoter. Interestingly, however, 
CREB in the absence of PKA activity is a repressor of c-Jun promoter. Moreover, the ability of 
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CREB to repress transcription from c-Jun promoter extends to both serum and PMA 
induction. Additionally, c-Jun promoter can be activated by Jun or Fos-Jun proteins, but 
CREB can still interfere with this transactivation (179). This paper not only suggest that there 
is a promising interaction between CREB and AP-1, but also showed that transcription factor 
CREB may have a pleiotropic function, acting as a potent repressor of transcription, but 
reversing its role after phosphorylation. 
 
1.2.6. Mitogen Activated Protein Kinases (MAPKs) 
MAPKs are protein kinases that are specific to the amino acids serine, threonine, and 
tyrosine. They are involved in modulating different cellular activities, such as gene 
expression, differentiation, proliferation and cell survival/apoptosis (180). In mammalian 
cells, there are six subgroups of serine/threonine-specific protein kinases. Extracellular signal 
regulated kinase (ERK)-1 and −2, Jun N-terminal kinase (JNK)-1, −2 and −3 and p38 kinase 
isoenzymes (α, β, γ and δ) are the three classical MAPK subfamilies and were the first to be 
elucidated. Recently three more subfamilies have been discovered, termed ERK-3/4, ERK-5 
and ERK-7/8. The first three are by far the most studied and have been implicated in a 
number of pathological processes, from cancer to heart disease. The JNK and p38 pathways 
are characteristically activated by different stress signals, while the ERK pathway responds to 
growth factors. A series of potential interactions between cAMP and MAPKs has been 
identified, for example, cAMP activates Epac1/2, which acts as guanine nucleotide exchange 
factors for Rap proteins and Rap activation leads to activation of MAPK (181, 182). Recent 
study from our group has demonstrated that MAPK activation mediated the cAMP effects 
on COX-2 expression and that PGE2 acts through EP2 to activate MAPK and increase COX-2 
(183). In addition, a direct interaction between cAMP and ERK has been identified in Rat1 
and NIH3T3 fibroblasts (184-186). Song et al. observed that ERK phosphorylation of 
phosphodiesterases (PDE) 4 isoforms reduces its activity, resulting in increased levels of 
cAMP (187). Intriguingly, some GPCRs, can switch their signalling from Gαs stimulation of 
adenylyl cyclases to Gi coupled activation of ERK (188, 189).  
In rat myometrium during pregnancy, the regulation of ERK activity is controversial. ERK has 
been reported to increase with advancing gestation (190), although some studies have 
documented a fall in ERK gene expression immediately before the onset of parturition (182, 
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190). Our group has shown that exposure of human uterine myocytes to both stretch and IL-
1β activates the MAPK system, which is responsible for the increase in COX-2 and IL-8 mRNA 
expression (32). In addition, an interaction between MAPK and PR also has been identified. 
It has been demonstrated that MAPK-mediated cell signalling modulates the ratio of PR-
A/PR-B expression at the post-translational level, and imbalance in the ratio of PR-A/PR-B 
might switch cellular responses to hormonal stimuli and aid the pathogenesis of PTL. 
As part of MAPKs metabolism and to regulate their expression, a number of phosphatases 
called MAP kinase phosphatases (MKPs), inactive MAPKs and repress their expression.  As 
their name implies, these enzymes are capable of hydrolysing the phosphate from both 
phosphotyrosine and the phosphothreonine residues. In an attempt to understand the 
molecular mechanism of progesterone in reducing the risk of preterm labour, our group has 
published a study which showed progesterone acted via progesterone-induced and GR-
mediated MKP-1 activation to repress IL-1β-driven COX-2 (191). 
 
1.3. Oxytocin and oxytocin receptor (OTR) in parturition 
 
1.3.1. Oxytocin and oxytocin receptor (OTR) 
In pregnancy the oxytocin (OT) system plays an essential role in the onset of uterine 
contractions before and at term. Prior to the onset of labour, the myometrium becomes 
increasingly sensitive to the contractile effects of OT. This is due to increased oxytocin 
receptor (OTR) expression that occurs around the time of labour (166, 192). Indeed, the 
activation of the myometrial OT system is probably solely dependent on increased OTR 
expression as although a gradual rise in OT levels has been described with advancing preg-
nancy there is no dramatic increase with the onset of labour (193). The significance of OT/ 
OTR system in pregnancy and parturition has been investigated previously. Young et al. have 
shown that in mice that are deficient in OT can still deliver normally (194). On the other 
hand, the fact that OT infusion can induce labour and the administration of OTR antagonist 
atosiban is able to delay preterm labour, suggests that the OT/ OTR system does indeed play 
an important role in mediating uterine contractions in preterm and term labour. To date, 
our attempts to understand the regulation of OTR expression have been hindered by the 
lack of a reliable stimulus to study the myometrial OTR expression. 
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Atosiban, acts on both myometrial and decidual OTR to block the Gq/Phospholipase C 
(PLC)/calcium signalling pathway, to reduce contractions and decrease prostaglandin 
synthesis. A randomised trial comparing atosiban and ritodrine (beta-2 adrenergic receptor 
agonist) demonstrated a similar tocolytic effect, but that atosiban was associated with 
fewer adverse effects (195). A more recent meta-analysis summarising the use of atosiban 
for the delay in premature labour have failed to demonstrate an improvement in neonatal 
outcomes, perhaps due to the underlying cause of prematurity resulting in a hostile 
intrauterine environment for the fetus (196).  Because of the low side effects profile, 
atosiban is a widely used tocolytic in Europe; however, the exact molecular and cellular 
mechanism for the mode of action is still not fully understood. 
As OT acts to increase uterine contractility, it is routinely used to prevent and treat 
postpartum haemorrhage. Clinical trials comparing prophylactic OT versus expectant 
management of third stage of labour concluded that OT reduced the risk of PPH by 60% and 
the need for therapeutic oxytocin by about 50% (197). 
 
1.3.2. Transcriptional regulation of OTR 
The OTR promoter has multiple DNA binding elements for AP-1, AP-2, SP-1, GATA,-1, acute 
phase response factor (APRF alternatively known as STAT 3), nuclear factor-IL-6 (NF-IL6, 
alternatively known as C/EBPβ) and NFκB (Fig. 1-4) (198, 199). Despite this, there is still no 
transactivator has been identified which up-regulates OTR expression in myometrium in 
vivo.  
In an in vitro study on rabbit amnion cells, treatment with forskolin and cortisol significantly 
enhances OTR mRNA expression (200). In other systems the combination of cAMP and 
cortisol act to enhance OTR gene transcription involving a CRE and the sequence im-
mediately upstream of this site (201). 
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Figure 1-5. Schematic design of putative transcription factor binding sites for OTR promoter.  
The DNA region responsible for synergistic up-regulation of the OTR promoter by RELA and CEBPB is narrowed 
down to a 20-bp sequence, between −712 and −692 from the transcription start site (TSS) (198). 
 
1.3.2.1 Transcriptional activation of OTR 
Steroids  
In the rats study, OTR is reported to be up-regulated by oestrogen and down-regulated by 
progesterone (202, 203) and typically, OTR is thought of as a reproductive steroids regulated 
gene. In contrast to the rat, the human OTR promoter does not contain any full consensus of 
oestrogen or progesterone response elements (ERE, PRE) and there is no evidence of a 
direct interaction of either steroid on OTR gene promoter (204). Data published in our group 
shows minimal effect of either oestrogen or progesterone on OTR expression in human 
myometrial cells (205). Our stretch study recently demonstrated that mechanical stretch, IL-
1ß and anisomycin activate myometrial OTR mRNA expression (34, 205). 
 
Stretch  
It is possible to differentiate the effect of endocrine and mechanical signals on gene 
expression in animals with a double uterus. Parry and Bathgate initially reported that in the 
tammar wallaby, the expression of the mesotocin receptor, the wallaby equivalent of OTR, 
only increased in the pregnant, but not in the non-pregnant, uterus at term (204). Similar 
findings were also noted in the rat and sheep (206, 207). These imply that OTR mRNA 
expression may be elevated by mechanical stretch and hence, explain the high rate of 
preterm labour in human pregnancies complicated by multiple gestations, polyhydramnios, 
unicornuate uterus and singleton pregnancies with fetal macrosomia. In line with this fact, 
Manabe et al. demostrated that abortion in the second trimester and labour at term can be 
brought by mechanical distension of the uterus (208, 209). Stretch of primary cultures of 
pregnant human uterine smooth muscle cells increases OTR, COX-2 and IL-8 expression, and 
52 
 
results in MAPK activation. Transfection of reporter constructs for the promoters of OTR and 
IL-8 confirmed that stretch of human uterine smooth muscle cells is associated with the 
increase in the promoter activity (34, 102). Moreover, we have also demonstrated that 
stretch of human uterine smooth muscle cells results in activation of transcription factors 
namely AP-1, C/EBPß (34), and NFκB (103). Overexpression of C/EBP, but not AP-1, 
contributes to the increased in OTR promoter activity.  
 
Inflammation  
Given the association between intrauterine infection and the ability of LPS to induce 
parturition in animal models, it would seem likely that proinflammatory cytokines would 
increase OTR expression. Indeed, IL-6 stimulation to uterine smooth muscle cells obtained at 
the time of pre labour term Caesarean section increased OTR expression in a tyrosine kinase 
dependent manner (210). However, another study using a human myometrial cell line did 
not confirm this finding, and reported that although both IL-1β and IL-6 increased C/EBP 
levels, the activity of an OTR reporter construct containing a C/EBP response element was 
interestingly suppressed (211). Another study by Helmer et al. found that IL-6 had no effect 
on OTR expression and that IL-1β had a negative effect (212). On the other hand, IL-6 
treatment of uterine explants in the rats increased OTR expression (213). Other groups have 
explored the effect of IL-1β on OTR expression and have reported a negative effect (214, 
215). Overall, these data seem to be counterintuitive as uterine IL-1β concentrations in-
crease with term and preterm labour in parallel with several “labour-associated proteins” 
including OTR, COX-2 and IL-8 (216). Indeed, COX-2 and IL-8 are both characteristically up-
regulated by IL-1β. Furthermore, no appropriate time controls used was used in either of 
the study, and the study of Schmidt et al. was performed using an immortalized cell line 
derived from non-pregnant human myometrium (211). On the other hand, a study by 
Khanjani et al. found that IL-1β stimulates OTR mRNA expression via C/EBP and RelA (198). 
They found that IL- 1β increased COX-2 and IL-8 in a MAPK-dependent mechanism, however 
the role for MAPK in the IL-1β-induced increase of OTR remains unclear. It appears that IL-
1β acts through a combination of NFKB and C/EBP in driving OTR expression (198).  
It was observed that while using anisomycin as a positive control for MAPK activation in 
human uterine smooth muscle cells, anisomycin also noted to increase OTR mRNA 
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expression. However, the increased in OTR mRNA was not inhibited when using specific 
MAPK inhibitors suggesting that it acts through a MAPK-independent mechanism (205). 
These findings are supported by Hoffmann et al. who demonstrated that inflammation 
indirectly increases OT secretion in in primary cultures of human decidua in a time 
dependent fashion and that this increase in OT peptide may down-regulate OTR and its 
signalling pathway (217). These findings might explain the poor effectiveness of atosiban as 
tocolytic agents in the setting of intrauterine infection. 
 
1.3.2.2 Transcriptional repression of OTR 
The role of cyclic adenosine monophosphate (cAMP) 
There is extensive evidence to suggest that substances that are capable of increasing cAMP 
levels are also capable of regulating OTR (218, 219). Cyclic AMP acts as a second messenger 
in intracellular signalling pathways and acts through its direct activator of protein kinase A 
(PKA) promote uterine quiescence (220). These include the repression of phospholipase C 
(PLC) activation and calcium entry mechanisms, while also promoting calcium-activated 
potassium currents (221).  
The inhibitory effects of cAMP on the OT system have been demonstrated in several studies 
(222, 223). In the oestrogen-primed non-pregnant rat myometrial cell, PLC activation by a 
uterotonic was inhibited by cAMP. This effect was abolished with PKA inhibition, suggesting 
that PKA is the key cAMP effector responsible for mediating uterine relaxation (223, 224). In 
a study to explore the effects of relaxin on OTR regulation, prolonged relaxin incubation of 
human uterine smooth muscle cells inhibited as much as 40% of OTR binding and both OTR 
mRNA expression and protein levels were reduced by about 50% and 35% respectively 
(225). This study supports the idea that high local uterine relaxin concentrations may be 
involved in the maintenance of uterine quiescence during human pregnancy by down-
regulating OTR. Furthermore, since relaxin action is mediated by cAMP, it seems possible 
that cAMP mediates the inhibitory effect of relaxin on OTR expression. In rat myometrial 
plasma membrane, Wen et al. showed that cAMP acting via PKA inhibited the activation of 
PLC activity, suggesting that cAMP inhibits G protein activation of PLC independent of its 
associated GPCR (226). However, others have shown that cAMP inhibits the coupling of Gαq 
to PLC in the myometrium directly (224, 227). 
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Pertussis toxin is an agent that is frequently used to inhibit Gαi, with the potential to 
promote PKA activation indirectly (228). In rat myometrium, the inhibition of Gαi by 
pertussis toxin has been found to elevate cAMP level (229). Administration of a protein 
kinase inhibitor reversed the inhibitory effect of pertussis toxin on OT stimulated phosphati-
dylinositide turnover therefore demonstrating the interaction of Gαi and PKA and, 
potentially, the interaction between PKA and OT system. Studies performed by other groups 
are however less supportive of cAMP’s inhibitory effect on the G protein-PLC pathway. 
Phaneuf et al. showed that forskolin did not inhibit the OT-stimulated increase in phosphati-
dylinositide turnover in human myocytes (230). Further, despite the fact that forskolin 
increased cAMP levels, the inhibition of PLC in day 21 pregnant rat myometrium was not 
demonstrated. Interestingly, in the same study, an inhibitory effect of isoproterenol on OTR 
was observed in the absence of an increase in cAMP (231). 
 
Desensitisation of OTR 
OTR appears to be down-regulated and desensitised when exposed to prolonged high doses 
of OT or OT agonists (232). This process may occur at the transcriptional, translational, and 
protein level (233). The process of desensitisation controls cell response and helps to 
prevent overstimulation of cells when there is prolonged agonist activity. OTR inhibition has 
also been observed in primary myometrial cells with prolonged exposure to OT. Primary 
human myometrial cells exposed to OT for up to 20 hours results in an almost 10-fold 
reduction in OT binding capacity. Although the total amount of OTR protein appeared not to 
be affected by OT treatment for up to 48 hours, the level of OTR mRNA was decreased 
(234). 
Clinically, prolonged exposure of the myometrium to OT during labour may reduce the OTR 
response of OT when OT is used to treat PPH. In a study on pregnant rats, Balki et al. has 
demonstrated that pre-treatment with OT caused a significant reduction in the in vitro OT-
induced myometrial contractions in a concentration-dependent manner (235). The same 
group has also recently investigated the contractile response of human pregnant 
myometrium to OT after pretreatment with different concentrations of OT for variable 
duration. They discovered that in myometrial strips obtained at term prelabour Caesarean 
delivery from women not receiving OT, in vitro pre-treatment with OT at concentration 
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higher than 10-10 M reduced the subsequent contractile response to OT (236). Thus OT-
induced desensitisation might explain the higher OT dose required and thus more incidence 
of PPH in women whose labour are induced. 
One of the other mechanisms that result in the down-regulation of OTR includes the process 
of DNA methylation. DNA methylation is an epigenetic mechanism by which cells control 
transcription process through alteration of chromatin structure; a methyl group is added 
covalently to a cytosine residue directly followed by a guanine (CpG) (237). The OTR gene in 
particular has been found to be highly methylated. DNA methylation of the OTR decreases 
the expression of the gene and may have an important role in the regulation of OTR 
expression. Kusui et al. has discovered that DNA methylation in human hepatocytes 
decreased OTR expression (237). In the animal model, there is evidence that the 
transcription of the murine OTR is regulated by DNA methylation of its promoter. Another 
study showed that changes in the methylation of murine OTR promoter around parturition 
time correlates with modulation of the gene transcription in a tissue-specific manner (238). 
These data and the above suggest that DNA methylation plays a crucial role in regulation of 
the OT/OTR signalling pathway at the genomic level. Despite these promising findings, DNA 
methylation of the OTR gene in myometrium is currently not well understood. 
 
1.3.3. OTR signal transduction  
OTR belongs to a member of the rhodopsin-type class I GPCR superfamily. OT agonists or an-
tagonists and arginine vasopressin (AVP) are example of other molecules with similar 
structure and hence can bind to OTR. OTR activation follows when OT binds to the cell 
surface transmembrane part and leads to the activation of various intracellular signalling 
pathways, which leads to smooth muscle contraction (221). 
OTRs are functionally coupled to Gαq/11 class guanosine triphosphate (GTP) binding 
proteins (239). OT binding stimulates PLC activity of the PLCβ subclass, which hydrolyses 
phosphatidylinositol 4,5-bisphosphate (PIP2) to release second messengers, inositol 1,4,5- 
triphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 promotes calcium release from 
intracellular stores via its receptors (IP3Rs), and DAG activates protein kinases type C (PKC), 
which consequently phosphorylates other target proteins.  
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An increase in intracellular free calcium binds to calmodulin, and leads to a variety of 
cellular events, for example, in myometrial smooth muscle cells, the calcium-calmodulin 
system generates the activation of myosin light-chain kinase activity which triggers 
contraction and a trophic effect on myometrial cells. In most cell-based experiments 
examined performed to date, OT-induced increase in intracellular calcium has been 
demonstrated to be greater in the presence of extracellular calcium than in its absence. This 
suggests OT regulates calcium flux through voltage-gated or receptor-coupled channels. The 
activation of Gαq also leads to membrane depolarisation, which activates voltage gated 
calcium channels, that aids in intracellular movement of calcium. Subsequently, this cascade 
of events leads to various cellular responses and stimulates smooth muscle contractility. In 
addition, OT was shown to inhibit Ca2+/Mg2+-ATPase activity in rat uterine myometrium, 
which causes transient increases in intracellular calcium and thus prolonged OT effects. 
(221) 
In animal and human studies on myometrial cells, the OT-stimulated phosphoinositide 
hydrolysis was found to be mediated by pertussis toxin-sensitive and pertussis toxin-
resistant G proteins. Incubation with antibodies directed at the COOH termini of Gqα/11 led 
to reduced OT-stimulated GTPase and PLC activity (239). Moreover, experiments with 
pertussis toxin have provided evidence that rat OTR can bind to both Gαq/11 and Gαi 
proteins in transfected pregnant rat myometrium cells (240).  
OTR has been reported to be associated with the activation of mitogen-activated protein ki-
nase (MAPK) and the activation of both OTR and MAPK results in an elevation in cytosolic 
phospholipase A2 (cPLA2) activity. A study performed in cultured uterine myometrial cells 
showed that OT caused tyrosine phosphorylation of mitogen-activated protein (MAP) kinase 
through an islet-activating protein-sensitive G protein (241). cPLA2 hydrolyses phospholipids 
while liberating AA, which subsequently increases the production of prostaglandins via COX-
2. The prostaglandins released induce uterine contractions as well as increase myometrial 
sensitivity to OT (242). In short, the above mechanisms result in muscle contractility via OT-
OTR stimulation.  
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1.4. Progesterone in human pregnancy and parturition 
Progesterone is a steroid hormone that plays fundamental roles in normal human 
physiology. Progesterone is not only essential in reproductive tissues such as uterus and 
ovary but also in non-reproductive tissues such as bone, cardiovascular and central nervous 
systems (243-246). It is commonly believed that progesterone is crucial in establishing and 
maintaining pregnancy. In human pregnancy, progesterone is mainly synthesised by the 
corpus luteum until around 8 weeks of gestation, afterwards progesterone production is 
taken over by the placenta, a process called luteal-placental shift (247).  
Early work from Csapo showed that the removal of the ovary bearing the corpus luteum 
before 6 weeks of gestation resulted in miscarriage and declining circulating progesterone 
levels increased the sensitivity of the uterus to exogenous oxytocin and prostaglandins (12, 
248). Frydman supported the essential role of progesterone in pregnancy by demonstrating 
that the administration of the progesterone antagonist, mifepristone, successfully induced 
the onset of labour both before and at term (104, 249, 250). Csapo also proposed the theory 
of “progesterone block” which suggested that parturition was initiated by the withdrawal of 
the progesterone block (5). This theory was confirmed in most laboratory animals such as 
rats, mice, rabbits, goats, cows and sheep, in which peripheral progesterone levels markedly 
decrease before the onset of labour (6-9) The phenomenon is called “systemic withdrawal 
of progesterone”, accompanied by a concurrent increase in oestrogen concentration. 
However, in humans and non-human primates the maternal, fetal and amniotic 
progesterone levels remain elevated throughout pregnancy until the placenta is expelled 
suggesting an alternative concept of ‘a functional progesterone withdrawal’ has been 
presumed to occur, in which there is loss progesterone effect on the uterus, despite the 
continuing high systemic and local levels (12).  
Additional evidence to support the different role played by progesterone in human and 
animal pregnancies are: 1) in the mouse and rat, progesterone maintains pregnancy by 
blocking the stretch-induced expression of pro-labour genes (251). 2) parturition can be 
prevented completely by the artificial maintenance of progesterone levels in both rat and 
mouse (252). 3) in the human, labour starts despite the maintenance of circulating 
progesterone levels (253-255), and stretch-induced preterm labour, as seen in multiple 
pregnancies, is not delayed by the administration of progesterone supplements (27). 
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Moreover, our in vitro study showed that progesterone does not inhibit the stretch-induced 
increase in prolabour genes (30). 
 
1.4.1. The role of progesterone receptor in pregnancy and parturition 
The effect of progesterone is mediated through progesterone receptors (PRs), which act via 
genomic and non-genomic pathways (Fig.1-6) (256). 
 
 
 
Figure 1-6. Schematic model of the genomic and non-genomic pathways in the control of myometrial 
contractility by progesterone.  
For most of pregnancy both genomic and non-genomic pathways cause myometrial relaxation (upper panel). 
Progesterone, via its interaction with PR-B, inhibits expression of CAP genes indirectly by inhibiting (oestrogen 
receptors) ERα expression. Progesterone also exerts non-genomic effects on the pregnancy myometrium by 
interacting with a variety of membrane-associated progesterone receptor (mPR). The effects of non-genomic 
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progesterone actions on myometrial contractility are not well understood, but it is largely considered that 
progesterone decreases contractility via this pathway. At parturition, the genomic actions of progesterone are 
nullified by an increase in myometrial expression of PR-A and/or PR-C whereby the relaxatory actions 
mediated through PR-B are suppressed, a process termed functional progesterone withdrawal. Consequently, 
As ERα expression increases and the myometrium becomes more responsive to circulating oestrogens which 
leads to increased CAP expression and transforms the myometrium from a quiescent to a contractile state. 
Furthemore, myometrial contractility is enhanced by the activation of mPRβ, which results in a decrease in 
myometrial cAMP levels. Altogether, this cascade of events leads to the onset of labour (256). 
 
The genomic progesterone actions in human myometrium are mediated by the classic 
nuclear PRs, which are stimulated as transcriptional factors upon ligand binding. PR exists as 
two major isoforms, PR-A (~94 kDa) and PR-B (~116kDa), both of which are encoded by a 
single gene but independently modulated by two distinct promoters (257, 258). PR-A is a 
truncated form of PR-B lacking the first 164 N-terminal amino acids, where the activator 
element 3 (AF3) is situated (259). As a result, PR-B is the principal transcriptional activator of 
progesterone responsive genes whereas PR-A is predominantly a transcriptional repressor 
(260-262). Besides these two main isoforms, the existence and function of other truncated 
forms of PR, such as PR-C, have been proposed (263). PR-C, which is a truncated form of PR-
B that lacks a larger N-terminal segment, is able to bind to progesterone, but is unable to 
bind to DNA as it lacks part of the DNA-binding PR domain. PR-C is exclusively distributed in 
the cytoplasm and its expression before labour is low in the fundal myometrium (264). 
Intriguingly, PR-C expression increases with the onset of labour and contributes to the 
repression of PR-B function. The roles of other PR splice variants however remain unclear 
(265, 266). These show that the subtype and the expression level of these PR isoforms may 
lead to different progesterone responsiveness. To evaluate this theory, some groups have 
investigated the levels of PRs in non-pregnant and pregnant myometrium at different 
gestational ages. They demonstrated that there was an increase in the myometrial ratio of 
PR-A/PR-B expression at the onset of labour (267-269). In spite of this, the mechanisms 
which are responsible to explain this change remain unclear apart from the fact that certain 
factors such as PGE2, PGF2α, and TNF-α may be involved (268-270). In an immortalised 
pregnant human myometrial cell line, Madsen et al. evaluated the change in expression of 
PR-A and PR-B when subjected to PG treatment and showed that PGF2α increased the 
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expression of PR-A, while PGE2 increased the expression of both PR-A and PR-B, although 
the increase in PR-A predominates (268). However, data from PR knockout mice suggest 
that the roles of PR-A and PR-B in vivo could be more complex. Mice lacking either both 
isoforms or only PR-A are infertile with defects in uterine and ovarian function (271, 272), 
whereas mice lacking only PR-B still have a normal pregnancy as it only affects normal 
mammary development (273), which suggests that in this species the reproductive actions 
of progesterone are mediated primarily through PR-A. Similarly, it is suggested that the 
increased expression of PR-A in the myometrium may contribute to the initiation of labour 
in humans (274). Interestingly, when the isoforms PR-A and B were co-transfected, PR-A 
exhibited a marked inhibitory effect on PR-B mediated transcription (275). Taken together, 
these results support the hypothesis that the ‘functional’ withdrawal of progesterone action 
is achieved via increased expression of PR-A and PR-C in the human myometrium. 
Other possible mechanisms for the loss of genomic progesterone action are: (1) reduction of 
the amount of free active progesterone by binding to a high affinity protein (276, 277); (2) 
metabolism of progesterone to an inactive form (278, 279); (3) competition between 
progesterone and cortisol for binding to GR in the late gestation (280). With regards to the 
non-genomic progesterone actions, progesterone and its metabolites exert direct effects 
and interact with a family of membrane PRs (mPRs), progesterone receptor membrane 
components (PGRMCs), nuclear PRs, OTR and gamma-aminobutyric acid (GABA) type A 
receptor to regulate myometrial cells contractility by controlling intracellular signalling 
pathways (256, 281, 282).  
 
1.4.2. Molecular mechanisms of progesterone action 
As previously mentioned that spontaneous preterm labour is an inflammatory event, many 
studies have suggested that progesterone support pregnancy by acting primarily as an anti-
inflammatory agent in the human, repressing the action of NFB through a direct 
interaction between its receptor, PR-B, and the principle NFB subunit, p65 (162, 283, 284), 
and by increasing IB, which binds p65 maintaining it in an inactive state (284). With the 
onset of human labour, it is proposed that the repressive effects of progesterone are 
reversed by a combination of increased expression of PR-A (267, 275), which inhibits PR-B, a 
reduction in the level of the PR co-activator, steroid receptor coactivator-1 (SRC1) (266) and 
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by increased activity of NFB, which in turn represses PR activity via a direct interaction 
(160, 162, 283). Much of these data have depended on over-expression of PR and p65 and 
have often been performed in various types of cell lines. Our group has recently investigated 
the ability of progesterone to repress IL-1β-driven COX-2 expression in primary human 
myometrial cells collected from women at term before the onset of labour, and found that 
progesterone acts via the glucocorticoid receptor (GR) and not PR to repress IL-1β-driven 
COX-2 expression (191). These results were observed despite the presence of sufficient PR 
to modulate gene expression. Next, our group have also shown that progesterone does not 
repress NFB activity, either directly or via increased IκB in primary cells as others have 
suggested (284). To support these observations, we focussed on IL-1β-driven IL-8 mRNA 
expression as it was previously reported that IL-8 was the most p65-responsive gene in 
human myometrial cells (285), and found that progesterone had minimal effect on IL-1β-
driven IL-8 mRNA expression. In spite of this, IL-8 levels in the supernatant were significantly 
reduced by progesterone, suggesting that progesterone either inhibits the translation of IL-8 
mRNA or increases its metabolism. Indeed, in support of the former possibility, 
progesterone has previously been suggested to influence the regulation of miRNA 
expression, for example, progesterone repression of LPS-induced expression of IL-6 and IFNγ 
in macrophages is mediated through inhibition of miR-155 expression (286) and in 
myometrial cells progesterone has been shown to act via miR-199 to repress COX-2 levels 
(287). 
Subsequently, our group demonstrated that progesterone acted via GR to drive mitogen-
activated protein kinase phosphatase-1 (MKP-1), which played a significant role in mediating 
progesterone’s inhibitory effect on IL-1β’s acute actions (1 h) and contributed to 
progesterone’s inhibitory effect on IL-1β’s intermediate effect (6 h) (191). Overall, the data 
demonstrated from our group suggests that the anti-inflammatory effects of progesterone 
are mediated via MKP-1 and further studies are required to identify and investigate the 
downstream target of MKP-1 in regulating the IL-1β effect and progesterone’s suppression 
(191). Another potential second mechanism may involve the effect of microRNAs, which 
need to be explored further. 
Besides acting primarily as an anti-inflammatory, progesterone maintains myometrial 
quiescence by activation of relaxant pathways and inhibition of stimulatory pathways. 
62 
 
Consistent with this, study by Chwalisz et al. in guinea pigs show that progesterone can 
directly inhibit binding of OT to OTR and that treatment with progesterone antagonist 
onapristone increases myometrial OT sensitivity (288). 
 
1.4.3. Regulation of progesterone action 
1.4.3.1 Progesterone is repressed by inflammation 
Since progesterone plays an essential role in maintaining pregnancy, it is expected that 
progesterone action must either be repressed or overcome with the onset of labour. 
Progesterone action can be altered in different aspects, such as the level and post-
translational modification changes of its receptors and co-regulators, the variation of its 
associated transcription factors. Current theories involve a repression of action of 
progesterone are by the increased expression of PR-A, increased activity of NFκB and/or 
altered expression of PR co-modulators (13, 160, 289). Data from our group showed that 
over-expression of PR-A did not repress progesterone mediated up-regulation of FKBP-51 
(one of the most sensitive genes to progesterone) or repress the ability of progesterone to 
repress IL-1β-driven COX-2 expression, but it was noted that pre-treatment with IL-1β 
limited the ability of progesterone to drive FKBP51 expression in primary human myometrial 
cells (191), suggesting that inflammation may suppress progesterone action. These 
observations are consistent with the conclusions from modelling studies of human labour 
(290). Remarkably, changes from a PR-B dominant myometrium to a PR-A dominant 
myometrium are also associated with a change to a pro-inflammatory pattern of gene 
expression (289).  
 
1.4.3.2. PR co-modulators 
The progesterone receptor interacts with elements in the regulatory regions of target genes 
to control transcription. However, many of the putative target genes of progesterone do not 
possess such response elements in their promoters. Thus, other intermediary transcription 
factors, co-regulators and genes may be involved in the regulation of progesterone 
responsive genes. Co-modulators interact with the progesterone receptor family to enhance 
or repress their transcriptional activities (291). The relative abundance of these co-
modulators ultimately could have an impact on progesterone sensitivity. Indeed data from 
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animal studies revealed the integral role co-activators in steroid hormone sensitivity, largely 
in reproductive tissues (292, 293). Altered expression of the co-modulators could potentially 
initiate a functional progesterone withdrawal, and reducing PR binding. 
Unpublished data from our group showed that there was an increase in heat shock protein 
70 (HSP-70), heat shock protein 90 (HSP-90) and silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT) mRNA expression in lower uterine segment samples with 
the onset of labour, suggesting that repression may be achieved by reduced and/or 
antagonism of nuclear receptor availability. Animal and human studies showed that in 
pregnant mice at term, there is a significant decrease in myometrial steroid receptor 
coactivator-1 (SRC) and CBP co-activator levels (266), and a decline in SRC-2, SRC-3 and CBP 
in labouring compared with non-labouring human myometrium respectively (266). 
Furthermore, Leite et al. found that TNFα inhibited progesterone/PR-mediated transcription 
via a reduction in SRC-1 and SRC-2 in cultured human myometrial cells (270).  In addition to 
the above, PSF, which promotes PR degradation via the proteasome pathway, is reported to 
inhibit PR binding in pregnant rat myometrium at term (294). Overall, these data suggest 
that there is altered expression of various PR co-modulators that may reduce PR 
transcriptional activity near onset of labour (295, 296).  
 
1.4.3.3. PR interacts with other transcription factors 
One of the potential mechanisms to explain functional progesterone withdrawal is the 
interaction of PR with other transcription factors, such as NFκB, AP-1, CCAAT-enhancer-
binding protein (C/EBP), and CREB to alter PR binding to PRE. These transcription factors 
serve to up-regulate the inflammatory response pathways and in doing so might impair PR 
function. As it was previously described that labour is inflammatory process and 
progesterone maintain pregnancy by acting primarily as anti-inflammatory, it is fair to say 
that the balance between PR and pro-inflammatory transcription factors will partly 
determine the balance between uterine quiescence and contractility. Once initiated, the 
inflammatory response can be augmented by the release of further chemokines either in 
response to the inflammatory cytokines or mechanical stretch (31, 297) resulting in further 
infiltration of the myometrium, cervix, and fetal membranes by neutrophils and 
macrophages (15, 17, 298). Consequently, this cascade of events may contribute to the 
64 
 
activation of NFκB, which promotes the expression of labour-associated genes, including the 
gap junction protein connexion-43 (165), matrix metalloproteinase (MMPs) (299), the OTR 
(166), and COX-2 (162, 300). 
In human myometrium, progesterone is thought to repress NF-κB action by increasing the 
synthesis of IκB (284). Similarly, progesterone caused a rapid induction of IκBα mRNA and 
protein expression in the immortalised myometrial cells, macrophage cell line (301) and in 
T47D cells (302, 303), and subsequently inhibited IL-1β-induced COX-2 expression (284). In 
different cell types (284, 304, 305), there is a direct negative interaction between PR and 
NFκB, such that PR transcriptional activity can be inhibited by TNF-α induced activation of 
NFκB, which may repress PR function through a direct protein-protein or protein-DNA 
interaction between PR and NFκB (162, 283).  
The C/EBP family of transcription factors consist of six functionally related basic leucine 
zipper binding proteins named from C/EBPα to C/EBPζ. C/EBPβ contains two isforms: the 
full-length activator liver-enriched activatory protein (LAP) and the truncated inhibitor liver-
enriched inhibitory protein (LIP), which can form heterodimers with both PR-A and PR-B in 
vitro and modulate the expression of C/EBPβ-dependent genes or activate progesterone 
response element (PRE)-driven promoters (306). C/EBPδ was reported to be up-regulated by 
PR-B in human breast cancer cells (307). Studies performed by our group demonstrated that 
stretch of myometrial cells reduced the expression of PR-B, which is associated with 
activation of both C/EBPβ and AP-1 (30, 34). The interaction between PR and AP-1 was 
described earlier in AP-1 section.  
Consequently, crosstalk between PR and various transcription factors may exist via genomic 
or non-genomic pathways, and the combination of these effects may determine the effect 
of progesterone on human reproductive behaviour 
 
1.5. Cyclic Adenosine Monophosphate  
Cyclic adenosine monophosphate (cAMP) is a diffusible intracellular second messenger 
molecule which plays significant role in influencing many physiological events by 
transducing hormone into activation of protein kinases, modulating calcium transport and 
regulation gene expression (308). Cyclic AMP is produced upon binding of a ligand to a 
receptor linked to adenylyl cyclase, most commonly, a GPCR. Upon ligand binding, the Gα(s) 
65 
 
subunit is released from the Gαβγ complex and activates adenylyl cyclase, an enzyme that 
converts ATP into cAMP (220). To date, ten known AC isoforms with differential cell type-
specific expression have been identified (309). The most important downstream target of 
cAMP is the cAMP-dependent protein kinase A (PKA), a heterotetrameric protein complex, 
which in its inactive state is made up of two regulatory (R) and two catalytic (C) subunits. 
When two cAMP molecules bind to each regulatory subunit within the PKA holoenzyme, 
they undergo a conformational change that results in the activation of the catalytic 
subunits. The catalytic subunits may phosphorylate target molecules in the cytoplasm or 
transfer into the nucleus and alter the activity of transcription factors by phosphorylation. 
They drive the phosphorylation of cAMP-dependent transcription factors such as cAMP 
response element-binding protein (CREB), cAMP response element modulator protein 
(CREM), and activating transcription factor (ATF) family, thereby allowing them to regulate 
gene expression. After the catalytic subunit has phosphorylated its target substrate, it must 
reunite with the regulatory subunits before PKA can be reactivated by cAMP (220). 
In the PKA heterotetramer, there are two subtypes of the regulatory (R) subunits (RI and 
RII), each with two isoforms (RIα/RIβ and RIIα/RIIβ) that can form homodimers and 
heterodimers, and three isoforms of the catalytic (C) subunit (Cα, Cβ, and Cγ) that can freely 
associate with different R subunit homodimers and heterodimers. The intracellular site of 
PKA activation is largely determined by a family of specific anchor proteins A-kinase 
anchoring proteins (AKAPs), which is brought about by protein-protein interactions with R 
subunit species. Activation by cAMP of AKAP-bound particulate PKA holoenzymes triggers 
dissociation of C subunits resulting in greater enzyme activity and phosphorylation events. 
The AKAPs restrict catalytic activity to a small area, reducing non-specific phosphorylation 
and ensuring that phosphorylated substrates are correctly localised with in the cell to play 
their physiological role, such as smooth muscle relaxation. MacDougall et al. has studied the 
expression of two specific AKAPs, AKAP95 and AKAP79, which have high binding affinities 
for PKARIIα subunits, but there was no significant difference in their levels of expression in 
non-pregnant and pregnant myometrial tissue samples (220). 
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Figure 1-7. Schematic diagram of the myometrial cAMP signaling cascade.  
Upon ligand binding to a receptor linked to adenylyl cyclase, most commonly, a G-protein coupled receptor 
(GPCR), adenylyl cyclase is activated, which in turn convert ATP to cAMP. The most important downstream 
target of cAMP is the cAMP-dependent PKA, a cytoplasmic enzyme, which in its inactive state is made up of 
two regulatory and two catalytic subunits. When two cAMP molecules bind to each regulatory subunit, they 
undergo a conformational change that results in the activation of the catalytic subunits. The catalytic subunits 
may phosphorylate target molecules in the cytoplasm or translocate into the nucleus and alter the activity of 
transcription factors by phosphorylation. One of the best known transcription factors is CREB. Phosphorylated 
CREB stimulates the transcription of a plethora of genes harbouring CREB-responsive elements. Besides PKA, 
cAMP can also bind to exchange proteins directly activated by cAMP (Epacs), and 5' adenosine 
monophosphate-activated protein kinase (AMPK), and other cAMP effectors. The intracellular concentration of 
cAMP is regulated by phosphodiesterases, which degrade cAMP to 5’AMP (151). 
 
1.5.1. The role of cAMP in myometrium 
It is well recognised that cAMP influences a wide range of reproductive processes, such as, 
ovarian cell proliferation, apoptosis, and secretory activity, and oocyte maturation.  In 
addition, cAMP also modulates the function of many of the regulators of these processes 
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(310, 311). Indeed, with regards to pregnancy, many investigators believe that cAMP-
signalling pathway is up-regulated as to maintain the uterine quiescence (220, 308). 
Researchers have shown that increased positive coupling of receptors to adenylyl cylase 
may play a part in promoting myometrial relaxation during pregnancy. Compared to non-
pregnant myometrium, G-protein-dependent adenylyl cyclase activity is higher during 
pregnancy, and the activity declines with the onset of labour. Others believed that cAMP 
reduces myometrial contractility, primarily via inhibition of calcium mobilisation and the 
contractile apparatus through the activation of cAMP-dependent PKA, which 
phosphorylates and inhibits target proteins such as myosin light chain kinase (MYLK), thus 
decreasing the affinity of this enzyme for the calcium–calmodulin complex (312). 
Furthermore, PKA may promote myometrial relaxation by preventing PLC activation and 
calcium entry mechanisms, and by activating calcium-stimulated potassium channels and 
calcium pumps (313). However, the exact mechanism through which cAMP induces a 
specific cellular response to promote myometrial relaxation remains uncertain. Another 
theory suggests that there is compartmentalisation of cAMP signalling, facilitated by 
scaffold proteins. The scaffold proteins bring specific components of the signalling pathway 
together to ensure the precise subcellular targeting of cAMP actions (314). Plasma 
membrane AKAPS, have high affinitiy, and thus bind with RII subunits of PKA to form AKAP–
RII complexes (315). Studies on the functional effects the AKAP–RII complexes suggested 
that PKA anchoring may enhance the interactions of PKA with its physiological substrates 
(316) and, in pregnant human myometrium, this may be fundamental in maintaining uterine 
quiescence. Co-immunoprecipitation of PKA using an antibody against the AKAP150 (human 
equivalent to AKAP79) found in rat myometrium, showed an increase in PKA association 
with AKAP during pregnancy which decreased at term, possibly suggesting a role in the 
reduction of myometrial quiescence (317). Besides this, cAMP may also act via one or 
several its effectors, such as PKA, Epac, AMPK, PDZ-GEF1, PDZ-GEF2 or other potential 
pathways to regulate myometrial contractility.  
During pregnancy, the increase in cAMP level affects the expression of genes through 
phosphorylation of the transcription factor CREM and the ATF family, which then bind to the 
CRE elements in the regulatory region of responsive genes (318). There are significant 
changes in the expression of protein isoforms CREB, CREM, ATF2 in the human myometrium 
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during pregnancy. For instance, CREMt2α isoform decreases in myometrial tissue during 
pregnancy and labour, whereas CREMα is significantly increased by several-fold in 
pregnancy tissue compared to non-pregnant. The CREMα functions as a transrepressor and 
can also dimerise with CREB, the resulting dimers binding strongly to CREs and acting as 
transrepressor in the majority of cases (318, 319). Bailey et al. has identified a novel small 
variant ATF2 (320). In the reporter study, the repressive effect of CREMα alone appears to 
be cancelled out by the activating effect of ATF2. As the expression of ATF2 is greater in the 
upper compared to lower uterine segment during pregnancy and labour, it may be possible 
that ATF2 promote the expression of genes that stimulate contraction before and at the 
onset of labour. Such genes could include OTR, COX-2, connexin-43, all of which have CRE 
motifs in their promoter region and whose expression within the myometrium during 
gestation and labour is co-localised with ATF2 isoforms (320). 
Although most investigators agree that cAMP contributes to myometrial relaxation, a recent 
study showed that cAMP may also be responsible for priming the myometrium, enhancing 
its response to a contractile stimulus. Fetalvero et al. examined myometrial tissue from 
term pregnant women and found that prostacyclin stimulation, which activates the 
cAMP/PKA pathway and was previously only thought to promote myometrial quiescence, 
can actually promote myometrial activation over time by increasing the expression of 
contraction associated proteins connexin 43, α-SMA, h-caldesmon, calponin and SM2-MHC 
(321). On a similar context, recent paper published in our group by Li et al. showed that 
cAMP increased COX-2 expression in myometrium via MAPK, and that PGE2 acts through 
EP2 to activate MAPK and increase COX-2 expression (183). These data taken with those 
Fetalvero et al. provide further evidence in support of a dual role for cAMP in the regulation 
of myometrial function, and it is possible that the balance of these opposing effects 
determines the overall contractile state of human myometrium (183, 321). 
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Figure 1-8. Possible pathways of cAMP actions in human myometrial cells. 
 
In myomtrial cells, prostacyclin act via Gαs-coupled receptor to activate adenyl cyclase (AC), which leads to the 
increase in the intracellular cAMP levels. Typically, cAMP is thought to act via PKA bound to anchoring 
proteins, to phosphorylate intracellular proteins that promote myometrial relaxation and quiescence. 
However, a new theory suggests that the Gαs-coupled human prostacyclin receptor (hIP), induces positive 
transcription of genes encoding several proteins that promote uterine activation prior to labour, such as SM2-
MHC, h-caldesmon, a-SMA, calponin and Cx43 by raising cAMP levels  (322). 
 
1.5.2. The role of other cAMP effectors in myometrium 
 
Exchange protein activated by cAMP (Epac) 
The Epacs are cyclic AMP-activated guanine nucleotide exchange factors for Ras-like 
GTPases. They are the second major group of proteins to be identified as cAMP effectors. 
Similar to PKA, they control key cellular functions such as cell division, migration and 
secretion. Two Epac subtypes exist: Epac1 (also known as cAMP-GEF-I) and Epac2 (also 
known as cAMP-GEF-II) (323). Recent studies have indicated that Epac proteins may play a 
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role in the regulation of cell adhesion and insulin secretion (189, 324, 325). In animal models 
PKA and Epacs have been shown to work synergistically to inhibit smooth muscle cell 
proliferation in injured rat vascular smooth muscle cells (189). 
The expression of both Epac1 and Epac2 are present in mature and developing tissues. 
Although Epac1 mRNA expression is expressed in all human tissues, it was described to be 
most abundant in the heart and kidney (181). Moreover, the expression of Epac1 has been 
found in monocytes, macrophages, B and T lymphocytes, eosinophils, neutrophils, platelets, 
and in CD34-positive haematopoietic cells (326-328).  Epac2 expression, on the other hand, 
is prominent in the brain and adrenal glands (182), but undetectable in all hematopoietic 
cell types (326).  
In the literature, the effect of Epacs on inflammation has been inconsistent. Although in 
some cells such as human alveolar macrophages, mouse macrophage cell line, and bone 
marrow-derived mouse dendritic cells, Epacs are anti-inflammatory (327, 329-332), in other 
cell types, such as human osteoclast and RAW264.7 mouse macrophage line, Epac activation 
results in NFκB activation which then increases pro-inflammatory cytokine production to 
drive the inflammation process (333-335). In another human study, Epac1 modulated IL-6 
signalling in human umbilical vein endothelial cells (HUVECs) identifying this cAMP effector 
as a potential anti-inflammatory agent in vascular endothelial cells (336). Taken together, 
these studies indicate that Epacs may either reduce or increase inflammatory mediator 
production in different phagocytotic cells, suggesting that Epac action is cell-specific. Clearly, 
the underlying molecular mechanisms of the regulation of inflammation by Epacs remain to 
be elucidated and islikely to be strictly cell type-dependent. The scientific research 
conducted to date has not explored the level of Epac1 and/or Epac2 expression in 
myometrial tissue and no observation has been made regarding the effect of Epac1 
activation in myometrial cells.  
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Figure 1-9. Epac-mediates various biological functions through Gαs-protein coupled receptors (GsPCR). 
Epac proteins are activated when there is an increase in intracellular cAMP levels as a result from agonist-
binding to Gαs-coupled receptors. The figure illustrates the effects of Epac in different tissues and organs (323). 
 
5' adenosine monophosphate-activated protein kinase (AMPK) 
AMPK is a serine/threonine kinase, which plays an important role in the regulation of the 
cellular energy status, including the cellular uptake of glucose, the β-oxidation of fatty acids 
and the biogenesis of glucose transporter 4 (GLUT4). Structurally, the heterotrimeric protein 
AMPK is formed by α, β, and γ subunits. Each of these three subunits plays significant role in 
maintaining the stability and activity of AMPK (337). 
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In mammals, AMPK is active at multiple sites and in different conditions such as a low 
ATP/AMP ratio, glucose deprivation, oxidative stress, ischaemia as well as exercise and 
starvation. Drugs that inhibit ATP synthesis, thus reducing the cellular ATP/AMP ratio, 
activate AMPK (337-340). In cultured adipocytes, agents that increase intracellular cAMP 
also increase the activity of AMPK (341). Furthermore, a recent study suggested that AMPK 
is activated not only by nutrients or ATP deficiency, but also by various hormones and 
factors that increase cAMP, such as forskolin (342). PDE3B and PDE4, which regulate cAMP 
pools, may also affect the activation/phosphorylation state of AMPK (343). 
A study showed that activation of AMPK markedly suppressed both hypertonicity-induced 
NFκB nuclear translocation and COX-2 activity (344). In a similar context, Nagata et al. 
recently suggested that AMPK could inhibit the growth of vascular smooth muscle through 
MEK–ERK pathway inhibition (345), implying that AMPK could be another cAMP effector in 
myometrial cells.  
 
PDZ-GEF1 
PDZ-GEF1 (also known as RAGEF, nRapGEP or CNrasGEF) is a guanine nucleotide exchange 
factor (GEF) for Rap1 GTPase. It contains two putative regulatory domains: a domain with an 
amino acid sequence related to cAMP-binding domains and a PDZ domain, thus the name 
PDZ-GEF1. PDZ-GEF1 is found to be activated by cAMP in a PKA independent manner (346). 
PDZ-GEF is an important upstream regulator of the MAPK pathway and modulator of 
morphogenesis, but it has other roles that are independent of the MAPK signalling pathways 
(347). It can trigger the activation of the Rap/D-Raf pathway to regulate differentiation 
processes in Drosophila (348). Its primary role is to activate Rap, which is critical in the 
process of epithelial cell shape change that is required for sheet migration and homeostatic 
cell shape maintenance during the genesis of the wing marginal disc epithelium. In addition, 
PDZ-GEF2 has been shown to play a role in cell-cell junctions in human epithelial and 
endothelial cells.  Study by Boettner et al. suggested that dPDZ-GEF signaling is linked to 
myosin II function. Both dPDZ-GEF and canoe, the adherens junctional multidomain protein 
which functions as an effector of Rap, showed strong genetic interactions with the myosin 
II-encoding gene, and the dPDZGEF/Rap/canoe complex is believed to play a role in the 
maintenance and modulation of cell shape and plasticity in epithelial tissues (348).   
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To investigate the mechanism responsible for cAMP upregulation of COX-2 expression in 
myometrial cells, Li et al. found that cAMP induced activation of all MAPK isoforms and that 
MAPK inhibition blocked the cAMP-induced increase in COX-2 synthesis (183). These 
findings suggested that the cAMP could possibly be working through GEF to activate MAPK. 
Cyclic-AMP-dependent Ras/MAPK activation has been described in many cell types, but the 
Ras activator involved was not always identified. In melanoma cells, PDZ-GEF was reported 
to mediate the cAMP activation of Ras/ERK pathway, leading to alterations in 
melanogenesis (349). However, when Li et al. knocked down PDZ-GEF, they established that 
the forskolin induced changes in COX-2 mRNA expression were unaltered (183). Collectively, 
these data suggest that cAMP up-regulates COX-2 expression via MAPK, but that the exact 
pathway involved is as yet unidentified. 
  
1.5.3. The role of phosphodiesterases (PDE) in myometrium 
The effect of cAMP in myometrial cells is terminated by family of cyclic nucleotide 
phosphodiesterases (PDEs), of which there are 11 family members (PDE1 to PDE11), and 
most of these members have more than one gene product (308). In addition, each gene 
product may have various splice variants. It is estimated that in the human, there are more 
than 100 PDEs, which are expressed in a tissue-specific manner.  Various PDEs have been 
found to play a role in wide-range biological cellular processes namely: PDE10A is shown to 
be increased in the pulmonary arteries of patients with pulmonary hypertension, suggesting 
that PDE10A may have a central role in regulating pulmonary vascular tone and possibly 
structure (350), PDE1C has been identified to be involved in the regulation of collagen 
homeostasis during pathological vascular remodelling (351), and PDE5 inhibition is known to 
be an effective treatment of idiopathic arterial pulmonary hypertension and is associated 
with protective antihypertrophic, antiapoptic effects on the myocardium (352).  
In human myometrial cells, PDE4 (the predominant subfamily in this tissue) accounts for 
more than 75% of the PDE activity (308, 353). PDE4 consists of two classes of isoforms, long 
or short PDE4, depending upon the presence or absence of upstream conserved regions. 
Long forms of PDE4 are involved in fast cAMP signalling loops through PKA activation at 
conserved phosphorylation domains, while short forms of PDE4 are associated with long-
term responses promoted by cAMP, for example, gene transcription. Both classes of PDE4 
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have a much higher affinity for cAMP than for cGMP (354). Early in vitro and in vivo studies 
using rolipram, the specific inhibitor PDE4 inhibitor, showed that rolipram reduces both pro-
labour gene expression and myometrial contractility (355, 356). Moreover, rolipram can 
repress inflammation-induced preterm delivery in mice (357). The beneficial effect of 
rolipram in preventing preterm labour is further enhanced with the addition of β(2)-
agonists. This combination not only contributes to the inhibition of uterine contractions but 
also reduce the side effects in the rat (358). On a different note, PGE2 stimulation activates 
selective PDE4 subtypes that might accelerate cAMP hydrolysis in myometrial tissue (359). 
Before the onset of labour, most of the myometrial PDE activity is inhibited by the high 
levels of circulating progesterone (360-362), suggesting that cAMP-PDE inhibition may be 
part of the mechanism for myometrial relaxation and pregnancy maintenance (Fig.1-10). 
Therefore, a better understanding of the regulation of PDE4 isoforms in pregnant human 
myometrium may help to develop more effective tocolytic medicines with a high uterine 
selectivity, which not only enhances AMP synthesis, but also inhibiting its metabolism.  
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Figure 1-10. The effects of PDE4 inhibition in gestational tissues in the case of intrauterine inflammation. 
Intrauterine inflammation triggers a massive production of cytokines and chemokines, which consequently 
stimulates myometrial contraction. PDE4 inhibition may decrease the production of cytokines in the 
myometrium and fetal membranes, either directly or indirectly. As a results, PDE4 inhibition reduces uterine 
contractility and delay preterm labour. Furthermore, PDE4 inhibitors may promote the normal development of 
the fetal brain and lungs (363). 
 
1.5.4. Cyclic AMP: a selective modulator of NFκB action 
Cyclic AMP is well known for its potent anti-inflammatory actions (151). However, the 
interaction between cAMP and NFκB has been described as inconsistent in the studies 
investigating the relationship between the two. Although the majority of studies reported 
inhibition of NFκB activity by cAMP-elevating agent (364-367), several papers have, in 
contrast, found that cAMP positively affects NFκB activity (368-371), or that it does not 
intervene with NFκB activation (372, 373). 
Two earliest studies undertaken to evaluate the effect of cAMP on NFκB function were 
carried out in the 70Z/3 pre-B cell line (374, 375). Even with using a simple mode of 
intracellular elevation of cAMP concentration by means of membrane-permeable cAMP 
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analogues in these two studies, conflicting results were obtained. One group found that 
cAMP could induce NFκB binding to the κ light chain enhancer and activate a κB reporter 
gene (375), while the other group found no effect of cAMP by itself and reported that 
instead of inhibiting IL-1β-induced NFκB activation, cAMP actually stimulated late phase 
NFκB activation (374).  
Neumann et al. proposed that inhibition of NFκB in activated T cells by adenylyl cyclase 
activator forskolin or prostaglandin E2 (PGE2) was the result of elevation of intracellular and 
cytoplasmic levels of IκB via CREB-mediated transcription of the IκB gene and by blocking 
IKKβ activity, thus preventing IκB degradation (376).  Cyclic AMP has also been described to 
be able to maintain the IκB levels by interfering with IκB ubiquitinylation and subsequent 
proteasomal degradation. Zhong et al. has described that as cAMP and NFκB both depend 
on cofactor CBP for transcriptional activation of their respective target genes, elevated 
intracellular level of cAMP leads to the phosphorylation of CREB, and since phosphorylated 
CREB has a higher affinity for CBP than NFκB, CBP will preferentially associate with active 
CREB, enhancing CREB dependent transcription at the cost of NFκB-dependent transcription 
(377).  
By using COS-7 cells, Hao et al. has elegantly described that cAMP induces the exchange of 
transactivating NFκB complexes (i.e. p50–p65) for repressive complexes (i.e. p50–p50) 
(378). Others believed that at certain NFκB promoters containing CREB responsive elements 
(i.e. the TNF-α promoter), cAMP induces replacement of transactivating CREB-c-jun 
complexes at the CRE by repressive CREB-ICER complexes, leading to transcriptional 
inhibition (379). Moreover, another study has shown that cAMP induces the expression of c-
Fos which prevents p65 homodimers from binding to their cognate response elements, 
leading to inhibited transcription of a subset of NFκB target genes (380). 
One of the mechanisms responsible for the positive effects of cAMP on NFκB activity is that 
cAMP activates PKA, which then phosphorylates p65 at its ser276 residue, leading to 
enhanced NFκB transactivation. Others described that at promoters containing CREB and 
NF-κB responsive elements in close proximity, both transcription factors co-operatively 
recruit the CBP co-activator, leading to enhanced NFκB-dependent gene expression (151). A 
possible explanation for the contradictory effects of cAMP/PKA on NFκB activation could be 
due to the existence of different PKA pools, with different subcellular localisation and 
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functions, depending on the composition of the multiprotein complexes of which they are a 
part. Like many other signalling enzymes, it is known that the specificity of PKA action is 
regulated at the molecular level by scaffolding, anchoring, and adaptor proteins (151). 
Clearly, further research is required to clarify the mechanisms that determine which 
direction PKA, albeit in a cAMP-dependent or -independent manner, modulates NFκB 
activity.  
Recently, Gao et al. demonstrated that the nuclear PKA scaffolding protein A kinase 
interacting protein 1 (AKIP1) promotes PKA-dependent p65 ser276 phosphorylation and 
nuclear retention of p65, by preferentially targeting PKA to p65-containing promoters (381). 
Most importantly, they subsequently showed that PKA positively affects p65 transactivation 
in cells expressing high levels of AKIP1, whereas PKA oppositely inhibited NFκB activity in 
cells containing low levels of AKIP1, suggesting AKIP1 functions as a molecular switch 
determining whether PKA positively or negatively affects NFκB activity (369, 381). 
Subsequent studies by Lin et al. on oesophageal squamous cell carcinoma (ESCC) showed 
that AKIP1 is found to be overexpressed in breast and prostate cancers, suggesting that 
AKIP1 might act as a potent oncogenic protein (382). They have also found that AKIP1 is 
markedly overexpressed in ESCC cell lines and clinical ESCC samples, and that AKIP1 
expression was significantly associated with ESCC progression and a shorter survival time. 
Most importantly, they have demonstrated that overexpressing AKIP1 induces, whereas 
silencing AKIP1 represses, ESCC angiogenesis and lymphangiogenesis both in vitro and in 
vivo (382). 
Gerlo et al. has summarised that mechanisms on how cAMP positively or negatively 
interacts with NFκB in the presence or absence of AKIP1 expression (151). In cells expressing 
AKIP1, cAMP-activated PKA is targeted to NFκB-dependent promoters, where it 
phosphorylates p65 at ser276, leading to recruitment of CBP and enhanced transcriptional 
activation. In cells that do not express or have low levels of AKIP1, PKA preferentially 
phosphorylates CREB, leading to competition between CREB and NFκB for CBP and 
consequently reduced NFκB dependent gene expression (151). 
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Figure 1-11. Mechanisms of NFκB modulation by cAMP. 
A. An increase in cAMP level activates PKA, which phosphorylates p65 at its ser276 residue, leading to the 
increase of NFκB transactivation. B. At promoters, containing CREB and NFκB responsive element, both 
transcription factors recruit CBP co-activator, resulting in the enhancement of NFκB-dependent gene 
expression. C. In cells expressing abundant AKIP1 expression, cAMP-activated PKA is targeted to NFκB-
dependent promoters, where it phosphorylates p65 at ser276, leading to recruitment of CBP and enhanced 
transcriptional activation. In cells that do not express AKIP1, however, PKA has higher affinitiy and 
preferentially phosphorylates CREB, resulting in competition between CREB and NFκB for CBP and 
consequently leading to a reduced level of NFκB-dependent gene expression (151). 
 
Indeed, apart from context-dependent cAMP actions appear to be highly cell type-
dependent. Some studies have reported cell type-specific effects of cAMP. For example, 
cAMP repressed NFκB in 3T3 fibroblasts, whereas it induced NFκB in brown adipocytes 
(383). Recently, it was also reported that cAMP enhances TNF-α-induced NFκB activity in 
breast cancer cells, whereas it inhibited NFκB in HEK293 cells (369). The cAMP/PKA pathway 
interacts at multiple levels with the NFκB cascade and the outcome of these interactions at 
the level of NFκB-dependent gene expression can be either positive or negative. The 
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expression of AKIP1 in myometrial cells or tissues has yet to be elucidated and further 
studies on how AKIP1 is involved in the interconnecting cAMP and NFκB signaling cascades 
will undoubtedly shed light on at least some of the most intriguing questions in this field of 
study. 
 
1.6. Interaction between progesterone and cAMP 
Clinically, progesterone treatment has been shown to reduce the risk of preterm labour in 
high-risk singleton pregnancy by up to 40% (65). However, the administration of 17 alpha-
hydroxyprogesterone caproate failed to reduce the risk of preterm labour in women with 
multiple pregnancies (27). Cordeaux et al. have demonstrated that stretch enhanced the 
contractile response to oxytocin and progesterone exposure reduced the response to both 
stimuli in myometrial strips kept at low but not at high tension (384). Similarly, stretch data 
from our group showed that progesterone does not inhibit stretch-induced changes in 
intracellular signalling or gene expression. Despite the fact that stretch reduced 
progesterone receptor (PR) expression, this did not alter the ability of progesterone to 
regulate gene expression, activate a PRE, or suppress IL-1β-induced gene expression (30). 
Collectively, these results may explain why progesterone is ineffective in the prevention of 
stretch-induced preterm labour. 
These lead us to explore that progesterone action may be enhanced if it is combined with 
another agent. One possibility is an agent that increases intracellular cAMP levels. Studies 
over the years have shown that cAMP acting alone, has potent immunosuppressive and 
anti-inflammatory actions (364) (365-367). These actions have been recognised due to the 
ability of cAMP-induced signals to interfere with the function of the proinflammatory 
transcription factor NFκB.  
Besides acting as an anti-inflammatory, cAMP working via PKA, has also been shown to 
promote myometrial quiescence acting through independent pathways (220). Gellersen et al. 
demonstrated that the combination of cAMP and progesterone is better than cAMP or 
progesterone alone in promoting decidualisation in endometrial stromal cells (385). Several 
studies have also established that cAMP, can not only enhance agonist bound PR activity 
(386-388) but also convert the PR antagonist, RU486, into a partial agonist (386, 388).  
Thus, it is possible that progesterone and cAMP could act together to prolong pregnancy. 
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Although the mechanism responsible for the cAMP-induced potentiation of progesterone 
action still remains unclear, some recent data suggest that additional of cAMP could involve 
in an increase in the interaction between co-activators such as steroid receptor coactivator 1 
(SRC-1), CREB binding protein (CBP) and/or a decrease in the interaction between the 
receptor and the co-repressors nuclear receptor co-repressor (NCoR) and silencing mediator 
for retinoid and thyroid hormone receptor (SMRT) (389-391). In addition, 8-bromo-cAMP 
has been reported to up-regulate PR-A and PR-B mRNA levels (268), and to drive ligand 
independent PR-mediated gene expression (387). 
 
 
Figure 1-12. Model for 8-bromo-cAMP-mediated phosphorylation of SRC-1 and progesterone receptor 
activation in COS-1 cell.  
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An increase in the intracellular level of cAMP leads to PKA-dependent activation of ERK-1/2, which 
subsequently phosphorylates SRC at Thr-1179 and Ser-1185. When these sites are fully phosphorylated, SRC-1 
forms a functional complex that results in maximal gene transcription (top). In the absence or reduction in 
phosphorylation at Thr-1179 and Ser-1185, SRC-1 is unable to form a functional complex with CBP, and 
therefore, the transcriptional synergism is lost (bottom). Activation of PKA and MAPK will also target other 
essential cofactors for PR activation. P/CAF, P300/CBP-associated factor; GTFs, general transcription factors; P, 
phosphorylation site (389). 
 
Recent data from our group provide strong evidence that cAMP enhances progesterone 
action in human primary myometrial cells. We demonstrated that forskolin enhanced the 
ability of progesterone to repress IL-1ß-driven COX-2 expression, p65 nuclear transfer and 
DNA binding. In addition, we have also showed that forskolin enhanced progesterone 
transcriptional activity by increasing progesterone/PR-B DNA binding and PRE activation, 
while at the same time increasing PR-B levels and reducing the PR-A:PR-B ratio. Moreover, 
the addition of forskolin is associated with a reduction in PR and NCoR interaction and 
decreased NCoR levels (392). These data collectively showed that cAMP enhances both 
progesterone trans-activation and repression and implies that the addition of a cAMP 
agonist might enhance progesterone’s therapeutic effect. 
 
1.7. Uterine Stretch 
1.7.1. The role of stretch in normal pregnancy 
Besides the chemical and hormonal signals, many smooth muscle cells are also exposed to 
mechanical forces. The uterus is no exception, from the moment of conception the entire 
myometrium is continuously stretched by the growing fetus. In normal pregnancy, 
oestrogen regulates the myometrial proliferation and the growth of the uterus. Despite the 
fact that the fetus and placenta increase in size during pregnancy, the intra-amniotic 
pressure stays relatively constant throughout this period (393, 394). This is most likely due 
to the effect of progesterone and some endogenous myometrial relaxants such as nitric 
oxide (395) and cAMP (396), which contributes to myometrial hyperplasia and hypertrophy 
hence preventing the uterus from the influence of stretch-induced CAP gene expressions 
(22, 23, 206). As the uterine growth slowed down towards the end of pregnancy, there is a 
loss of coordination between the growth of uterus and fetus contributing to the increase of 
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uterine wall tension. In short, the effect of stretch in late gestation, together with the 
increased production of placental CRH and amniotic fluid surfactant proteins and lipids, 
stimulate the onset of labour (22, 165, 298, 397). Indeed, the rate of preterm labour 
increases in the events where uterine over-distension is most marked, such as in women 
with multiple pregnancy (398), polyhydramnios (399), and mullerian duct abnormalities 
(400), which are associated with uterine over-distension. 
1.7.2. Mechanisms of preterm labour in multiple pregnancies 
In clinical setting, progesterone is commonly prescribed to reduce the incidence of preterm 
labour in high-risk singleton pregnancy but it has no effect in multiple pregnancies (27). This 
implies that there are different pathways involved in modulating singleton and multiple 
pregnancies. It is highly likely that the physiological stimuli, such as CRH, surfactant protein-
A (SP-A), and platelet-activating factor (PAF), may be produce in larger quantities in multiple 
pregnancies, (298, 401, 402), thus increasing the possibility of early labour (403). This theory 
is supported by TambyRaja et al. as they found that levels of placental CRH were higher in 
twin pregnancies than in singleton pregnancies, however, there is no difference in CRH 
levels in relation to the time of the delivery in the twins group (401). Numerous attempts 
have also been made to study the difference in the basic functional properties of 
myometrium from both singleton and multiple pregnancies. Although there was no 
statistically significant difference in the number of proliferating cells, the uteri from multiple 
pregnancies were observed to have contracted more frequently than singleton controls 
(404, 405).  
With regards to the myometrial thickness, although ultrasound evaluations showed that the 
lower uterine segment of twin pregnancies became thinner with increasing gestation, there 
was no significant difference in singleton groups. The increased level of stretch-induced 
protein expression in twin pregnancies may play a role in contributing to the increase the 
length of the uterine wall rather than the myometrial thickness (406). These data are 
consistent with an earlier study that demonstrated that myometrial thickness of the upper 
uterine segment in singletons pregnancy remained relatively constant throughout gestation, 
whereas that of the lower uterine segment decreased with advancing gestational age. 
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Many studies have been conducted to evaluate the role of stretch in the initiation of labour 
in multiple pregnancies. Animal studies have shown that stretch increases myometrial 
expression of CAPs such as OTR, COX-2, connexin-43, and AP-1 family members (22, 23, 
407). As the uterus is continuously stretched, the stretch action also affects the fetal 
membranes, which adhere to the inner surface of the uterus. In vitro studies on human 
myometrial and amnion epithelial cells revealed that labour-associated proteins are also up-
regulated by mechanical stretch via one or more transcription factors, such as AP-1 and 
NFκB (31, 34, 408). These transcription factors are also found to be involved in stretch-
induced gene expression in other cell types including airway smooth muscle cells (409) and 
endothelial cells (410). Another in vitro study tested the expression of gap junction proteins, 
prostaglandin E receptors, and G-protein subunit Gαs and found that their expression levels 
were not altered by stretch (404). These results suggest that the mechanisms involved in 
stretch-induced myometrial contraction are complex and require additional research. In 
those cases where multiple pregnancies do not deliver preterm, the uterus may perhaps 
compensate for the increased stretch by preventing aberrant expression of the CAPs.  
 
1.8. Conclusion 
The role played by cAMP as an important mediator in the regulation of myometrial function 
is beyond dispute. Much is known about the pathways for cAMP synthesis and hydrolysis. 
However, the exact mechanisms of action of cAMP and its effectors in human myometrium 
during pregnancy and labour are unclear. It is believed that cAMP acts via its main effector, 
PKA to promote myometrial relaxation during pregnancy (220). Some also believe that 
cAMP is a potent anti-inflammatory agent, capable of repressing NFκB, and so reducing 
inflammation (365, 376, 411, 412), which is one of the triggers for the onset of labour (16, 
17). Nevertheless, to date, the full extent and nature of cAMP/NFκB crosstalk remains 
unclear. 
In conclusion, there are a multitude of potential cAMP-generating pathways in human 
myometrium. The levels of many of the components of these pathways are changed during 
pregnancy and labour. The mechanisms underlying the maintenance of uterine relaxation 
during pregnancy and the induction of contractility at term are extremely complex, and it is 
likely that a reduction in, or complete loss of, pro-relaxatory pathways is essential for 
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successful parturition. More research is necessary to explore the mechanisms involved and 
to clarify the role of cAMP in pregnancy maintenance. Improved understanding may provide 
novel targets for uterine-selective therapeutic interventions. 
 
1.9. Hypotheses and Objectives 
Despite intense clinical and laboratory research, the origins of preterm and term labour 
remain obscure. A better understanding of the key regulators and molecular mechanisms 
which drive normal human labour, particularly the action of progesterone, cAMP and their 
interaction with the pathological processes, may help us to design more effective therapies 
and preventative approaches in the future, ultimately reducing the risks and the 
consequences of preterm labour. 
 
The hypotheses to be tested in this study are: 
1. Cyclic AMP action is reduced prior to the onset of labour.  
2. Cyclic AMP exerts anti-inflammatory effects to promote myometrial quiescence. 
3. Cyclic AMP enhances the myometrial response to progesterone. 
 
The objectives of this study are: 
1. To investigate whether a fall in cAMP/PKA tone occurs in the myometrium prior to 
labour. 
2. To investigate the mechanism(s) through which cAMP exerts anti-inflammatory 
actions in pregnant human myometrium.  
3. To define whether cAMP enhances progesterone modulation of gene expression and 
the mechanisms involved. 
4. To define which IL-1β-driven genes are repressed by progesterone/cAMP and via 
which receptor(s) and mechanism(s) this occurs. 
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Chapter 2: 
Materials and Methods 
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2.0. Materials and Methods 
 
2.1. Materials  
2.1.1. Chemicals, Reagents and Solvents  
Absolute Ethanol:     Fisher Scientific, Hemel Hempstead, UK 
Aminophylline:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
Ampicillin:      Sigma-Aldrich Co. Ltd., St. Louis, USA 
AICAR (AMPK agonist):    Merck Chemicals Ltd., Beeston, Nottingham, UK 
Bench top protein marker:    Invitrogen, Paisley, UK  
Blot Qualified BSA:     Promega, USA 
Bovine Serum Albumin (BSA):   Sigma-Aldrich Co. Ltd. , Dorset, UK 
Brefeldin A (Epac inhibitor):    Sigma-Aldrich Co. Ltd. , Dorset, UK 
8-bromo-cAMP:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
Compound C (AMPK inhibitor):   Merck Chemicals Ltd. ,Southampton, UK 
Deoxynucleotide triphosphate (dNTP):  Invitrogen, Paisley, UK  
Dibutyryl-cAMP:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
Dimethyl Sulfoxide (DMSO):    Sigma-Aldrich Co. Ltd. , Dorset, UK 
Dithiothreitol (DTT):                                            Bio-Rad, Hemel Hempstead, UK 
PF 04418948 (EP2 antagonist):   Tocris Bioscience, Bristol, UK 
Ethylenediaminetetraacetic Acid (EDTA):  Sigma-Aldrich Co. Ltd. , Dorset, UK 
Forskolin:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
HEPES:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Isopropanol:      Fisher Scientific, Hemel Hempstead, UK 
Interleukin 1β (IL-1β):    Sigma-Aldrich Co. Ltd. , Dorset, UK 
KCl:       Sigma-Aldrich Co. Ltd. , Dorset, UK 
KH 7 (Adenylyl Cyclase inhibitor):   Tocris Bioscience, Bristol, UK 
KT5720 (PKA inhibitor):    Sigma-Aldrich Co. Ltd. , Dorset, UK 
Methanol:      Fisher Scientific, Hemel Hempstead, UK  
MgCl2:       Sigma-Aldrich Co. Ltd. , Dorset, UK 
NaCl:       Sigma-Aldrich Co. Ltd. , Dorset, UK 
NaOH:       Sigma-Aldrich Co. Ltd. , Dorset, UK 
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Dibutyryl cAMP sodium salt:    Sigma-Aldrich Co. Ltd. , Dorset, UK 
NP-40 Alternative:     Calbiochem, Merck Millipore, Watford, UK 
NuPAGE (LDS Sample Buffer):   Life Technologies, USA 
Oligo-dT random primers:    Applied Biosystems, Paisley, UK  
Oligonucleotides and primers:   Invitrogen, Paisley, UK 
8pCPT-2'-O-Me-cAMP (Epac agonist):  BIOLOG Life Science Institute, Germany 
Pertussis Toxin (GαI inhibitor):   Tocris Bioscience, Bristol, UK 
Phosphatase inhibitor cocktail:   Thermo Scientific, Epsom, UK 
Bisindolylmaleimide II (PKC inhibitor):  Sigma-Aldrich Co. Ltd. , Dorset, UK 
U-73122 (PLC inhibitor):    Sigma-Aldrich Co. Ltd. , Dorset, UK 
PGE2:       Sigma-Aldrich Co. Ltd. , Dorset, UK 
Progesterone:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
Puromycin:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Rolipram:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
RU486:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Sanguinarine Chloride:    Tocris Bioscience, Bristol, UK 
Skimmed Milk Powder:    Marvel, UK  
Sp-6-phe-cAMP (PKA agonist):   BIOLOG Life Science Institute, Germany 
SYBR Green Reagents:    Applied Biosystems, Paisley, UK  
Syntocinon:      Alliance Pharmaceuticals Limited, UK 
Tris Base:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Triton X-100:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Tween 20:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
 
2.1.2. Antibodies  
2.1.2.1. Primary antibodies 
A cyclase 2 (A-21):     Santa Cruz Biochemicals, SC-130676, Texas, USA 
A cyclase 7 (H-120):     Santa Cruz Biochemicals, SC-25501, Texas, USA 
A cyclase 4 (C-20):     Santa Cruz Biochemicals, SC-589, Texas, USA 
AKIP1 (Anti-C11orf17 23kDa):   Abcam Ltd., ab135996, Cambridge, UK 
AKAP95/AKAP8 (95kDa):    Origene. TA309570, Rockville, USA 
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AKAP79 (79kDa):    New England BioLabs Ltd., D28G3, Herts, UK 
AMPKα (62 kDa):     New England BioLabs Ltd., 2532, Herts, UK 
α-tubulin (55 kDa):     Santa Cruz Biochemicals, SC-8035, Texas, USA 
11βHSD1 (32 kDa):     Abcam Ltd., ab83522, Cambridge, UK 
CCL8 (11 kDa):     Abcam Ltd., ab967, Cambridge, UK 
CBP (C-20) (265 kDa):     Santa Cruz Biochemicals, SC-583, Texas, USA 
GR (E-20) (95kDa):     Santa Cruz Biochemicals, SC-1003, Texas, USA 
COX-2 (70-72 kDa):     Santa Cruz Biochemicals, SC-1745, Texas, USA 
EPAC1 (100 kDa):     New England BioLabs Ltd., 4155, Herts, UK 
FKBP51 (F-13) (51kDa):    Santa Cruz Biochemicals, SC-11514, Texas, USA 
CREB (43kDa):     Millipore, 04-767, Watford, UK 
Gαs (46 kDa):      Abcam Ltd., ab83735, Cambridge, UK 
Gαq/11 (C-19) (40-41 kDa):    Santa Cruz Biochemicals, SC-392, Texas, USA 
Gαq/11/14 (H-300) (40-41 kDa):   Santa Cruz Biochemicals, SC-28587, Texas, USA 
IκBα (C-21) (39 KDa):     Santa Cruz Biochemicals, SC-371, Texas, USA 
ICER (43KDa):      Santa Cruz Biochemicals, SC-440, Texas, USA 
PDE4B (83 kDa):     Abcam Ltd., ab112014, Cambridge, UK 
PKAR2α (45-55 kDa):     Abcam Ltd., ab38949, Cambridge, UK 
CREB3L1 (57 kDa):     Abcam Ltd., ab33051, Cambridge, UK 
GPR124 (142 kDa):     Abcam Ltd., ab67280, Cambridge, UK 
GPR125 (146 kDa):     Abcam Ltd., ab51705, Cambridge, UK 
PRKG1 (76 kDa):     Abcam Ltd., ab97339, Cambridge, UK 
GUCY1A3 (77 kDa):     Abcam Ltd., ab166699, Cambridge, UK 
PTGES (18 kDa):     Abcam Ltd., ab62050, Cambridge, UK 
GAPDH (38kDa):     Millipore MAB374, Watford, UK 
JNK (46, 54 KDa):     New England BioLabs Ltd., 9252, Herts, UK 
OTR-R (C-20) (66 kDa):    Santa Cruz Biochemicals, SC-8013, Texas, USA 
PR (94, 114 kDa):     Leica, NCL-PGR-312, USA  
PRB (118 kDa):     New England BioLabs Ltd., 3157, Herts, UK 
p38 (43 kDa):      New England BioLabs Ltd., 9212, Herts, UK 
phospho-ATF-2 (Thr71) (70kDa):   New England BioLabs Ltd., 9221, Herts, UK 
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phospho-p38 (43 kDa):    New England BioLabs Ltd., 9211, Herts, UK 
phospho-JNK (46, 54 KDa):    New England BioLabs Ltd., 9251, Herts, UK 
PKA C-α (42 KDa):     New England BioLabs Ltd., 4782, Herts, UK 
NF-κB p65 (65 KDa):     Santa Cruz Biochemicals, SC-8008, Texas, USA 
phospho-NF-κB p65 (65 kDa):   New England BioLabs Ltd., 3031, Herts, UK 
TATA binding protein(38 kDa):   Abcam Ltd., ab818, Cambridge, UK 
phospho-CREB (Ser133):    New England BioLabs Ltd., 9191, Herts, UK 
c-jun (43-48 kDa):     New England BioLabs Ltd., 9165, Herts, UK 
c-fos (62 kDa):      New England BioLabs Ltd., 4384, Herts, UK 
phospho-c-jun:     New England BioLabs Ltd.,54B3, Herts, UK 
phospho-c-fos:     New England BioLabs Ltd.,D82C12, Herts, UK 
MKP1 (c-19) (40kDa):     Santa Cruz Biochemicals, SC-370, Texas, USA 
2.1.2.2. Secondary antibodies 
Donkey anti-Goat:     Santa Cruz Biochemicals, SC-2020, Texas, USA 
Anti-mouse IgG, HRP-linked Antibody:  New England BioLabs Ltd., 7076, Herts, UK 
Anti-rabbit IgG, HRP-linked Antibody:  New England BioLabs Ltd., 7074, Herts, UK 
 
2.1.3. Buffers and Solutions  
Cytosolic Buffer A  
10mM HEPES ,  
10mM KCl,  
0.1mM EDTA,  
0.1mM EGTA,  
2mM DTT , 1% (v/v) NP-40,  
Complete protease inhibitor tablets (Roche) 
Nuclear Buffer B 
10mM HEPES,  
10mM KCl,  
0.1mM EDTA,  
0.1mM EGTA,  
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2mM DTT,  
400mM NaCl,  
1 % NP-40 (v/v),  
Complete protease inhibitor tablets (Roche) 
Phosphate Buffered Saline (PBS)  
140mM NaCl,  
2.5mM KCl,  
1.5mM KH2PO4, pH 7.2,  
10mM Na2HPO4, pH7.2 
Tris Buffered Saline (TBS) 
130mM NaCl,  
20mM Tris-HCl, pH7.6,  
Adjusted to pH7.4 with HCl 
TBS-Tween 20 (TBS-T) 
0.1% Tween 20 in TBS 
Western Blocking Buffer  
5% (w/v) non-fat milk in TBS-T 
Western Antibody Incubation Buffer 
1% (w/v) non-fat milk in TBS-T 
 
2.1.4. Cell culture materials and media 
Cell strainer (2mm):     Falcon, London, UK 
Collagenase XI and 1A:    Sigma-Aldrich Co. Ltd. , Dorset, UK 
Dulbecco’s Modified Eagles’ Medium:  Sigma-Aldrich Co. Ltd. , Dorset, UK 
Fetal Bovine Serum:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
Filter Unit (0.20μm):     Sartorius, Epsom, UK  
L-glutamine:      Sigma-Aldrich Co. Ltd. , Dorset, UK 
Nutrient Mixture F-12 Ham:    Sigma-Aldrich Co. Ltd. , Dorset, UK 
Penicillin/Streptomycin:    Sigma-Aldrich Co. Ltd. , Dorset, UK 
Tissue Culture Plastic-ware:    Corning, Falcon, Orange, Cheshire, UK  
91 
 
Trypsin/EDTA:     Sigma-Aldrich Co. Ltd. , Dorset, UK 
 
2.1.5. Competent cells  
Escherichia coli DH5α:    Invitrogen, Paisley, UK 
 
2.1.6. Kits  
Amaxa Nucleofector Kit:      Lonza, Cologne, Germany  
Bio-Plex Pro Human Cytokine Standard 23-Plex, Group II:  Bio-Rad, USA 
cAMP Parameter Kits:      R&D System, Oxfordshire, UK 
Direct Cyclic AMP Chemiluminescent Immunoassay Kit:  Arbor Assay, USA. 
cDNA synthesis and SYBR Green for qPCR:    Applied Biosystems, Paisley, UK 
IL-8 ELISA Kit:        R&D System, Oxfordshire, UK 
Endofree Plasmid Kits:      Qiagen, Manchester, UK 
Fluo-4 Direct Calcium Assay Kit, Starter Pack:   Life Technologies, USA.  
QIA quick PCR purification kit:     Qiagen, Manchester, UK 
RNeasy mini Kit:       Qiagen, Manchester, UK 
 
2.1.7. SDS-PAGE electrophoresis and Western blotting materials  
Cell Lysis buffer:      Cell Signaling, Herts, UK 
ECL Plus Western Blotting Detection System:  GE Healthcare, UK 
NuPAGE LDS Samples buffer:    Invitrogen, Paisley, UK 
SDS PAGE pre-cast gels:     Invitrogen, Paisley, UK 
Precast polyacrylamide gels:     Bio-Rad, USA 
SuperSignal West Pico Chemiluminescent:   Pierce, Paisley, UK 
Trans-Blot Turbo Transfer Pack:    Bio-Rad, USA 
 
2.1.8. siRNA and shRNA  
ON-TARGET plus Non-Targeting siRNA:   Dharmacon, D-001810-01-05, UK 
ON-TARGETplus SMARTpool for GR:    Dharmacon, L-003424-00-0005, UK 
ON-TARGETplus SMARTpool for PR:    Dharmacon, L-003433-00-0005, UK  
ON-TARGETplus SMARTpool for MKP-1:   Dharmacon, L-003484-02-0005, UK 
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GαS siRNA:      Santa Cruz Biochemicals, SC-29328 Texas, USA 
ON-TARGETplus SMARTpool for AKIP1:  Dharmacon, L-015631-01-0005, UK 
ON-TARGETplus SMARTpool for GalphaQ:  Dharmacon, L-008562-00-0005, UK 
FlexiTube GeneSolution GS2767 for GNA11: QIAGEN, GS2767, Manchester, UK 
ON-TARGETplus SMARTpool for PKAC:  Dharmacon, L-004649-00-0005, UK 
ON-TARGETplus SMARTpool for EPAC1:  Dharmacon, L-007676-00-0005, UK 
shAMPK:      OriGene Technologies, Rockville, USA 
 
2.2. Methods 
2.2.1. Tissue collection 
A large tissue bank of myometrial tissue samples is available to the research group. Biopsies 
were obtained from the upper margin of the uterine lower segment incision at the time of 
Caesarean section from different groups of non-labouring and labouring women. Women 
were recruited and categorised into four main defined groups: preterm not in labour (PTNL) 
(24-36 weeks), term not in labour (TNL) (>37 weeks), term early labour (TEaL) (3-4 
contractions in 10 minutes and <3cm dilated) and term established labour (TEsL) (3-4 
contractions in 10 minutes and >3cm dilated). The indications for lower segment Caesarean 
section in labouring group were those independent of uterine contractions such as, slow 
labour, cephalo-pelvic disproportion, fetal distress, and breech presentation (all without 
oxytocin infusion), and in the non-labouring group, fetal indication, previous lower segment 
Caesarean section, breech presentation, and maternal request.  
 
In the preterm group, the samples from the following groups of women were also collected: 
  
(A) Preterm labour due to chorioamnionitis (infection-induced preterm labour (24-36 
weeks, defined by offensive vaginal discharge, pyrexia, tachycardia, uterine 
tenderness, raised inflammatory markers in the blood, and/or positive culture in the 
amniotic fluid and placental)). 
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(B) Preterm twins gestation (24-36 weeks, uncomplicated twin pregnancies delivered by 
planned Caesarean section or in spontaneous preterm labour with no evidence of 
infection, abruption or uterine anomaly). 
(C) Preterm delivery due to placental abruption (24-36 weeks, delivered due to one or 
more of the following: PV bleeding, shock, abdominal tenderness, compromised 
fetus, tachysystole, disseminate intravascular coagulation, retro-placental clot).  
(D) Idiopathic preterm labour (24-36 weeks, women who were delivered preterm with no 
evidence of infection, abruption or polyhydramnios and excluding fibroids, previous 
cervical surgery, mid-trimester loss, previous pelvic inflammatory disease or sexually 
transmitted disease).     
All the tissue samples were snapped frozen were snap-frozen immediately after collection at 
-80oC for mRNA and protein extraction. For myometrial tissue explants and cell culture, the 
myometrial biopsies from TNL group were then put into Dulbecco’s modified Eagle’s 
Medium (DMEM) medium containing L-glutamine and 100 mU/mL penicillin and 100 g/mL 
streptomycin and were stored at 4oC for no more than 3 hours prior to tissue explants and 
cell preparation for culture. Approval for the collection of myometrial biopsies was obtained 
from The Riverside Ethics Committee. All specimens were obtained after fully informed, 
written patient consent.  
 
Table 2-1. Demographic data for term myometrial tissue samples collected. 
 Preterm non labour Term non labour Term early labour Term established 
labour 
No of samples 16 20 21 24 
Mean 
gestational age 
(GASD) 
31.72.2 39.21.3 38.5 1.1 39.3 ±0.9 
Maternal 
characteristics 
    
Age 35.17.3 34.15.6 35.1 3.4 34.5 3.4 
BMI 25.35.0 26.06.4 22.4 2.5 22.7 3.2 
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Table 2-2. Demographic data for preterm myometrial tissue samples collected. 
 PTNL Chorioamnionitis 
PTL 
Idiopathic PTL Abruption PTL Twins NL Twins 
PTL 
No of samples 13 11 9 6 12 8 
Mean 
gestational age 
(GASD) 
1.1.1.1.1 30.23.5 1.1.1.1 2 29.52.9 1.1.1.1.3 35.41.8 1.1.1.1.4 32.43.5 1.1.1.1.5 35.21.1 1.1.1. .6 34.71.3
6 
Maternal 
characteristics 
      
Age 1.1.1.1.7 36.26.8 1.1.1.1 33.45.3 1.1.1.1.9 34.25.3 1.1.1.1.10 33.86.6 1.1.1.1.11 385.1 1.1.1. .12 32.86.3 
BMI 1.1.1.1.13 26.94.2 1.1.1.1 14 24.24.8 1.1.1.1.15 26.05.9 1.1.1.1.16 23.02.9 1.1.1.1.17 22.22.9 1.1.1.1.18 20.82.4 
 
2.2.2. Myometrial cell isolation and culture  
The myometrial tissue was carefully dissected and washed in ice-cold PBS several times to 
remove other impurities such as blood. The tissue samples were digested for about 45 
minutes at 37°C in a collagenase solution which included 0.5 mg/mL collagenase 1A and XI 
(Sigma) and 1 mg/mL bovine serum albumin in DMEM. Digestion was stopped by addition of 
DMEM supplemented with 7.5% fetal calf serum. The myometrial tissue suspension was 
agitated to further disperse the cells. The resulting suspension was then passed through a 
cell strainer (70μm nylon cell strainer) and individual cells were collected by centrifugation 
at 3000 rpm for 5 minutes. The cells were then grown in DMEM with supplementation of 
7.5% fetal calf serum (FCS), 1% L-glutamine and 1% penicillin-streptomycin at 37℃ in an 
atmosphere consisting of 5% CO2. Once the cells were confluent, the cells were passaged to 
a bigger flask. The old medium was removed and the cells were washed with PBS before 
Trypsin was then added to the flask. The flask was then incubated in the incubator for 5 
minutes and the cells were spun at 1000rpm for 5 minutes. The cells were grown in DMEM 
with supplementation of 7.5% fetal calf serum (FCS), 1% L-glutamine and 1% penicillin-
streptomycin at 37℃ in an atmosphere consisting of 5% CO2. The medium was changed at 
lease once a week. The myometrial cells used were either in the third or fourth passages. In 
all of the experiments described in the following chapters, the cells were serum-starved 18-
24 hours prior to initiation of experiments. The old medium was removed and replaced with 
2ml of DMEM supplemented with 1% dextran coated charcoal (DCC) and L-glutamine, 100 
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mU/ml penicillin and 100 g/ml streptomycin. In all cases, at the end of the specified time 
medium was removed and cells were frozen at -80oC for extraction of mRNA and whole-cell 
protein. For cytosolic and nuclear protein extraction, the cells were harvested and 
processed directly after treatment.  
 
2.2.3. The stretch model  
When the cells were approximately 80% confluent, the cells were plated in six-well, flexible-
bottom culture plates precoated with collagen type I in 2 ml of DMEM medium for stretch. 
The cells were serum-starved for 18-24 h prior stretch. The old medium was removed and 
replaced with 2ml of DMEM supplemented with 1% dextran coated charcoal (DCC) and L-
glutamine, 100 mU/ml penicillin and 100 g/ml streptomycin. The cells were subjected to a 
static stretch of 11% using a Flexercell strain unit (for more details, please see 
http://www.flexcellint.com/; Flexcell International Corporation, McKeesport, PA). The cells 
were stretched for 30 hours in total. After being stretched for 24 hours, the cells were 
incubated with and without progesterone (1,10μΜ), forskolin (100μΜ) either alone or in 
combination, in the absence and presence of IL-1β (1 ng/ml). On a separate experiment, the 
cells were incubated with 10nM of PGE2. The cells were then stretched again for 6 hours. 
Unstretched cells grown and treated similarly were aliquoted and used as controls. Although 
this stretch model is unable to directly reflect the stretch strength in singleton pregnancies, 
it has been used for many years in our laboratory and shown to be a good method to study 
stretch-induced cell signalling and gene expression.  
 
2.2.4. Myometrial tissue explants  
The impurities such as chorion and fetal membranes were removed from the myometrial 
tissue biopsy. Myometrial tissue were washed several times with PBS and were then cut 
uniformly to several explants tissue, each measuring approximately of 3x3mm size. Then the 
explants tissue were incubated in 24-wells plate with 1 ml of DMEM supplemented with 1% 
L-glutamine and 1% penicillin-streptomycin at 37℃ in an atmosphere consisting of 5% CO2. 
The explants tissues were pre-incubated with 1 μM of progesterone and 10 μM of 
aminophylline, either alone or in combination for 6 hours. After 6 hours, IL-1β (1 ng/ml) 
were added for further 24 hours. In another separate experiment, the explants tissues were 
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incubated with 10nM PGE2 for 24 hours. The explants tissue were then removed from the 
media and stored in -80℃ for protein extraction.  
 
2.2.5. Forskolin array 
Cells from TNL biopsies were cultured and incubated with and without 100µM forskolin for 
48h, RNA were extracted and subjected to Affimetrix Human Genome U133 plus 2.0 array 
gene analysis. A total of 28870 genes were interrogated (n=3). Two gene lists were generated 
by combining the top 50 up-regulated and down-regulated genes. Only those genes with 
p<0.05 and fold change >1.5 were analysed.  
 
2.2.5. Protein extraction 
2.2.5.1. Tissue protein extraction 
Myometrial tissue samples and explants were homogenised in lysis buffer using the 
Precellys®24 Dual system.  The samples were placed in precellys tube type CK Mix #03961-1-
00 and spun at 5000rpm for 20 seconds. The homogenate was centrifuged for 15 minutes at 
5000rpm and the total protein was extracted. The concentrations of the protein were 
determined by protein assay (Bio-Rad Laboratories, USA) using bovine serum albumin (BSA) 
as reference standards. Protein concentration of standards and samples were measured 
using a spectrophotometer at a wavelength of 562nm. A standard curve was calculated 
from the absorbance of the standards and used to determine the sample protein 
concentration. 
2.2.5.2. Whole-cell protein extraction 
Monolayers of myometrial cells were lysed in cell lysis buffer obtained from New England 
BioLabs (UK) Ltd. The cells were scraped from the bottom of each wells with cells scrapers 
(Corning) and the samples were centrifuged at 13 000g for 15 minutes at 4℃. Supernatants 
were then transferred and stored at -80℃. The concentrations of the protein were 
determined by protein assay (Bio-Rad Laboratories, USA) using BSA as reference standards. 
Protein concentration of standards and samples were measured using a spectrophotometer 
at a wavelength of 562nm. A standard curve was calculated from the absorbance of the 
standards and used to determine the sample protein concentration.  
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2.2.6. Cytosolic and nuclear protein extraction 
At the end of the specified treatment time points, medium was aspirated. The cells were 
then washed with sterile PBS once. On ice, the monolayers of myometrial cells were lysed in 
Buffer A.  The cells were scraped from the bottom of each well with cells scrapers (Corning), 
and the lysates were incubated on ice for 15-20 minutes. 20% of NP-40 alternative was then 
added to the lysates and were vortexed for 10 seconds at a high speed followed by 
centrifugation at 16 000×g for 30 seconds at 4℃. The supernatants were reserved as the 
cytosolic protein extracts. The pellets were washed with ice-cold PBS once and resuspended 
in buffer B and incubated on ice for 15 minutes with shaking (~200rpm). Subsequently the 
suspension was centrifuged for 5 minutes at 16 000×g for at 4℃. After the last 
centrifugation, the supernatant (nuclear extract) was transferred to a separate tube. These 
can be used directly or stored at -80℃ for western blotting. 
 
2.2.7. Western blotting 
Protein samples were denatured by adding NuPAGE LDS samples Buffer (Invitrogen) and 
heating at 800C for 10 minutes. Equal quantities of protein (as measured by BCA assay) were 
added to each lane on a polyacrylamide gel, with one lane reserved for pre-stained 
molecular weight marker (Invitrogen). The protein samples were subjected onto a 10% SDS-
PAGE for 30min at 80V, and then 40-60 minutes at 125V, followed by a transfer to a Trans-
Blot Turbo Transfer Pack (Bio-Rad). The membrane was then blocked with 5% milk protein 
solution at room temperature for 1 hour, washed in 1x TBST and hybridized with the 
primary antibody overnight at 40C. After that the membrane was washed again in 1x TBST 
and then incubated with the secondary antibody at a dilution of 1:2000 at room 
temperature for 2 hours. SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA) 
or ECL Plus was used for detection. Protein band size was determined using Novex Sharp 
Pre-stained Protein Standard (Invitrogen). Exposure for detection was at 250C for maximum 
of 5 minutes.  
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2.2.8. RNA extraction and Quantitative RT-PCR 
2.2.8.1 Tissue RNA extraction  
Myometrial tissue samples and explants were homogenised in 1ml of RNA stat using the 
Precellys®24 Dual system.  The samples were placed in precellys tube type CK Mix #03961-1-
00 and spun at 5000rpm for 20 seconds. The homogenate was centrifuged for 15 minutes at 
5000rpm and the total RNA was extracted and purified using an RNeasy mini kit (Qiagen Ltd, 
UK). The samples were nanodropped to determine the RNA concentration. 
2.2.8.2. Cells RNA extraction  
Total RNA was extracted and purified from myometrial cells grown in 6-well plates using an 
RNAeasy kit (Qiagen Ltd, UK). The samples were nanodropped to determine the RNA 
concentration.  
2.2.8.3. Quantitative RT-PCR 
After quantification 1.0 μg was reverse transcribed with oligo dT random primers using 
MuLV reverse transcriptase (Applied Biosystems). Primer sets for labour-associated genes 
and dehydrogenase (GAPDH) were designed and obtained from Amersham Pharmacia 
Biotech. Quantitative PCR was performed in the presence of SYBR Green (Roche 
Diagnostics), and amplicon yield was monitored during cycling in a RotorGene Sequence 
Detector (Corbett Research Ltd., Mortlake, Sydney, Australia) that continually measures 
fluorescence caused by the binding of the dye to double-stranded DNA. Pre-PCR cycle was 
10 minutes at 95℃ followed by up to 45 cycles of 95℃ for 20 seconds, 58-60℃ for 20 
seconds and 72℃ for 20 seconds. The final procedure involves a melt over the temperature 
range of 72-99℃ rising by 1 degree steps with a wait for 15 seconds on the first step 
followed by a wait of 5 seconds for each subsequent step. The cycle in which fluorescence 
reached a preset threshold (cycle threshold) was used for quantitative analyses. The cycle 
threshold in each assay was set at a level where the exponential increase in amplicon 
abundance was approximately parallel between all samples. For each set of primers, a 
standard curve was derived from a ten-fold dilution series of the concentrated DNA 
template.  All mRNA abundance data were expressed relative to the amount of 
constitutively expressed GAPDH.  
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Table 2-3. Primer pair sequences with gene accession numbers (human). 
 
Name  
 
 
Primer sequence (5’–3’) 
 
 
GenBank/ 
EMBL accession no. 
GAPDH F: tgatgacatcagaaggtggtgaag  
R: tccttggaggccatgtaggccat 
BC014085 
 
OTR F: agaagcactcgcgcctctt 
R: aggtgatgtcccacagcaact 
NM000916 
 
11βHSD1 F: accttcgcagagcaatttgt 
R: gccagagaggagacgacaac 
NM_005525 
MKP-1 
 
F: cagctgctgcagtttgagtc  
R: aggtagctcagcgcactgtt  
NM_004417 
PTGES F:catgtgagtccctgtgatgg 
R:ctgcagcaaagacatccaaa 
NM_004878 
GPR125 F:ttggcgcagatgtgatagag 
R:aagttggctgcttccacagt 
NM_145290 
CCL8 F:tcacctgctgctttaacgtg 
R:atccctgacccatctctcct 
NM_005623 
PDE4B F:ccctgttgtccagtccaact 
R:tgcagactctcacggtgaac 
NM_001037339 
G-alpha-S F:gaggcttctggcctacactg 
R:gcaaggtctgggacctgtaa 
NM_000516 
GPR124 F:ctggaagagcgaaactaccg 
F:gcgtgtttctgggattgtct 
NM_032777 
CREB3L1 F:cagatggctgggaaatcaac 
R:tccttggagtgggagaagtc 
NM_052854.3 
 
GUCY1A3 F:caagttgtgcaagccaagaa 
R: atccagctctccacactgct 
NM_000856 
PRKG1 F:caggcccagatcctatgaaa 
R:ccctcaaaccatttgtgctt 
NM_001098512 
PKAR2α F:cctagcagatttaatagacg 
R:atcatctccttggtcaatga 
NM_001144956.1 
 
AKAP79 F:cggaaagatggtgatgaggt 
R:tactggctgctgatggtctg 
NM_004857 
EPAC1 F:ccttctgtctccctgactgc  
R:ctgcttgacctcctttcagg 
NM_001098531 
CREB F:gcgaagggaaattctttcaa 
R:cctctctctttcgtgctgct 
AY347527.1 
 
COX-2 F: tgtgcaacacttgagtggct    
R: actttctgtactgcgggtgg  
 
AY151286 
FKBP51 F: tccctcgaatgcaactctct    
R: gccacatctctgcagtcaaa  
 
NM_001145775 
IL-8 
 
F: gccttcctgattttgcagc     
R: cgcagtgtggtccactctca  
 
NM_000584 
PRB F: aactcagcgagggactgaga     X51730 
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 R: gaggactggagacgcagagt  
 
PR Total F: agcccacaatacagcttcgag     
R: tttcgacctccaaggaccat  
 
NM_000926 
IL-1β F: gctgaggaagatgctggttc     
R: tccatatcctgtccctggag  
 
NM_000576 
IκBα   F: ccagggctattctccctacc 
  R: gctcgtcctctgtgaactcc 
NM_020529 
IRAK3   F: ccaactcctcctgagttcca 
  R: acaaccaagtcatgccacaa 
NM_001142523 
IL-11   F: aagttctagctcgccaacca 
  R: ggcagctatcgtcaacatca 
NM_000641 
IL-24   F: gcccagtaaggacaattcca 
  R: atttctgcatccaggtcagg 
NM_001185156 
AKAP95   F:tatgacagcaccatgcccta 
  R:ttcatctcctgagcggaagt 
NM_005858 
AKIP1   F:cctggtcttccctgtgtgat 
  R:tgggcaacagagtgagactg 
NM_001206647.1 
CBP   F:cacgtacacacccacacaca 
  R:gagcgcttgcatgatttaca 
NM_001079846 
ICER   F: cctccaccaggtgctacaat 
  R: tttgcgtgttgcttcttctg 
NM_001267562 
AC1   F: actgaggctggaggatgaga 
  R: tcagcaaacaggatgctcac 
NM_001281768 
AC2   F: gccttcatcctcttcgtctg 
  R: tggagggattgtttcctctg 
NM_020546 
AC3   F: tgtgctgtggtcttctccag 
  R: gaagatctgggcggttatga 
NM_004036 
AC8   F: aggtatgtgcggtcaaggac 
  R: tcaccgttgagacagtccag 
NM_001115 
AC9   F: cctcagtgcagaaccacaga 
  R: gcaattgcaactcaaagcaa 
NM_001116 
 
Table 2-4. Primer pair sequences with gene accession numbers (mouse). 
 
Name  
 
 
Primer sequence (5’–3’) 
 
 
GenBank/ 
EMBL accession no. 
Β-actin F: aggctgtgctgtccctgtat 
R: gctgtggtggtgaagctgta 
NM_007393 
 
YWHAZ F: agcaggcagagcgatatgat 
R: ttctcagcaaattccgtctt 
NM_001253805 
ATP5B F: gagggattaccacccatcct 
R: catgattctgcccaggtct 
NM_016774 
MKP-1 
 
F: ccaactcctcctgagttcca 
R: gcgaagaaactgcctcaaac 
NM_013642 
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OTR F: agaagcactcgcgcctctt 
R: aggtgatgtcccacagcaact 
NM_001081147 
11βHSD1 F: ttattgtcaaggcgggaaag 
R: gcaatcataggctgggtcat 
NM_001044751 
COX-2 F: tgcagaattgaaagccctct 
R: gctcggcttccagtattgag 
NM_011198 
IL-24 F: fcccagtaaggacaattcca 
R: atttctgcatccaggtcagg 
NM_053095 
IL-11 F: aagttctagctcgccaacca 
R: ggcagctatcgtcaacatca 
NM_000641 
CXCL2 F:agtgaactgcgctggtgaatg 
R: ttcagggtcaaggcaaactt 
NM_002089 
IRAK3 F: tcaccatcagcagccagtag 
R: acaaccaagtcatgccacaa 
NM_028679 
FKBP51 F: gtgggttctacatcggcact 
R: agtctgcgaaaggacttgga 
NM_010220 
 
 
2.2.9. Transient transfection 
Transient transfection on myometrial cells were carried out using the using primary smooth 
muscle cells nucleofector kits transfection reagent (Lonza, UK) according to the 
manufacturer’s protocol. Confluent cells were harvested by trypsinization as described 
above. Approximately 1×106 cells were resuspended in 100 μl Nucleofector solution and 
mixed with 30 pmol siRNA at room temperature. The siRNA suspension was then 
transferred into certified cuvette and electroporated in the Nucleofector Cuvette Holder 
with the Nucleofector Program A-033. The cells were suspended with 500 μl pre-warmed 
full culture medium immediately after electroporation, and gently transferred into 6-well 
plates. The cells were incubated in a humidified 37˚C/5% CO2 incubator until analysis and 
change medium 16-18 hours post Nucleofection. The medium was changed to one 
containing DMEM with supplementation of 7.5% FCS, 1% L-glutamine and 1% penicillin-
streptomycin at 37℃ in an atmosphere consisting of 5% CO2, then after another 48 hours, 
the cells were serum starved in 1% DCC, supplemented with L-glutamine, 100 mU/ml 
penicillin and 100 g/ml streptomycin. The next day, the cells were treated under different 
conditions for 6 hours. At the end of the 6 hours, the medium was removed and cells were 
frozen at -80oC for mRNA and protein extraction. 
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2.2.10. Enzyme-linked immunosorbent assay (ELISA) 
Following stimulation of cultured cells, the medium was collected and frozen at −80OC prior 
to analysis. Levels of IL-8, IL-6, ICAM, CCL2, CCL11, CCL20, IL-1β, IL-1α, RANTES, LIF, GRO-β 
(CXCL2), and GRO-α (CXCL1) were measured by ELISA using different kits. The ELISA assays 
were performed according to the manufacturer’s protocol.  
 
2.2.11. Measurement of intracellular cAMP levels 
2.2.11.1. Cyclic AMP assay on myometrial tissue 
Frozen preterm and term myometrial tissue biopsies were grinded in a stainless steel 
mortar under liquid nitrogen until they were in a fine powder form. The powdered tissues 
were weighed and 1ml of sample diluent was added for every 100mg of tissue. The tissues 
were then incubated in the sample diluent for 10 minutes on ice, and were then centrifuged 
at≥ 600x g at 4oC for 15 minutes. The supernatants were collected and assays were 
performed using High Sensitivity Direct Cyclic AMP Chemiluminescent Immunoassay Kit 
(Arbor Assay, USA) according to the manufacturer’s protocol.  
2.2.11.2. Cyclic AMP assay on cells supernatants 
Following stimulation of cultured cells, the medium was collected and frozen at −80OC prior 
to analysis. The Levels of cAMP were measured using cAMP Parameter Kits (R&D System, 
Oxfordshire, UK) according to the manufacturer’s protocol.  
 
2.2.12. Measurement of intracellular calcium levels 
Confluent primary myometrial cells were plated onto 35-mm glass bottomed dishes (name 
of the company). 18-24 hours prior to incubation, cells were serum starved with clear DCC. 
Cells were then pre-incubated with forskolin (100μM) for 6 hours. After 6 hours, cells were 
loaded with the calcium dye Fluo-4-AM Direct (Invitrogen) for 30 minutes at 37°C in a 
humidified 5% CO2 incubator and then at room temperature for a further 30 minutes. Cells 
were then imaged using a TCS-SP5 confocal microscope (Leica) with a "20 dry objective". 
Cells were imaged for approximately 2 minutes before Oxytocin treatment (100nM), and 10-
15 minutes after oxytocin addition, capturing every 1.2 seconds. Timelapse movies and 
fluorescent intensity plots were generated with the Leica LASAF software. 
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2.3. Mouse study 
Preterm labour was induced in pregnant CD1 mice at E16, by intrauterine injection of 10ug 
0111:B4 LPS. Mice were pre-treated with either vehicle or 10mg/kg aminophylline i.p 2 
hours prior to LPS administration, followed by either vehicle or 5mg progesterone s.c 30 
minutes prior to LPS injection. Latency to labour was monitored by infra-red CCTV imaging. 
Myometrial tissue samples were collected from a second group of animals at the time of 
labour or 7 hours post LPS injection (whichever was the later time). Total mRNA and protein 
was isolated from myometrial samples using the method described above. Myometrial 
cytokine/chemokine expression levels were measured on a Bioplex Pro Cytokine Multiplex 
Assay (BioRad), using 500ug protein lysate produced according to the manufacturer's 
instructions.  
 
2.4. Statistical analysis 
All data were initially tested for normality using a Kolmogorov-Smirnoff test. These 
experiments were performed with at least 6 different patients’ samples unless otherwise 
stated. Normally distributed data were analysed using a Student t test for two groups and 
an ANOVA followed by a Dunnett post hoc test for three groups or more. Data that were not 
normally distributed were analysed using a Mann–Whitney U test for non-paired data and a 
Wilcoxon matched pairs test for paired data (two groups) and when comparing three groups 
or more we used a Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test. 
p<0.05 was considered statistically significant. 
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Chapter 3: 
Cyclic AMP regulates myometrial oxytocin 
receptor expression 
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3. Cyclic AMP regulates myometrial oxytocin receptor during gestation 
 
3.1. Introduction 
Preterm labour is the most important cause of perinatal death and long-term morbidity 
worldwide (413, 414). The majority of these deliveries are due to the spontaneous onset of 
uterine contractions (58), although an increasing proportion of cases of preterm labour are 
induced secondary to pre-existing fetal or maternal conditions. Despite the advancement in 
obstetric medicine, the rate of preterm labour has increased by more than 30% over the last 
20 years (60). So far, our ability to successfully treat women whose pregnancies are 
complicated by preterm labour is hindered by a lack of knowledge of the endocrine and 
biochemical factors that initiate human parturition. In pregnancy, the uterus must remain 
quiescence until the onset of labour when it starts to contract in a regular and coordinated 
fashion to forcibly expel the fetus. One of the most common and versatile second 
messengers, cAMP, controls a range of physiological processes, including calcium handling 
and smooth muscle contraction, its intracellular concentration is tightly controlled by GPCRs 
which are linked to adenylyl cyclases and drive production and by the specific PDEs which 
convert cAMP to AMP (308). There is extensive evidence to suggest that components of 
cAMP signalling pathway are up-regulated in the human myometrium during pregnancy to 
maintenance uterine quiescence until term (220). This includes the adenylyl cyclase 
stimulatory G protein Gαs (415-417), whose levels of expression are significantly increased 
within the myometrium during pregnancy, resulting in the increased production of cAMP, 
which is further increased by the progesterone-induced down-regulation of myometrial 
cAMP PDEs activity (361). 
Cyclic AMP is a direct activator of PKA, through which it acts to promote uterine quiescence. 
Previous studies have shown that the increase in uterine cAMP and activation of PKA has 
been associated with uterine relaxation (312), and thus cAMP pathways have been the focus 
of targeted therapy in the suppression of preterm labour.  PKA was earlier thought to be the 
primary effector of cAMP in eukaryotic cells (327). Subsequently, Epac has also been shown 
to function as a cAMP effector (327). Several reports suggest that PKA, rather than Epac, is 
important for cAMP-mediated suppression of cytokine production, while activation of Epac, 
but not PKA, dose dependently suppresses phagocytosis (327, 330, 332, 418). However, the 
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anti-inflammatory effect downstream of PKA or Epac still remains obscure. The initiation 
and progression of labour requires the myometrium to shift from a quiescent to a 
contractile state. The inhibition of contraction during uterine quiescence is diminished with 
a loss in the ability of the uterus to increase or maintain cAMP at the end of pregnancy 
(308). A decline in myometrial cAMP activity may be attributed to a decline in any of the 
signalling molecules involved in cAMP production or the factors that mediate cAMP 
inhibitory effects. Thus, it is feasible that the loss of the cAMP effect may potentially drive 
the onset of labour.  
The oxytocin system plays a critical role in the onset of uterine contractions both before and 
at term. Its importance is shown by the ability of an oxytocin infusion to induce labour (419, 
420) and of OTR antagonists to interrupt established preterm labour (195). Normally, prior 
to the onset of labour, the myometrium becomes increasingly sensitive to the contractile 
effects of oxytocin. This is due to increased OTR expression that with advancing gestation 
and the onset of labour whether it is at term or before (166, 192). Indeed, the activation of 
the myometrial oxytocin system is probably exclusively dependent on increased OTR expres-
sion as although a gradual rise in oxytocin levels has been described with advancing preg-
nancy there is no dramatic increase with the onset of labour (193). However, the molecular 
mechanisms regulating myometrial OTR gene expression in the human myometrium during 
pregnancy and parturition remain largely undefined. 
There is extensive evidence to suggest that substances which increase myometrial cAMP 
levels are able to modulate the oxytocin system (218, 222, 223, 421). In the oestrogen-
primed non-pregnant rat myometrial cell, PLC activation by a uterotonic was inhibited by 
cAMP enhancing agents, such as, isoproterenol, relaxin, forskolin and chlorophenylthio–
cAMP (CPT-cAMP). These effects were abolished with PKA inhibition, suggesting that PKA is 
the key cAMP effector responsible for PLC inhibition (223, 224). In a study to explore the 
effects of relaxin on OTR regulation, prolonged relaxin incubation of human uterine smooth 
muscle cells was found to inhibit as much as 40% of OTR binding. Further, OTR mRNA 
expression and protein level were both reduced by about 50% and 35% respectively (225). 
This study supports the evidence that high local uterine relaxin concentrations may be 
involved in uterine quiescence during human pregnancy by down regulating the OTR. 
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Moreover, since relaxin action is mediated by cAMP, it seems possible that cAMP inhibits 
OTR expression.  
It is well recognised that human parturition is an inflammatory process, characterised by 
influx of inflammatory cells into the myometrium and cervix, with a subsequent increase in 
cytokines production (15, 17). These inflammatory cytokines have been shown to increase 
prostaglandin synthesis, which lead to myometrial contraction, and thus the onset and 
progression of labour (15). There are several reports on the effects of cAMP-modulating 
agents, either physiological or pharmacological, on multiple aspects of immune function 
(422, 423). The studies concluded that cAMP mainly has an anti-inflammatory action, 
interfering with both innate and adaptive immune responses at multiple levels (422-425). 
Moreover, evidence shows that cAMP decreases inflammation (426, 427) and vice versa 
(428, 429). The hypothesis of this chapter is that high cAMP tone during gestation 
contributes to the maintenance of myometrial quiescence by inhibiting inflammation, and 
thus repressing the contractile associated genes, and that labour is initiated when there is a 
reduction of cAMP tone and thus a reduction of myometrial relaxant may be key to the 
initiation of the labour process.  
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3.2. Results 
 
3.2.1. A functional assessment of myometrial cAMP action with the onset of labour.  
Forskolin is an agent that stimulates adenylyl cyclase, which in turn increases the 
intracellular levels of cAMP (430). Cultured myocytes were treated with forskolin and an 
array was performed to identify the genes that are regulated by forskolin.  
 
Table 3-1. Forskolin array – up-regulated genes 
Gene Symbol RefSeq Fold-Change 
CCL8 NM_005623 9.72165 
11βHSD1 NM_005525 8.00056 
MKP-1 NM_004417 4.07706 
PDE4B NM_002600 3.97811 
PTGES  NM_004878 1.94534 
GPR125  NM_145290 1.91453 
 
Table 3-2. Forskolin array – down-regulated genes 
Gene Symbol RefSeq Fold-Change 
GUCY1A3 NM_000856 3.30078 
GPR124 NM_032777 1.87172 
OTR NM_000916 1.85898 
CREB3L1   NM_052854 1.80952 
PRKG1  NM_001098512 1.80436 
 
Table 3-1 and Table 3-2. Forskolin array listing the up-regulated and down-regulated 
genes.  
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Figure 3-1. Elucidation of the cAMP axis from Forskolin Array – Up-regulated Genes. 
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Figure 3-2. Elucidation of the cAMP axis from Forskolin Array – Down-regulated Genes. 
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Figure 3-1 and Figure 3-2. Elucidation of the cAMP axis from Forskolin Array.  
Forskolin array was performed to establish which genes are regulated by forskolin. Myometrial cells were 
isolated from myometrial biopsies obtained from women at the time of pre-labour term Caesarean section. 
Cells were cultured and incubated with and without 100µM forskolin for 48 hours, mRNA were extracted and 
subjected to Affimetrix Human Genome U133 plus 2.0 array gene analysis. A total of 28870 genes were 
interrogated (n=3). Two gene lists were generated by combining the top 50 up-regulated and down-regulated 
genes. Only those genes with p<0.05 and fold change >1.5 were analysed. Six genes were up-regulated by 
cAMP (MKP-1, 11βHSD1, PTGES, PDE4B, GPR125, CCL8) and five genes were down-regulated by cAMP (PRKG1, 
GUCY1A3, GPR124, CREB3L1, OTR). We then studied the level of those genes expressions on mRNA and 
protein levels using rt-PCR and western blotting respectively on the human myometrial tissue samples 
collected from different groups of non-labouring and labouring women at the time of Caesarean section. 
Women were recruited in four defined groups: preterm not in labour (PTNL) (24-36 weeks), term not in labour 
(TNL) (>37 weeks), term early labour (TEaL) (3-4 contractions in 10 minutes and <3cm dilated cervix) and term 
established labour (TEsL) (3-4 contractions in 10 minutes and >3cm dilated cervix). Samples were snap frozen 
at -80
o
C for mRNA and protein extraction and the level of the genes which were up-regulated (MKP-1, 
11βHSD1, PTGES, PDE4B, GPR125, CCL8) (Figs. 3-1 A-L) and down-regulated by cAMP (PRKG1, GUCY1A3, 
GPR124, CREB3L1, OTR) (Figs. 3-2 A-J) were explored using rt-PCR and western blotting respectively. Data are 
expressed as the mean and SEM, and were analysed using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Bonferroni’s 
post-test for data that were normally distributed. * indicates a significant difference of p<0.05, **, of P<0.01, 
and ***, of P<0.001 (n=12 in each group). 
 
To test the hypothesis that a decline in cAMP function occurs with the onset of labour, a 
group of cAMP responsive genes in myometrial cells was identified. If the effect of cAMP is 
reduced with the onset of labour, then this should be evident in a change in gene 
expression. To define which genes were regulated in the myometrium by cAMP, the effect 
of exposure to forskolin (100µM for 6 hours) on gene expression was studied. Using a gene 
array, six genes that were up-regulated by forskolin, MKP-1, 11βHSD1, PTGES, PDE4B, 
GPR125 and CCL8 (Table 3-1 and Figs.3-1) and five genes that were down-regulated by 
forskolin, PRKG1, GUCY1A3, GPR124, CREB3L1 and OTR (Table 3-2 and Figs.3-2) were 
identified. Both sets of genes were confirmed by quantitative rt-PCR (Figs. 3-1 and 3-2).  
Next, the expression of cAMP-regulated genes in human myometrial tissue samples 
collected from different groups of non-labouring (preterm and term) and labouring (in early 
(cervical dilatation <3cms) and established (cervical dilatation > 3cms) women at the time of 
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Caesarean section was assessed. Of the six cAMP up-regulated genes, only MKP-1 (mRNA) 
and 11βHSD1 (mRNA and protein) showed a trend to decline in myometrial samples with 
advancing gestation and the onset of labour (Figs.3-1). Of the five cAMP down-regulated 
genes, GUCY1A3 (mRNA), GPR124 (mRNA), CREB3L1 (mRNA), and OTR (mRNA and protein) 
increased with advancing gestation (Figs.3-2). These data show that 4 out of 5 cAMP-
repressed genes behave in a manner consistent with a decline in cAMP function with 
advancing gestation and the onset of labour. The cAMP-upregulated genes did not follow 
this pattern, perhaps because they may be regulated by factors other than cAMP, such as 
inflammation. 
The changes in the cAMP-repressed genes shown above are highly suggestive that there 
may be a decline in cAMP tone with advancing gestation and the onset of labour. The 
myometrial oxytocin system is one of the key factors in determining the contractile status of 
the uterus. Clinically, the uterus becomes progressively more sensitive to oxytocin with 
advancing gestation, and this is consistent with the observation of a gradual increase in OTR 
expression (Figs. 3-2 E&J). A previous study also found that OTR expression declined in 
established labour (Figs. 3-2 E&J) (431). OTR is one of the genes that are down-regulated by 
forskolin and, to date, there have been no reports linking the potential association between 
a decline in cAMP and an increase in OTR mRNA expression. Different cAMP elevating 
agents other than forskolin, such as 8 bromo cAMP, dibutyryl-cAMP, rolipram, and 
aminophylline were also confirmed to decrease OTR mRNA expression (Figs. 3-3 A-D). As 
OTR is a labour associated gene and is one of the key genes in determining the contractile 
status of the uterus, the relationship between cAMP and OTR mRNA expression was 
explored further.  
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Figure 3-3. Different cAMP elevating agents are able to repress OTR gene expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with A. 8 bromo cAMP (250μM), B. dibutyryl-cAMP 
(50µM), C. rolipram (10μM) and D. aminophylline (10μM) for 6 hours. The levels OTR mRNA were measured 
using quantitative rt-PCR. Data were compared using Wilcoxon matched pairs test for data that were not 
normally distributed and paired t test for data that were normally distributed *P<0.05 when compared to 
control (n=6). 
 
In addition, the response of cAMP-regulated genes to other agents capable of raising 
intracellular cAMP levels (8 bromo cAMP, dibutryl-cAMP, and rolipram) was assessed. This 
results above showed that for the genes which are down-regulated by cAMP, treatment 
with cAMP agonists results in a consistent reduction in their expression compared to control 
(Table 3-4 and Appendix 1 i-iv). However, the effect of the cAMP agonists on the expression 
of the cAMP up-regulated genes was less consistent, for example, forskolin treatment is 
associated with a significant increase in four out of six genes (11βHSD1, MKP-1, CCL8, 
PDE4B), whereas treatment with 8 bromo cAMP is associated with a significant increase in 
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two of six genes which are up-regulated by cAMP (11βHSD1, PDE4B) (Table 3-3 and 
Appendix 1 i-iv). This suggests that the most consistent response is seen in the down-
regulated cAMP genes and that studying these may give a useful indication of a tissue’s 
cAMP “tone”. 
 
Table 3-3. The effects of cAMP agonists on genes which are up-regulated by cAMP. 
Gene  Forskolin  8 bromo cAMP Dibutyryl cAMP  Rolipram  
 Fold-Change    
CCL8 6.93 2.84 1.48 1.75 
11βHSD1 13.9 2.93 1.14 1.19 
MKP-1 3.66 1.21 1.03 1.25 
PDE4B 4.32 2.32 1.93 1.37 
PTGES  0.28 1.11 1.58 1.35 
GPR125  1.39 1.23 1.53 1.13 
 
Table 3-4. The effects of cAMP agonists on genes which are down-regulated by cAMP. 
Gene  Forskolin 8 bromo cAMP Dibutyryl cAMP Rolipram 
 Fold-Change    
GUCY1A3 0.31 0.51 0.68 0.58 
GPR124 0.33 0.58 0.67 0.76 
OTR 0.22 0.58 0.49 0.79 
CREB3L1   0.38 0.71 0.81 0.83 
PRKG1  0.24 0.58 0.65 0.74 
 
Symbol  
 increase 
 decrease 
 no significant change 
 
Table 3-3 and Table 3-4. The effects of cAMP agonists on genes which are up-regulated 
and down-regulated by cAMP. 
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3.2.2. Cyclic AMP acts via PKA to reduce OTR mRNA expression, but in the absence of PKA, 
cAMP acting via Epac1 increases OTR mRNA expression.  
 
 
 
Figure 3-4. Forskolin-induced phospho-CREB phosphorylation.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with froskolin (100μM) for 0, 15, 30, 60, 120 minutes. 
Cells were lysed and samples purified for cytoplasmic or nuclear protein as described in materials and 
methods. Blots were probed with phospho-CREB antibody and Tata binding protein (TBP) and α-tubulin were 
used as loading controls for nuclear and cytosolic proteins respectively (n=6).   
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Figure 3-5. Cyclic AMP act via PKA in reducing OTR expression in human primary myometrial cells and in the 
absence of PKA, cAMP worked via Epac1 in increasing OTR gene expression.  
A. Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-
labour Caesarean section. Cells were cultured and incubated with forskolin (100µM) for 6 hours. The levels 
OTR mRNA were measured using quantitative rt-PCR. B. On a separate experiment, myometrial cells were 
isolated as described above, and incubated with forskolin (100µM) for 6 hours. The levels OTR proteins were 
measured using western blotting.  C, D, E. On separate experiments, myometrial cells were isolated as 
described above, and PKAC-α, EPAC1 and AMPK were knocked down respectively using siRNA (siPKAC-α, 
siEpac1 and siAMPK, controlled with non-targeted siRNA [siNT]). Representative western blots to demonstrate 
transfection are shown above.  After transfection, myometrial cells were incubated for 96 hours before being 
treated with forskolin (100µM) for 6 hours; mRNA (F) and protein (G) were extracted, and the levels of OTR 
mRNA and protein were measured using rt-PCR and western blotting respectively. In a separate experiments, 
myometrial cells were isolated as described above, and incubated with forskolin (100µM), KT5720 (10μM), 
Brefeldin A (100µM), Compound C (100µM), either alone or in combination for 6 hours. The levels OTR mRNA 
(H) and proteins (I) were measured using rt-PCR and western blotting respectively. On a separate experiment, 
myometrial cells were isolated as described above, and incubated with forskolin (100µM), or Sp-6-phe-cAMP 
(100nM), for 6 hours. The levels OTR mRNA (J) and proteins (K) were measured using rt-PCR and western 
blotting respectively. L. Myometrial cells were isolated from myometrial biopsies obtained from women at the 
time of pre-labour term Caesarean section. PKAC-α was knocked down using siRNA (siPKAC-α, controlled with 
non-targeted siRNA [siNT]). Representative western blots to demonstrate transfection is shown above.  After 
transfection, cells were incubated for 96h before being treated with forskolin (100µM) or Brefeldin A (100µM) 
either alone or in combination for 6 hours; mRNA were extracted, and the levels of OTR mRNA were measured 
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using rt-PCR.M. On a separate experiment, myometrial cells were isolated from myometrial biopsies obtained 
from women at the time of pre-labour term Caesarean section. PKAC-α was knocked down using siRNA 
(siPKAC-α, controlled with non-targeted siRNA [siNT]). Representative western blots to demonstrate 
transfection are shown above.  After transfection, cells were incubated for 96 hours before being treated with 
forskolin (100µM) or 8pCPT-2'-O-Me-cAMP (50μM) either alone or in combination for 6 hours; mRNA were 
extracted, and the levels of OTR mRNA were measured using rt-PCR. Data are shown as the mean, and SEM, 
and were compared using Wilcoxon matched pairs test for data that were not normally distributed and paired 
t test for data that were normally distributed (A, B, L-M). For F-K, data are shown as the mean and SEM, and 
were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were 
not normally distributed, and using ANOVA, with Bonferroni’s post-test for data that were normally distributed 
*P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-9 in each experiment).  
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Figure 3-6. Cyclic AMP mediated reduction of OTR expression is associated with a reduction of intracellular 
calcium activation.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Myometrial cells were cultured and incubated with and without 100µM forskolin for 6 
hours (A-C). Cells were loaded with Fluo-4-AM calcium dye and imaged by confocal microscopy. An arrow 
indicates the addition of the Oxytocin (100nM). A and B, Representative fluorescent intensity plots expressed 
in arbitrary units (AU), over time (seconds, s). C. The average maximal fluorescent intensities from cells treated 
as in A and B. Data are shown as the mean, and SEM, and were compared using paired t test for data that were 
normally distributed (C). *P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-9).  
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Figure 3-7. The comparison of transfection efficiency between Amaxa (nucleofection) and Gene Juice. 
Myometrial cells were transiently transfected with a green fluorescent protein (GFP) expressing plasmid, 
pmaxGFP using Amaxa (nucleofection) or Gene Juice. Cells were examined by fluorescence microscopy from 2 
day post-transfection to day 5. BF, bright field. This experiment is performed in collaboration with Dr Kaiyu Lei.  
 
OTR regulation was studied in depth in this chapter as it plays one of the key roles in labour 
process. Forskolin (100μM) was used to increase myometrial cells cAMP levels (Fig. 3-4). 
Forskolin decreased OTR mRNA expression and protein levels (Figs. 3-5 A&B) and this was 
associated with a reduction in calcium mobilisation (Figs. 3-6).  As mentioned above, apart 
from forskolin, different cAMP stimulating agents are also able to decrease OTR mRNA 
expression (Figs. 3-3 A-D).  Then the molecular mechanisms responsible for the cAMP-
induced reduction in OTR mRNA expression were explored. The expression of the cAMP 
effectors was reduced using siRNA to PKACα, Epac1 and AMPK. The transfection efficiency, 
which was delivered by optimised electroporation method with Amaxa (nucleofection), is 
shown in Figure 3-7. Knockdown of PKA blocked the forskolin-induced reduction in OTR 
mRNA expression and protein synthesis (Figs. 3-5 F&G). To confirm the knockdown data, 
myometrial cells were incubated with forskolin (100μM) alone or in the presence of cAMP 
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effector antagonists: PKA (KT5720, 10μM), Epac (brefeldin A, 100μM), AMPK (compound C, 
100μM). It was noted based on the above experiments that only the PKA inhibitor could 
reverse the forskolin-induced reduction in OTR mRNA expression and protein synthesis (Figs. 
3-5 H&I). Finally, in order to prove that cAMP work via PKA in repressing OTR gene 
expression, the myometrial cells were treated with specific cAMP effector activators: PKA 
(Sp-6-phe-cAMP, 100nM) and our results showed that PKA agonist is able to reproduce the 
forskolin-induced decrease in OTR mRNA expression (Fig. 3-5 J) and protein synthesis (Fig. 3-
5 K). These data highly suggest that cAMP-induced reduction in OTR expression in human 
myometrial cells involves a PKA-dependent pathway.  
It was noted that when PKA was blocked (with either siRNA or antagonist), forskolin induced 
an increase in OTR mRNA expression and protein levels (Figs. 3-5 F-I). To investigate the 
mechanism responsible for this effect, PKA was knocked down and an Epac1 antagonist was 
added. This combination blocked the ability of forskolin to increase OTR mRNA expression in 
the absence of PKA (Fig. 3-5L). The addition of the Epac antagonist was not associated with 
greater reduction in OTR expression when compared to the effect of forskolin on its own 
(Fig. 3-5L).  Then, PKA was knocked down and an Epac agonist was added (Fig. 3-5M). This 
combination showed a marked increase in OTR expression (Fig. 3-5M). However, the Epac 
agonist had a minimal effect on its own and did not prevent the forskolin-induced reduction 
in OTR mRNA expression (Fig. 3-5M). These data propose that in the absence/reduction in 
PKA activity, cAMP increases OTR mRNA expression in a mechanism involving Epac1. 
However, it is interesting that the Epac1 agonist did not, in its own right, increase OTR 
expression after PKA knockdown, but that the effect of forskolin was enhanced in its 
presence. This suggests perhaps that Epac1 is necessary for forskolin to increase OTR mRNA 
expression in the absence of PKA, but that it is not itself directly responsible. 
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3.2.3. Cyclic AMP levels and PKA activity are reduced and Epac1 levels are increased with 
term labour. 
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Figure 3-8. Cyclic AMP levels and PKA activity are down-regulated with labour, whereas Epac1 levels are up-
regulated with term labour.  
Human myometrial tissue samples were collected from different groups of non-labouring and labouring 
women at the time of Caesarean section. Women were recruited in four defined groups: preterm not in labour 
(PTNL) (24-36 weeks), term not in labour (TNL) (>37 weeks), term early labour (TEaL) (3-4 contractions in 10 
minutes and <3cm dilated cervix) and term established labour (TEsL) (3-4 contractions in 10 minutes and >3cm 
dilated cervix). Samples were snap frozen at -80
o
C for cAMP assay, and mRNA and protein extraction. A. 
Myometrial tissue was ground in a mortar and pestle under liquid nitrogen and cAMP assay was subsequently 
performed using the cAMP Chemiluminescent Immunoassay kit (Arbor Assays, USA) following the 
manufacturer’s instructions. The levels of PKAR2α, AKAP79, CREB, Epac1 mRNA (B, D, F, I) and protein (C, E, G, 
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J) were measured using quantitative rt-PCR and western blotting respectively. H. Phospho-CREB protein levels 
were measured using western blotting. A representative western blot is shown next to each graph displaying 
the densitometry of the protein levels. Blots were probed with PKAR2α, AKAP79 and CREB, Phospho-CREB and 
Epac1 antibody, and GAPDH was used as a loading control. Data are shown as the mean and SEM, and were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Bonferroni’s post-test for data that were normally distributed. 
*P<0.05, **P<0.01, ***P<0.001 (n=12 in each group).  
 
Next the behaviour of the different components of the cAMP pathways were studied with 
the onset of labour at term. The myometrial levels of cAMP increased from the preterm no 
labour to the term no labour samples, before declining abruptly in early labour and 
remaining repressed in established labour (Fig. 3-8 A). PKA levels were at a peak in the 
preterm no labour samples, declining thereafter (Figs. 3-8 B&C). Contributing to the decline 
in PKA action, it was observed that there was a reduction in AKAP-79 expression, as has 
been reported previously (Figs. 3-8 D&E). The decline in PKA activity with advancing 
gestation was supported by demonstrating a reduction in phospho-CREB, with the lowest 
levels observed at the term established labour group (Figs. 3-8 F-H). Epac1 mRNA expression 
was noted to increase from preterm non labour group to term established labour, reaching 
a peak in the term established labour group (Fig. 3-8 I), but the protein levels peaked in the 
term early labour samples (Fig. 3-8 J). The in vitro data suggest that the reduction in PKA and 
increase in Epac1 would shift the effect of cAMP from repression to stimulation of OTR 
expression, which is what we observed in the transition into early labour (Figs. 3-8 E&J). 
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3.2.4. The effect of stretch, inflammation and the combination of stretch and 
inflammation on cAMP levels and pathway components in myometrial cells.  
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Figure 3-9. The effect of stretch, inflammation, and the combination of stretch and inflammation on cAMP 
levels and pathway components in myometrial cells.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Myometrial cells were grown up to passage 3 and plated on to the stretched plates. Cells 
were stretched for 30 hours in total. At 24 hour, cells were incubated for an additional 6 hours in the absence 
and presence of IL-1β (1ng/mL) and forskolin (100µM). A,B. Cells supernatants were collected and cAMP levels 
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(pmol/mL) were measured from the stored supernatants using an assay kit (cAMP assay, R&D Systems, UK) 
following the manufacturer’s instructions. C-T. Proteins were then extracted and the levels of PKAR2α, 
AKAP79, GαS, phospho-CREB, OTR, and Epac1 were measured using western blotting. Blots were probed with 
PKAR2α, AKAP79, GαS, phospho-CREB, OTR, and Epac1 antibodies, and GAPDH was used as a loading control. 
Data are shown as the mean, and SEM, and were compared using Wilcoxon matched pairs test for data that 
were not normally distributed and paired t test for data that were normally distributed. *P<0.05, **P<0.01, 
***P<0.001 when compared to control (n=6-9 in each experiment).  
 
Next, to understand the mechanisms that may be responsible for the changes in the cAMP 
effector pathways, the impact of stretch and inflammation were studied. The results 
showed that stretch reduced the ability of forskolin to increase cAMP levels (Fig. 3-9 A), 
both stretch and inflammation reduced basal levels of cAMP and the combination was 
greater than stretch alone (Fig. 3-9 B). Stretch and inflammation when tested separately 
reduced the levels of AKAP79, GαS and phospho-CREB (Figs. 3-9 F, G, I, J, L, M), but not 
PKAR2α (Figs. 3-9 C, D). Similarly, the combination of both stretch and inflammation 
reduced the levels of AKAP79, GαS and phospho-CREB maximally (Figs. 3-9 H, K, N), but had 
minimal effects on PKAR2α expression (Fig. 3-9 C). Both stretch and inflammation alone 
increase OTR and Epac1 protein levels (Figs. 3-9 O, P, R, S), the combination of stretch and 
inflammation is also associated with an increase in OTR and Epac1 protein expression, but 
this increase was no greater when compared to stretch or inflammation alone (Figs. 3-9 Q, 
T). 
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3.2.5. The effect inflammation and stretch on cAMP levels and pathway components in  
myometrial tissues.  
 
Inflammation 
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Figure 3-10. The effect of inflammation on cAMP levels and pathways components in myometrial tissue 
samples. 
Human myometrial tissue samples collected from different groups of non-labouring and labouring women at 
the time of Caesarean section. Women were recruited in two defined groups: preterm not in labour (PTNL) 
(24-36 weeks), and preterm labour due to chorioamnionitis (infection-induced preterm labour defined by 
offensive vaginal discharge, pyrexia, tachycardia, uterine tenderness, raised inflammatory markers in the 
blood, and/or positive culture in the amniotic fluid and placental) (24-36 weeks). Samples were snap frozen at -
80
o
C for cAMP assay, mRNA and protein extraction. A. Myometrial tissue was ground in a mortar and pestle 
under liquid nitrogen and cAMP assay was subsequently performed using the cAMP Chemiluminescent 
Immunoassay kit (Arbor Assays, USA) following the manufacturer’s instructions. The levels of PKAR2α, GαS, 
AKAP79, CREB, OTR, Epac1 mRNA (B, D, F, H, K, M) and protein (C, E, G, I, L, N) were measured using 
quantitative rt-PCR and western blotting respectively. J. Phospho-CREB protein levels were measured using 
western blotting. A representative western blot is shown next to each graph displaying the densitometry of the 
protein levels. Blots were probed with PKAR2α, GαS, AKAP79 and CREB, Phospho-CREB, OTR, and Epac1 
antibody, and GAPDH was used as a loading control. Data are shown as the mean and SEM, and were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Bonferroni’s post-test for data that were normally distributed. 
*P<0.05, **P<0.01, ***P<0.001 (n=11-17 in each group).  
 
As the results above showed that inflammation and stretch was associated with the down-
regulation of cAMP levels and pathways components in myometrial cells, it is possible that a 
similar trend may be observed in myometrial tissue. This was further explored by 
investigating the cAMP levels and pathway components on myometrial tissues collected 
from women whose pregnancies were complicated by preterm labour in the presence of 
chorioamnionitis and twin pregnancy. Consistent with the earlier findings on myometrial 
cells, pregnancies affected by chorioamnionitis was to noted to be associated with a 
significant reduction of cAMP levels compared to preterm non labour group (Fig. 3-10 A). 
Although the level of PKAR2α and CREB expression were significantly higher at mRNA level 
in the preterm labour chorioamnionitis group (Figs. 3-10 B&H), the protein levels were 
significantly lower (Figs. 3-10 C&I), compared to preterm non-labour group. With regards to 
GαS, the expression was significantly higher at mRNA level in the preterm labour 
chorioamnionitis group, but there was no significant difference observed between the two 
groups at protein level (Figs. 3-10 D&E). AKAP79 expression was significantly lower at both 
mRNA and protein levels in preterm chorioamnionitis compared to preterm non-labour 
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group (Figs. 3-10 F&G). With regards to phospho-CREB expression, although inflammation 
was associated with a downward trend in the choriamnionitis group, there was no 
statistically significant difference between the two groups (Fig. 3-10 J). The reduction in 
cAMP levels in the chorioamnionitis preterm labour group was associated with a significant 
increase in OTR and Epac1 expression at both mRNA and protein levels (Figs. 3-10 K-N). In 
the case of PKAR2α and CREB, the mRNA increased markedly, but the protein levels of both 
declined, perhaps because there was lag between mRNA and protein changes and a decline 
in functional protein levels may induce an increase in mRNA expression to compensate. 
Overall, the in vitro changes produced by IL-1β in myometrial cell cultures were broadly 
replicated in the in vivo situation of chorioamnionitis and support the concept that 
inflammation may be involved in the changes in the cAMP effector pathways.  
 
3.2.5. The effect inflammation and stretch on cAMP levels and pathway components in  
myometrial tissues.  
 
Stretch 
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Figure 3-11. The effect of uterine stretch on cAMP levels and pathways components in myometrial tissue 
samples. 
Human myometrial tissue samples collected from different groups of non-labouring and labouring women at 
the time of Caesarean section. Women were recruited in two defined groups: uncomplicated preterm twins 
not in labour (24-36 weeks), and spontaneous preterm twins in labour with no evidence of infection, abruption 
or uterine anomaly (24-36 weeks). Samples were snap frozen at -80
o
C for cAMP assay, mRNA and protein 
extraction. A. Myometrial tissue was ground in a mortar and pestle under liquid nitrogen and cAMP assay was 
subsequently performed using the cAMP Chemiluminescent Immunoassay kit (Arbor Assays, USA) following 
the manufacturer’s instructions. The levels of PKAR2α, Gαs, AKAP79, CREB, OTR, Epac1 mRNA (B, D, F, H, K, M) 
and protein (C, E, G, I, L, N) were measured using quantitative rt-PCR and western blotting respectively. J. 
Phospho-CREB protein levels were measured using western blotting. A representative Western blot is shown 
next to each graph displaying the densitometry of the protein levels. Blots were probed with PKAR2α, AKAP79, 
Gαs, CREB, Phospho-CREB, OTR, and Epac1 antibody, and GAPDH was used as a loading control. Data are 
shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Bonferroni’s post-test for 
data that were normally distributed. *P<0.05, **P<0.01, ***P<0.001 (n=9-12 in each group).  
 
 
The effect of myometrial stretch was investigated in vivo by comparing myometrial samples 
from preterm twins who were not in non labour to myometrial samples from preterm twins 
in labour. Based on the results above, it was noted that the in vitro stretch of myometrial 
cells reduced cAMP, AKAP-79, Gαs (mRNA and protein), and phospho-CREB and increased 
Epac1 expression, but had no effect on PKAR2α. In myometrial samples from women in 
preterm twin labour, there was a significant decrease in PKAR2α (protein), Gαs (mRNA and 
protein), and CREB (protein) expression (Figs. 3-11) and a significant increase in OTR and 
Epac1 protein levels (Figs. 3-11 L&N). These results provide another piece of evidence to 
support the concept that a reduction in cAMP/PKA activity in association with an increase in 
Epac1 may results in an increase in OTR levels. The changes seen in twin labour 
myometrium were similar to those induced by stretch of myometrial cells in vitro, but there 
were inconsistent changes in mRNA and proteins levels. Again, this may reflect the delay in 
between mRNA and protein changes, miRNA expression, differences in metabolism and the 
fact that although stretch may have initiated the process, labour itself will have exerted 
changes in gene expression.  
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The combination of in vitro stretch and inflammation may be closer to the in vivo situation 
in pregnancy, since inflammation is common to most labours and all uteri are under some 
degree of stretch. Generally, although not directly compared, with either stimulus alone, the 
combination was noted to have more marked effects.  
 
3.2.6. Proposed theory for cAMP action in term myometrium.  
 
 
 
Figure 3-12. Proposed theory for cAMP action in term myometrium.  
In pregnancy, high level of cAMP act via PKA-dependent pathway to reduce OTR mRNA expression and to 
promote myometrial quiescence. With advancing gestation and the onset of labour, the reduction in 
cAMP/PKA activity results in an increase in OTR mRNA expression. In the absence of PKA, cAMP works via 
Epac1 to increase OTR mRNA expression. This process leads to influx of calcium into the cells, and promotes 
myometrial contractility and the onset of labour.  
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3.3. Summary and Discussion 
The cAMP-signalling pathway is up-regulated in the human myometrium during pregnancy 
contributing to the maintenance of uterine quiescence until term (220). The data presented 
in this chapter provide strong evidence that cAMP may be involved in the regulation of OTR 
expression in human myometrium. The effects of pregnancy and different stages of labour 
on the mRNA expression and protein synthesis of several cAMP-regulated genes have been 
studied. The data show that PKA-mediated cAMP signalling declines prior to the onset of 
labour with a reduction in myometrial AKAP79, PKA regulatory subunit IIα (PKARIIα) and 
cAMP response element-binding protein (CREB) (Fig. 3-8) (220, 318). These changes were 
associated with a reduction in phospho-CREB suggesting that there was a decline in PKA 
activity, at the same time, the abundance of a second cAMP effector, Epac1, increased (Fig. 
3-8). In parallel with these changes, OTR gene expression was down-regulated in pregnancy 
and increased with the process of labour, reaching its peak in early labour at term, before 
declining in established labour, consistent with previous observations of a decline in OTR 
with labour duration (Fig. 3-8)  (431). In addition, the results of the in vitro work shown in 
this chapter help to link these observations showing that forskolin, an adenylyl cyclase 
activator, inhibited OTR expression via PKA (Fig. 3-5). Knockdown of PKA not only reversed 
forskolin-induced OTR repression, but actually resulted in an increase in OTR mRNA 
expression, mediated via Epac1 (Fig. 3-5). Furthermore, stretch and inflammation 
reproduced some of these changes in cAMP-effector pathways, implying a role for these 
processes in the onset of labour. These data support the current hypothesis that a reduction 
in the cAMP/PKA effector pathway may be a key to the initiation of the labour process.  
OTR expression has been widely studied as a marker of labour in animal models of 
parturition (23, 204, 206). There has been conflicting evidence regarding the expression of 
OTR in human labour. Near the onset of labour, the uterus becomes more sensitive to OTR, 
in association with an up-regulation of uterine OTR mRNA expression (193), reaching a peak 
during early labour, and following labour, the levels decline abruptly (431). Although some 
groups demonstrated that OTR expression is increased in human labour, others reported 
that OTR expression does not increase with the onset of labour but with advancing 
gestation, prior to the onset of labour (432). The results from this chapter show that OTR 
expression increases with gestation, reaching a peak in early labour before it declines in 
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established labour (Fig. 3-8), perhaps explaining why many groups have failed to show an 
increase in OTR expression with labour. 
Both Epac1 and Epac2 are present in mature and developing tissues, Epac1 mRNA is most 
abundant in the heart and kidney (181), but has been found in monocytes, macrophages, B 
and T lymphocytes, eosinophils, neutrophils, platelets, and in CD34-positive haematopoietic 
cells (326-328). Epac2 expression, on the other hand, has been found to be prominent in the 
brain and adrenal glands (182) and to be undetectable in all hematopoietic cell types (326). 
In an attempt to study the expression of Epac1 and Epac2 in myometrial tissue, the 
expression of Epac2 mRNA was found to be very low in myometrial tissue, while the 
expression of Epac1 mRNA was much higher. Thus Epac1 expression was studied in this 
chapter. The results in this chapter showed that as PKA levels declined with gestation and 
the onset of labour, EPAC levels increased (Fig. 3-8). This is supported by the in vitro work, 
which suggested that in the absence of PKA, Epac1 may be responsible for the increase in 
OTR mRNA expression (Fig. 3-5).   
Previous data from the group reported that stretch of primary cultures of pregnant human 
uterine smooth muscle cells resulted in an increase in  OTR mRNA expression in association 
with increased in C/EBPβ DNA binding (34) and an increase in COX-2 mRNA expression in 
association with increased activity of the AP-1 system (31). Similar findings were also noted 
in animal studies (23, 204, 206). These findings may explain the high rate of preterm labour 
in human pregnancies complicated by multiple pregnancy (398), polyhydramnios (399), 
unicornuate uterus (400), and singleton pregnancies with fetal macrosomia (433). 
Consistent with this, Manabe et al. demonstrated that abortion in the second trimester and 
labour at term can be induced by mechanical distension of the uterus (209, 434). In this 
chapter, in vitro stretch was associated with a reduction in the levels of cAMP, GαS and 
phospho-CREB protein and an increase in OTR and Epac1 expression (Figs. ). Moreover, 
stretch reduced the ability of forskolin to increase cAMP levels (Figs. ). More importantly, 
both stretch and inflammation reduced basal levels of cAMP and the combination was 
greater than stretch action alone (Figs. ). In short, these findings highly suggest that stretch 
and inflammation may be associated with a reduction in cAMP levels, thus a reduction of 
cAMP repressive effect on OTR expression, resulting in the increase of OTR expression.   
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As the elevation of cAMP promotes myometrial quiescence by regulating multiple 
intracellular targets, including calcium channels, potassium channels and myosin light chain 
kinase, it also influences a wide array of physiological and pathological events including 
smooth muscle contractility and inflammation (308). Indeed, both physiological (relaxin, 
CRH, and calcitonin gene related peptide) and pharmacological (β2 agonist) agents act via 
cAMP to induce myometrial relaxation (396, 435, 436). However, therapeutically in the 
management of PTL, β2 agonists are limited both by severe, potentially life threatening side 
effects and tachyphylaxis, the latter mediated by β2 agonist-induced down-regulation of 
myometrial adrenergic receptors (437, 438). Based on the results shown in this chapter, 
another possible reason for the limited use of β2 agonists in the management to prevent 
preterm labour is that with the onset of labour, increasing cAMP in the context of low PKA 
and high Epac1 levels might increase OTR expression and thus promote myometrial 
contractions. Other mechanisms to increase myometrial cAMP levels have been explored 
and a recent publication showed that using the PDE4 inhibitor, rolipram, has successfully 
reduced the rates of PTL in a mouse model of pregnancy (363). 
In summary, the data in this chapter suggest that myometrial quiescence in pregnancy is 
characterised by high cAMP/PKA activity and may be associated with the reduction in OTR 
expression. In addition, the data strongly suggest that the process of labour in human may 
be associated with the decline in cAMP/PKA activity and an increase in the levels of Epac1 
expression, thus contributing to the increase in OTR expression and promoting uterine 
contractility (Fig. 3-12). These findings may contribute to the design of treatment strategies 
for the prevention of preterm labour and suggests that the cAMP/PKA pathway may be a 
novel therapeutic target. 
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Chapter 4: 
The Role of cAMP as an Anti-inflammatory in 
Human Myometrium 
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4. The role of Cyclic AMP as an Anti-inflammatory in Human Myometrium 
 
4.1. Introduction 
Spontaneous preterm labour is a pervasive and expensive health problem, with around 
60,000 babies being born prematurely in the UK every year (54-56). Spontaneous preterm 
labour remains the most important cause or premature births and, significantly, babies born 
after spontaneous preterm labour have a worse prognosis due to the associated fetal 
inflammation (58). Intrauterine infection and inflammation are recognised as a major 
contributing factor to preterm labour in human (73, 75). The transcription factor, NFκB, is a 
key modulator of these pathways, exerting its role by promoting the expression of 
prostaglandin synthetic enzymes and of proinflammatory chemokines involved in both 
preterm and term labour (19). NFκB activation occurs in both the human myometrium (15, 
75) and the fetal membranes (439) prior to the onset of labour. Most studies of labour-
associated gene expression in myometrium have shown up-regulation of NFκB regulated 
genes, such as IL-8 and COX-2, and other chemokines in the myometrium before the onset 
labour (15, 439). In addition, activation of NFκB is suggested not only to play a pivotal role in 
the process of preterm labour (73), but also it may be involved in the associated fetal brain 
damage (440). 
Previous studies have demonstrated that elevation of intracellular cAMP induces the 
expression of numerous genes through the PKA-mediated phosphorylation of transcription 
factors, including CREB (441). Cyclic AMP has also been shown to play significant role in the 
respiratory and cardiovascular systems, for instance, medications used to treat asthma 
consist of active ingredients which involve cAMP (442), and PDE5 inhibition, which increase 
cAMP level, was found to be an effective treatment of idiopathic arterial pulmonary 
hypertension and is associated with protective antihypertrophic, antiapoptic effects on the 
heart (352). In addition, cAMP has been shown to be a potent immunomodulator, inhibiting 
NFκB activity and the induction of a distinct set of NFκB regulated genes through a variety of 
mechanisms in various cell types (365, 376, 411, 412). For instance, cAMP inhibits IL-2 
expression in activated T-lymphocytes (443, 444). In monocytes, pharmacological agents 
that elevate intracellular cAMP levels, such as pentoxifylline, iloprost, dibutyryl cAMP, 
forskolin, and isomethylxanthine, inhibit the production of TNFα and tissue factor 
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expression that are also under the control of NFκB (364, 445, 446). In endothelial cells, 
elevation of cAMP inhibits the induction of E-selectin and VCAM-1 mediated by IL-1β or 
TNFα (447, 448).  Minguet et al. demonstrated that cAMP acting via PKA is capable of 
selectively suppressing the activation both of NFκB downstream of the B cell antigen 
receptor and Toll-like receptor 4 in splenic B lymphocytes (365). This suppression is achieved 
by blocking the phosphorylation and subsequent degradation of the inhibitor of NFκB. In 
addition, Olsen and colleagues discovered the inhalation of JMF2-1, an analog of lidocaine, 
which prevents airway contraction and lung inflammation in experimental asthma models, is 
able to inhibit respiratory smooth muscle contraction as well as T cell proliferation and 
survival through enhancement of intracellular cAMP levels (449). These findings may help to 
explain the anti-inflammatory and antispasmodic effects of JMF2-1 observed previously 
(450). The above evidence collectively suggests that the elevation of intracellular cAMP 
and/or activation of PKA appear to modulate the transcriptional activity of NFκB in a 
negative way. 
In an attempt to explore the mechanism responsible for the anti-inflammatory action of 
cAMP, AKIP1 has been identified to act as a key molecular switch, determining whether 
cAMP/PKA positively or negatively affects NFκB activity (369). It was demonstrated 
previously that PKA positively affects p65 transactivation in cells expressing high levels of 
AKIP1, whereas PKA oppositely inhibited NFκB activity in cells containing low levels of AKIP1 
in breast cancer cell lines (369). So far, no study was done to investigate the role played by 
AKIP1 in human uterine smooth myometrial cells. The possible effect(s) of AKIP1 expression 
in myometrial human cells will be explored further in this chapter.  
As cAMP has been shown to supress NFκB activity and NFκB regulated genes in various cells 
types, thus it is possible that inflammation could also repress cAMP level. Indeed, an earlier 
study looking at human peritoneal macrophages by Adolfs et al. showed that there were 
marked changes in the cAMP levels, namely a sharp drop during the inflammatory condition 
and a return close to the original levels after the subjects recovered from the peritonitis 
(451).  
Similar observation was also noted by Ghosh et al., who reported that the pro-inflammatory 
cytokines, TNF-α, and IL-1β, produce a rapid and profound reduction in cAMP in microglia, 
which is accompanied by increased PDE4 expression and activity (452). They then 
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subsequently investigated the signaling pathways that mediated this effect. They found that 
TNF-α-induced reduction in cAMP could be antagonised by Rolipram, myristoylated-PKI, 
PD98059, or JSH-23, implicating a role for PDE4, PKA, MEK, and NFκB. Moreover, following 
TNF-α stimulation, there were significant increase in iNOS and COX-2 immunoreactivity, 
phosphorylated ERK1/2 and NFκB-p65, IκB degradation, and NF-κB p65 nuclear 
translocation, all of which were reduced in the presence of high levels of cAMP, suggesting 
that a reduction in cAMP during cytokine stimulation are fundamental for removing its 
inhibitory action on NFκB activation and subsequent proinflammatory gene expression 
(453).  
Given the key role played by cAMP in human body, it seems highly likely that cAMP would 
also play a similar crucial role in the reproductive system. The aim of this chapter is to 
examine the role of cAMP as an anti-inflammatory in human myometrium and to investigate 
the possible mechanism(s) for the anti-inflammatory action involved in the process, and to 
explore the effect of infection/inflammation on cAMP levels. In addition, the possible 
effect(s) of AKIP1 expression in myometrial human cells will be explored further. 
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4.2. Results 
 
4.2.1. The effect of cAMP on IL-1β-driven inflammation on inflammation associated genes 
expression. 
 
 
 
Figure 4-1. The effect of cAMP on IL-1β driven inflammation on inflammation-associated genes expression. 
Myometrial cells were isolated as described above in Materials and Methods, and treated with IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. mRNA were extracted, and the levels of 
IL-8 (A), IL-1β (B), COX-2 (C), OTR (D) mRNA expression were measured using quantitative rt-PCR. Data are 
shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. 
Analysis of 2 groups was performed using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-
1β is compared to 100F + IL-1β (n=8-9 in each experiment). 
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Figure 4-2. The effect of cAMP on IL-1β-driven inflammation on inflammation associated genes expression 
driven at protein level.   
Myometrial cells were isolated as described above, and treated with IL-1β (1ng/mL) and/or forskolin (100µM) 
either alone or in combination for 24 hours. The levels of IL-8 and IL-1β (A-B) protein were measured from the 
supernatants using ELISA assay. C and D. Myometrial cells were isolated as described above in Materials and 
Methods, and treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in combination for 24 
hours. Proteins were extracted, and the levels of OTR protein expression were measured using western 
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blotting. Data are shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's 
Multiple Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with 
Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 
when compared to control. Analysis of 2 groups was performed using Wilcoxon matched pairs test for data 
that were not normally distributed and paired t test for data that were normally distributed #P<0.05, ##P<0.01, 
###P<0.001 when IL-1β is compared to 100F + IL-1β (n=8-9 in each experiment). 
 
The effect of cAMP on IL-1β driven inflammation on inflammation-associated genes 
expression was studied. The ability of cAMP to repress IL-1β driven IL-8 and IL-1β expression 
was investigated as IL-8 was recognised as p-65 most responsive gene (285), and IL-1β was 
both responsive to the transcription factor NFκB and AP-1 (454). The effect of cAMP on IL-
1β-driven inflammation on labour associated genes such as COX-2 and OTR was also 
explored. The results above showed that with the exception of COX-2, cAMP acting on its 
own was capable of repressing IL-1β-induced inflammation on IL-8, IL-1β, and OTR mRNA 
expression (Figs. 4-1). The anti-inflammatory effect of cAMP was also shown by the 
repression of IL-8, IL-1β, OTR protein expression (Figs. 4-2), and the pro-inflammatory 
cytokines and chemokines levels (Appendix 2), where in cells treated with the combination 
of forskolin and IL-1β compared to cells treated with IL-1β alone, a significant reduction in 
the inflammation-associated genes expression was observed. Consistent with the findings 
shown in chapter 3, forskolin alone was able to reduce basal level of OTR mRNA and protein 
expression.  
 
With regards to labour associated gene COX-2, COX-2 mRNA and protein expression were 
increased by forskolin (Figs. 4-1 C & 4-2 C). The combination of forskolin and IL-1β compared 
to IL-1β alone was not associated with a reduction in COX-2 gene expression (Figs. 4-1 C & 4-
2 C). On the contrary, there was a statistically significant increase in COX-2 mRNA and 
protein expression with the combination of forskolin and IL-1β compared to IL-1β alone 
(Figs. 4-1 C & 4-2 C). This trend was consistent with earlier findings from our group where 
Chen et al. demonstrated that cAMP increases myometrial cell COX-2 expression via MAPK 
activation (183). 
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4.2.2. Cyclic AMP represses IL-1β driven p65 and c-jun. 
 
 
Figure 4-3. Cyclic AMP represses IL-1β-induced nuclear and cytosolic phospho p-65 and phospho c-jun 
protein expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods, and treated with forskolin (100µM) or IL-1β 
(1ng/mL) either alone or in combination for 1 hour. Cells were lysed and samples purified for cytoplasmic or 
nuclear protein. Western blotting was performed using antibodies directed against phospho-p65 (Ser536), and 
phospho c-jun. TATA-bind protein (TBP) and α-tubulin were used as the internal controls for nuclear and 
cytosolic fraction, respectively. Data are shown as the mean and SEM, and were compared using Friedman’s 
Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using 
ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, 
***P<0.001 when compared to control. Analysis of 2 groups was performed using Wilcoxon matched pairs test 
for data that were not normally distributed and paired t test for data that were normally distributed #P<0.05, 
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##P<0.01, ###P<0.001 when IL-1β is compared to 100F + IL-1β (n=6-7 in each experiment). The representative 
blots can be found on Figure 6-10. 
 
 
 
 
Figure 4-4. Cyclic AMP represses IL-1β-induced total p65 protein and total c-jun expression.  
Myometrial cells were isolated as described above in Materials and Methods, and treated with IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. Protein was extracted, and the levels of 
total p65, and total c-jun protein expression were measured using western blotting. Data are shown as the 
mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test 
for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. Analysis of 2 
groups was performed using Wilcoxon matched pairs test for data that were not normally distributed and 
paired t test for data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-1β is compared 
to 100F + IL-1β (n=6-7 in each experiment). 
 
The possibility of a link between AP-1, NFκB and cAMP was initially investigated in human 
myometrial cells. The ability of cAMP in repressing IL-1β-induced increase of transcription 
factors AP-1 and NFκB was observed, and it was noted that forskolin reduces IL-1β-induced 
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nuclear and cytosolic phospho p-65 and phospho c-jun protein expression at 1 hour, and 
total c-fos, total c-jun, and total p65 protein expression significantly (Figs. 4-3 and 4-4). 
Interestingly, in the absence of inflammation, total c-jun protein expression was reduced by 
forskolin alone, suggesting that forskolin reduced basal level of total c-jun (Figs 4-4 B). 
 
4.2.3. Cyclic AMP increases IL-1β driven MKP-1 and IκBα gene expression. 
 
Figure 4-5. Cyclic AMP increases IL-1β driven MKP-1 gene expression.  
Myometrial cells were isolated as described above in Materials and Methods, and treated with IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. mRNA were extracted, and the levels of 
MKP-1 mRNA expression were measured using quantitative rt-PCR. Data are shown as the mean and SEM, and 
were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were 
not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were 
normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. Analysis of 2 groups was 
performed using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for 
data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-1β is compared to 100F + IL-1β 
(n=8-9 in each experiment). 
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Figure 4-6. Cyclic AMP increases IκBα expression at both mRNA and protein level.  
Myometrial cells were isolated as described above in Materials and Methods, and treated with IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. mRNA (A) and protein (B) were 
extracted, and the levels of IκBα mRNA and IκBα proteins expression were measured using rt-PCR and western 
blotting respectively. C. On a separate experiment, myometrial cells were isolated from myometrial biopsies 
obtained from women at the time of pre-labour term Caesarean section as described above in Materials and 
Methods, and treated with forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 1 hour. Cells 
were lysed and samples purified for cytoplasmic protein. Western blotting was performed using antibodies 
directed against IκBα. α-tubulin were used as the control for cytosolic fraction. The representative blot can be 
found on Figure 6-10. Data are shown as the mean and SEM, and were compared using Friedman’s Test, with a 
Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with 
Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 
when compared to control. Analysis of 2 groups was performed using Wilcoxon matched pairs test for data 
that were not normally distributed and paired t test for data that were normally distributed #P<0.05, ##P<0.01, 
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###P<0.001 when IL-1β is compared to 100F + IL-1β (n=6-9 in each experiment). 
 
The ablilty of cAMP to increase MKP-1 and IκBα gene expression was also studied. As 
previously described, mitogen-activated protein kinase (MAPK) activation has been 
implicated in the onset of parturition. MKP-1 catalyses the dephosphorylation of active 
MAPK, and reduces c-jun binding to the COX-2 promoter. Lei et al. have recently reported 
that progesterone acts via GR-induced increase in MKP-1 activity to repress IL-1β-driven 
COX-2 mRNA expression. Thus, it may well be possible that the anti-inflammatory effect of 
cAMP is mediated via MKP-1. Figure 4-5 showed that treatment with forskolin increases the 
basal level of MKP-1 mRNA expression compared to control. The combination of forskolin 
and IL-1β compared to IL-1β alone is associated with a significant increase in MKP-1 mRNA 
expression.  
Figure 4-6 demonstrated the effect of forskolin on IL-1β-treated cells on IκBα gene 
expression.  Interestingly, IL-1β treatment caused an increase in IκBα mRNA level (Fig. 4-6 
A). However, this was not observed at protein level at both whole cell lysate and 
cytoplasmic portion of protein when under similar condition, IL-1β treatment caused a 
significant decrease in IκBα protein level (Fig. 4-6 B), and a trend towards a decrease in IκBα 
cytoplasmic protein level (Fig. 4-6 C). Forskolin treatment was associated with an increase in 
IκBα at both mRNA and protein expression (Figs. 4-6 A&B). The combination of forskolin and 
IL-1β compared to IL-1β alone was associated with a significant increase in IκBα mRNA and 
protein expression (Figs. 4-6 A&B), and a trend towards an increase in IκBα cytoplasmic 
protein level (Fig. 4-6 C). This increase in IκBα protein expression with the combination of 
forskolin and IL-1β could possibly explain the reduction in phospho p65 levels as shown in 
Fig. 4-3 A&B. 
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4.2.4. The effect of cAMP in IL-1β driven AKIP1 gene expression. 
 
Figure 4-7. The effect of cAMP in IL-1β driven AKIP1 gene expression. 
Myometrial cells were isolated as described above in Materials and Methods, and treated with IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. mRNA were extracted, and the levels of 
MKP-1 mRNA expression were measured using quantitative rt-PCR. Data are shown as the mean and SEM, and 
were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were 
not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were 
normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. Analysis of 2 groups was 
performed  using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for 
data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-1β is compared to 100F + IL-1β 
(n=8-9 in each experiment). 
 
As previously discussed, AKIP1 has recently been described to function as a molecular 
switch, determining whether cAMP/PKA positively or negatively affects NFκB activity (369). 
The effect of forskolin and IL-1β stimulation on primary myometrial cells, either alone or in 
combination was explored. Results shown in Figure 4-7 revealed that IL-1β and forskolin 
treatment drove and repressed AKIP1 mRNA and protein expression respectively. The 
combination of IL-1β and forskolin compared to IL-1β alone was associated with a significant 
reduction of AKIP1 expression at both mRNA and protein level.  
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4.2.5. AKIP1 acts a molecular switch in determining the anti-inflammatory action of cAMP 
in human myometrial cells. 
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Figure 4-8. The effects of cAMP effectors, nuclear receptors, and AKIP1 knock down on the ability of cAMP in 
mediating IL-1β-induced COX-2 mRNA expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
AKIP1, cAMP effectors such as PKAC-α, Epac1, AMPK, and nuclear receptors such as PR, GR and MKP-1 were 
knocked down using siRNA (siAKIP1, siPKAC-α, siEpac1, siAMPK, siPR, siGR and siMKP-1, controlled with non-
targeted siRNA [siNT]). A. Myometrial cells were knocked down using siNT. Representative western blots to 
demonstrate transfection is shown above (B-H). After transfection, cells were incubated for 96 hours before 
being treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in combination for 6 hours. The 
mRNA were extracted, and the levels of COX-2 mRNA were measured using rt-PCR. Data are shown as the 
mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test 
for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. Analysis of 2 
groups was performed using Wilcoxon matched pairs test for data that were not normally distributed and 
paired t test for data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-1β is compared 
to 100F + IL-1β (n=6-36). 
 
The effect of AKIP1, cAMP effectors, and nuclear receptor knock down on the abiliy of cAMP 
to enhance IL-1β-induced COX-2 mRNA expression was explored.  The results showed that 
compared to the siNT knockdown cells (Fig. 4-8 A), the ability of forskolin to increase IL-1β-
induced COX-2 mRNA expression is completely reversed with AKIP1 knockdown (Fig. 4-8 B). 
On the contrary, with AKIP1 knockdown, forskolin reduces IL-1β-induced COX-2 mRNA 
expression (Fig. 4-8 B).  Although it is not statistically significant there is a trend towards an 
increase in COX-2 mRNA expression when the combination of forskolin and IL-1β is 
compared to IL-1β alone in Epac, AMPK, and PR knocked down cells, and no difference in 
MKP-1 knocked down cells. In summary, in contrast to the dramatic effect of AKIP1 
knockdown, the knockdown of cAMP effectors and of GR and PR, and MKP-1 has a minimal 
effect on the ability of forskolin to enhance IL-1β-driven COX-2 expression (Figs. 4-8 C-H). 
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Figure 4-9. The effects of AKIP1 knock down on the ability of cAMP in mediating IL-1β-induced COX-2 protein 
expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
AKIP1, were knocked down using siRNA (siAKIP1, controlled with non-targeted siRNA [siNT]). Representative 
western blots to demonstrate transfection is shown above. After transfection, cells were incubated for 96 
hours before being treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in combination for 6 
hours. Proteins were extracted, and the levels of COX-2 protein were measured using western blotting. Data 
are shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and 
Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 (n=7-9). 
 
Based on the results shown in Fig 4-8 B, the effect of AKIP1 expression knockdown on the 
ability of forskolin to increase IL-1β-driven COX-2 mRNA expression were reflected at the 
protein level (Fig. 4-9).  
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Interestingly, there is a statistically significant decrease in COX-2 protein expression in AKIP1 
knocked down cells treated with forskolin and IL-1β compared to cells treated with non-
target siRNA (Fig. 4-9). Although it was not statistically significant, there was generally a 
trend towards a decrease in COX-2 protein gene expression in AKIP1 knocked down cells 
treated with IL-1β compared to cells knocked down with non-target siRNA treated with the 
same condition. These data implies that AKIP1 enhanced IL-1β-driven COX-2 protein 
expression. In contrast, AKIP1 knock down had no effect on the ability of forskolin to repress 
IL-1β driven IL-8, IL-1β, and OTR mRNA expression (Appendix 3). 
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4.2.6. The effect of AKIP1 knock down on the ability of forskolin in repressing IL-1β driven 
phospho p65 and phospho c-jun at nuclear and cytosolic protein level in human 
myometrial cells. 
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Figure 4-10. The effects of AKIP1 knock down on the ability of cAMP in repressing IL-1β-induced nuclear 
transfer of phospho p65.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
AKIP1 was knocked down using siRNA (siAKIP1, controlled with non-targeted siRNA [siNT]). Representative 
western blots to demonstrate the efficacy of the knockdown are shown above. After transfection, cells were 
incubated for 96 hours before being treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in 
combination for 30 minutes and 60 minutes. Cells were lysed and samples purified for cytoplasmic or nuclear 
protein. Western blotting was performed using antibodies directed against phospho-p65 (Ser536). α-tubulin 
and TATA-bind protein (TBP) were used as the internal controls for cytosolic (A) and nuclear (B) fraction, 
respectively. Data are shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's 
Multiple Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with 
Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 
(n=6). 
 
In order to establish whether AKIP1 changes the ability of cAMP to repressing IL-1β-induced 
nuclear transfer of phospho p65 and phospho c-jun, a nucleo-cytoplasmic study was 
performed. The results showed that at 30 minutes and 60 minutes time points, forskolin 
treatment is associated with a reduction of IL-1β induced phospho p-65 (Fig. 4-10) and 
phospho c-jun (Fig. 4-11) at both nuclear and cytosolic levels in both AKIP1 knocked down 
cells and cells treated with non-target siRNA. More reduction in phospho p-65 (Fig. 4-10) 
and phospho c-jun (Fig. 4-11) is observed in AKIP1 knocked down cells compared to cells 
treated with non-target siRNA. These data supports the earlier observation (Fig. 4-9), that 
the ability of IL-1β to drive phospho p-65 (Fig. 4-10) and phospho c-jun (Fig. 4-11) gene 
expression in AKIP1 knocked down cells is generally less when compared to cells treated with 
non-target siRNA. 
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Figure 4-11. The effects of AKIP1 knock down on the ability of cAMP to repress IL-1β-induced nuclear 
transfer of phospho c-jun.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
AKIP1, were knocked down using siRNA (siAKIP1, controlled with non-targeted siRNA [siNT]). Representative 
western blots to demonstrate the efficacy of the knockdown are shown above. After transfection, cells were 
incubated for 96 hours before being treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in 
combination for 30 minutes and 60 minutes. Cells were lysed and samples purified for cytoplasmic or nuclear 
protein. Western blotting was performed using antibodies directed against phospho-c-jun. α-tubulin and TBP 
were used as the internal controls for cytosolic (A) and nuclear (B) fraction, respectively. Data are shown as 
the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc 
test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 (n=6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
4.2.7. Cyclic AMP levels are down-regulated with labour, whereas AKIP1 and COX-2 levels 
are up-regulated with term labour.  
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Figure 4-12. Cyclic AMP levels are down-regulated with labour, whereas AKIP1 and COX-2 levels are up-
regulated with term labour.  
Human myometrial tissue samples were collected from different groups of non-labouring and labouring 
women at the time of Caesarean section. Women were recruited in four defined groups: preterm not in labour 
(PTNL) (24-36 weeks), term not in labour (TNL) (>37 weeks), term early labour (TEaL) (3-4 contractions in 10 
minutes and <3cm dilated cervix) and term established labour (TEsL) (3-4 contractions in 10 minutes and >3cm 
dilated cervix). Samples were snap frozen at -80
o
C for cAMP assay, and mRNA and protein extraction. A. 
Myometrial tissue was ground in a mortar and pestle under liquid nitrogen and cAMP assay was subsequently 
performed using the cAMP Chemiluminescent Immunoassay kit (Arbor Assays, USA) following the 
manufacturer’s instructions. The levels of AKIP1 (B), and COX-2 (D) mRNA and protein (C, E) were measured 
using quantitative rt-PCR and western blotting respectively. A representative Western blot is shown above 
each protein graph displaying the densitometry of the protein levels. Blots were probed with AKIP1 and COX-2 
antibody, and GAPDH was used as a loading control. Data are shown as the mean and SEM, and were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Bonferroni’s post-test for data that were normally distributed. 
*P<0.05, **P<0.01, ***P<0.001 (n=12 in each group).  
 
The effect of different stages of pregnancy and labour on cAMP level and AKIP1 gene 
expression in myometrial tissue were explored. The data showed that there was an increase 
in cAMP level from preterm non-labour group to term non labour group before it declined 
from term non labour group to term early labour group (Fig. 4-12 A). AKIP1 expression on 
the other hand, was down-regulated in pregnancy and increased with the process of labour, 
reaching its peak in the term early labour group at mRNA level (Fig. 4-12 B) and term 
established labour group at protein level (Fig. 4-12 C). The trend in AKIP1 gene expression at 
the end of pregnancy and labour was mirrored in COX-2 gene expression (Fig. 4-12 C,E). 
Earlier in pregnancy, the higher COX-2 coincided with lower AKIP implying that other factors 
may be driving its expression at this point. At the end of pregnancy, the changes in AKIP 
levels could help to explain the changes in COX-2 mRNA expression. Collectively, these data 
strongly suggest that during pregnancy, when the AKIP1 expression level was low, cAMP 
acts to inhibit inflammation in order to maintain uterine relaxation, hence the down-
regulation of COX-2 gene expression, this effect was then removed during parturition when 
AKIP1 expression level was at its peak, hence driving cAMP to act as pro-inflammatory, 
resulting in the up-regulation of COX-2 gene expression to promote uterine contractility.  
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Although it was not statistically significant, there was a trend towards a decrease in COX-2 
mRNA and protein from preterm non labour to term non labour group (Fig. 4-12 D&E). 
Unpublished findings from the group (Singh et al.) showed that there was a significant 
reduction in the expression of downstream enzymes PGF synthase (PGFS) protein from 
preterm non labour to term non labour group. PGFS is the enzyme that converts PGH2 into 
PGF2alpha, which plays a key pro-contractile role in the labour process (455). It is well 
recognised that the PG pathways play vital roles in the maintenance of pregnancy and the 
initiation of both preterm and term labour (109). Indeed, PGI2 has been reported to have a 
dual role, maintaining myometrial quiescence on the one hand and the other priming the 
myometrium for the initiation of labour at term (109).   
The mechanism of how AKIP1 interacts with cAMP remains to be investigated further. 
Previous work has investigated the effects of AKIP1 in breast cancer cells (369) but to date, 
this has not been investigated in myometrium. As labour is believed to be an inflammatory 
process, AKIP1 may function as a molecular switch in myometrium, influencing cAMP action 
towards NFκB activity. It is possible that in myometrium, AKIP1 may possess different 
functions or may alter the behaviour of cAMP in a manner different from other types of 
cells. Alternatively, AKIP1 may play a role in altering the expression of PG synthetic enzymes 
during gestation and at the onset of labour. For instance, a low AKIP1 expression during 
gestation may be in favour for the high expression of relaxatory PGs, thus the maintenance 
of myometrial quiescence, and increasing level of AKIP1 expression at the onset of labour is 
in favour of pro-contractile PGs. To date, there is no study that has explored this 
relationship and will be interesting to investigate this in the future. 
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4.2.8. The effect of stretch and inflammation on AKIP1 expression.  
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Figure 4-13. The effect of stretch and inflammation on AKIP1 expression.  
A. Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour 
term Caesarean section. Myometrial cells were grown up to passage 3 and plated on to the stretched plates. 
Cells were stretched for 30 hours in total. At 24 hour, cells were incubated for an additional 6 hours in the 
absence and presence of IL-1β (1ng/mL). mRNA was extracted and the level of AKIP1 mRNA were measured 
using rt-PCR (n=6-9). B-E. Human myometrial tissue samples were collected from different groups of non-
labouring and labouring women at the time of Caesarean section. Women were recruited in two defined 
groups: preterm not in labour (PTNL) (24-36 weeks), preterm in labour with evidence of chorioamnionitis as 
stated in Materials and Methods. Samples were snap frozen at -80
o
C for mRNA and protein extraction. The 
levels of AKIP1 mRNA (B,D), and AKIP1 (C,E) proteins were measured using rt-PCR and western blotting 
respectively. A representative western blot is shown above each protein graph displaying the densitometry of 
the protein levels. Blots were probed with AKIP1, and GAPDH was used as a loading control. Data are shown as 
the mean, and SEM, and were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed. *P<0.05, **P<0.01 (n=11-17 in each 
group).  
 
In order to find out what regulates AKIP1 expression in myometrium, the impact of stretch 
and inflammation was studied. Stretch and inflammation on its own is associated with a 
significant increase in AKIP1 mRNA expression (Figs. 4-13 A), but the combination of stretch 
and inflammation is not associated with a significant increase in AKIP1 expression, 
compared to stretch or inflammation alone. As inflammation and stretch is associated with 
an increase in AKIP1 expression in myometrial cells, we extended our observations to 
myometrial tissues. The relationship between inflammation and stretch was explored 
further by studying myometrial tissues collected from women whose pregnancies were 
complicated by preterm chorioamnionitis and twins (before and after labour onset).  
 
The results in Fig. 4-13 C showed that infection associated with chorioamnionitis and labour 
down-regulates AKIP1 mRNA expression, but AKIP1 protein levels are markedly elevated (Fig. 
4-13 B).  In contrast, in twin pregnancies, labour is associated with an increase in both AKIP 
mRNA expression and protein levels (Fig. 4-13 D&E). The differences in mRNA and protein 
have been discussed before, but these data may reflect that AKIP1 protein is stable and not 
broken down easily, and hence the higher expression at protein level. The increases in AKIP 
may contribute to the onset of labour in these situations.  
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The results above suggest that the process of infection may be associated with the increase 
in the AKIP1 expression, and this may contributes to a statistically significant increase in OTR, 
Epac1 (Figs. 3-10 I-L), and inducible cyclic AMP early repressor (ICER) mRNA and protein 
expression (Appendix 4). The activity of ICER is greatly affected by its intracellular 
concentration, as once increased, it may down-regulates its own expression, establishing an 
autoregulatory feedback loop (456). ICER has more effective binding activity than that of 
CREM activator, allowing it to competitively block the binding of the CREM activator, such as 
CREB. In addition to the above findings, although there is no significant difference between 
the two groups at protein level, infection also leads to the increase of CBP mRNA expression 
(Appendix 4).  
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4.3. Summary and Discussion 
The results shown in this chapter demonstrated the possible anti-inflammatory action of 
cAMP in human myometrial cells studied. This is consistent with the findings of others, 
where the anti-inflammatory action of cAMP in various cell types was demonstrated (364-
367).  Forskolin, an adenylyl cyclase activator, which increases the intracellular level of 
cAMP (430), was shown to repress IL-1β-induced pro-inflammatory cytokine expression in 
human myometrial cells studied in this chapter (Appendix 2). A similar trend is also noted in 
OTR mRNA and protein expression, where in cells treated with the combination of forskolin 
and IL-1β compared to cells treated with IL-1β alone, a significant reduction in OTR mRNA 
and protein expression is observed (Figs. 4-1, 4-2).  
Forskolin also reduces IL-1β-induced nuclear and cytosolic, and total c-jun, and total p65 
protein levels significantly (Figs. 4-3, 4-4). Moreover, in the absence of inflammation, total c-
jun protein levels were reduced by forskolin alone, suggesting that forskolin is able to reduce 
basal level of total c-jun (Fig. 4-4). In addition, treatment with forskolin increases the basal 
level of MKP-1 and IκBα gene expression, and the combination of forskolin and IL-1β 
compared to IL-1β alone is associated with a significant increase in MKP-1 and IκBα gene 
exresssion (Figs. 4-5, 4-6). These findings have been supported by earlier studies, which 
have shown that cAMP, acting via PKA, reduces NFκB activity by impairing its ability to bind 
DNA (376), altering the p65 transactivation domain (412) and inhibiting IκBα degradation 
(365, 411). The effect on IκBα degradation was blocked by H89, suggesting that it is 
mediated via PKA activation (457). 
In an attempt to understand the role of AKIP1 in the modulation of the cAMP pathway 
activity, AKIP1 expression was knocked down. In control cells (cells knocked down with non-
target siRNA), forskolin enhanced IL-1β-induced COX-2 mRNA and protein expression (Fig. 4-
8), however, knockdown of AKIP1 expression blocked the ability of forskolin to increase IL-
1β-induced COX-2 mRNA and protein expression and the addition of forskolin actually 
inhibited the IL-1β-induced increase in COX-2 mRNA and protein levels (Fig. 4-8). These 
findings suggest that AKIP1 may act as a molecular switch in myometrial cells, determining 
whether cAMP/PKA enhances or represses inflammation. Indeed, AKIP1 seems to enhance 
IL-1β -NFκB activation and nuclear translocation as others have found in other cells types 
(369, 381). However, although AKIP1 expression knockdown appeared to reduce cytosolic c-
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Jun phosphorylation, it had no effect on nuclear transfer (Fig. 4-11). These data suggest that 
when the AKIP1 expression level is low, cAMP may play a role in inhibiting NFκB activity to 
maintain uterine relaxation, conversely when AKIP1 expression is high, COX-2 expression is 
increased contributing to the process of labour. It would be interesting to explore whether 
AKIP1 influences other componenets of the PG synthetic pathway. 
As previously described in the introductory chapter that in cells expressing AKIP1, cAMP-
activated PKA is targeted to NFκB-dependent promoters, where it phosphorylates p65, 
leading to recruitment of CBP and enhanced transcriptional activation (151). In cells that do 
not express AKIP1 or have low levels of AKIP1 expression, PKA preferentially phosphorylates 
CREB and consequently reduced NFκB-dependent gene expression (151). Although this may 
be true for other types of cells, in the myometrium there was no evidence that this might be 
happening. There was no significant difference observed in the expression of phospho CREB 
in both nuclear and cytosolic protein between cells knocked down with siNT and siAKIP1 
treated under the same conditions in myometrium (results not shown), suggesting that 
myometrial cells that did not express AKIP1 or have low levels of AKIP1 expression, PKA did 
not preferentially phosphorylates CREB. More research needs to be done in human 
myometrial cells in order to explore how transcription factor(s) activation is modulated by 
AKIP1 knockdown. Only then will we be able to study the interaction of the transcription 
factor(s) with COX-2 promoter, and thus establish the possible mechanism(s) on how AKIP1 
expression knockdown contribute to the anti-inflammatory action of cAMP. 
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Chapter 5: 
The Molecular Mechanisms by which cAMP 
Enhances Progesterone Driven Gene 
Expression in Human Myometrial Cells 
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5. The Molecular Mechanisms by which cAMP Enhances Progesterone Driven 
Gene expression in Human Myometrial Cell 
 
5.1. Introduction 
Cyclic AMP enhances progesterone activity in various settings (385, 389, 390), and the 
reciprocal has also been shown to be true (385, 458). Previous studies have demonstrated 
that cAMP enhances the transcriptional activities of other nuclear receptors such as 
glucocorticoid receptor, oestrogen receptor, and retinoic acid receptor (459-461). In the 
clinical setting, the interaction between cAMP and the glucorticoid receptor play an 
essential role in the management of asthma, where β-agonists have been able to augment 
steroid action and to reverse steroid resistance (462, 463). In a similar context, the effect of 
increased in cAMP levels in the case of the oestrogen receptor may play an important role in 
tamoxifen resistance observed in breast cancer (464). 
Progesterone has been shown to play fundamental role in all aspects of female reproductive 
function from sexual behaviour, mammary gland development, ovulation and implantation, 
and most importantly in relation to this study, to the maintenance of pregnancy (465, 466). 
Studies over the years have shown that progesterone administration may be effective in 
reducing the risk of preterm labour in high-risk singleton pregnancies by up to 40% (65, 66). 
However, for others such as women whose pregnancies are complicated by multiple 
pregnancy, treatment with progesterone alone does not reduce the risk of preterm labour 
(27).  
Consequently, the ability of cAMP to enhance progesterone action may be important both 
physiologically and therapeutically. However, the mechanism(s) involved in cAMP 
potentiation of progesterone driven gene expression remains to be elucidated. As the 
myometrium is a potentially important site of cAMP/progesterone interaction, in this 
chapter the ability of a cAMP-elevating agent, forskolin, to enhance progesterone action in 
pregnant human myometrial cells and the mechanism(s) involved has been studied.  
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5.2. Results 
 
5.2.1 The effect of progesterone and cAMP on the expression of progesterone responsive 
genes 
 
 
 
Figure 5-1. The effect of progesterone and cAMP on mRNA expression of progesterone responsive genes.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with progesterone (at 0.1, 0.5, 1, 5 and 10μM) (A-C) or 
forskolin (1, 10 and 100µM) (D-F) for 24 hours. The levels of 11βHSD1, MKP-1, IκBα mRNA were measured 
using quantitative rt-PCR. Data are shown as the mean and SEM, and were compared using Friedman’s Test, 
with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using 
ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed. *P<0.05, **P<0.01, 
***P<0.001 when compared to control (n=7-8). 
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Figure 5-2. Cyclic AMP enhances progesterone in driving the mRNA expression of progesterone responsive 
genes. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with progesterone (at 0.1, 0.5, 1, 5 and 10μM) and 
forskolin (1, 10 and 100µM) either alone or in combination for 24 hours. The levels of 11βHSD1 (A), MKP-1 (B), 
IκBα (C) mRNA were measured using quantitative rt-PCR. Data are shown as the mean and SEM, and were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
distributed. $P<0.05, $$P<0.01, $$$P<0.001 when the combination of forskolin and progesterone was 
compared to the corresponding forskolin dose alone and # P<0.05, ## P<0.01, ### P<0.001 when the 
combination of forskolin and progesterone was compared to the corresponding progesterone dose alone (n=7-
8).  
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Figure 5-3. The effect of progesterone and cAMP on FKBP51 mRNA expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with progesterone (at 0.1, 0.5, 1, 5 and 10μM) (A) or 
forskolin (1, 10 and 100µM) (B) for 24 hours. The levels of FKBP51 mRNA were measured using quantitative rt-
PCR. Data are shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and 
Bonferroni’s post-test for data that were normally distributed. *P<0.05, **P<0.01, ***P<0.001 when 
compared to control (n=7-8). 
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Figure 5-4. Cyclic AMP enhances progesterone in driving the protein expression of progesterone responsive 
genes.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with progesterone (at 0.1, 1, and 10μM) and forskolin 
(100µM) either alone or in combination for 24 hours. The levels of 11βHSD1 (A,B), MKP-1 (C,D), and IκBα (E,F) 
proteins were measured using western blotting. Data are shown as the mean, and SEM and, were compared 
using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that 
were normally distributed (Figs B,D,F). *P<0.05, **P<0.01, ***P<0.001, $ P<0.05, $$ P<0.01 when compared 
with 100F (n=8-9). 
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In this chapter, the ability of progesterone in the presence and absence of forskolin to drive 
the expression of progesterone responsive genes such as, 11beta-hydroxysteroid 
dehydrogenase type I (11βHSD1), mitogen-activated protein kinase phosphatase 1 (MKP-1), 
and IκBα was assessed. 11βHSD1 gene was previously identified as being most sensitive to 
progesterone in myometrial cells. Results above showed that progesterone was found to 
increase the level of 11βHSD1 mRNA in a dose dependent manner with the highest 
response noted on the cells treated with 10µM progesterone (Fig. 5-1 A). With regards to 
MKP-1, treatment with 10µM progesterone significantly increased the level of gene 
expressions compared to control (Fig. 5-1 B). Although there was a trend observed with 
regards to the increased level of IκBα mRNA gene expressions with 5µM progesterone and 
10µM progesterone treatment, this increase was not statistically significant (Fig. 5-1 C). 
Treatment with forskolin alone increased the level of 11βHSD1, MKP-1 and IκBα mRNA in 
dose dependent manner, with the highest response noted on the cells treated with 100µM 
forskolin (Figs. 5-1 D-F).  It was observed that forskolin significantly increased the 
progesterone-induced expression of 11βHSD1, IκBα, and MKP-1 mRNA levels in a dose 
dependent manner (Figs. 5-2 A-C). In relation to 11βHSD1, the maximal up-regulation was 
seen with the combination of 10µM progesterone and 100µM forskolin at the 24h time 
point (Fig .5-2 A). For MKP-1, the optimal response was seen with the combination of 10µM 
P4 and 100µM forskolin at 24h time point (Fig. 5-2 B). With regards to IκBα, a statistically 
significant increase of the gene expression was noted with combination of 10µM P4 and 
100µM forskolin at the 24h time point (Fig. 5-2 C).  Besides 11βHSD1, FKBP51 was also one 
of progesterone most responsive genes. Although 5µM progesterone and 10µM 
progesterone treatment has significantly increased FKBP51 mRNA expression (Fig. 5-3 A), 
intriguingly, forskolin stimulation seemed to have down-regulate its expression (Fig. 5-3 B). 
The combination of progesterone and forskolin is not associated with significant increase of 
the level of FKBP51 mRNA expression (data not shown). Similar trends (statistically not 
significant) were also observed in PR-B and PR-Total gene expressions (data not shown). The 
enhancement expression of the progesterone responsive genes 11βHSD1, MKP-1, and IκBα 
by the addition of forskolin to progesterone was also mirrored in the protein levels (Figs. 5-4 
A-F).  
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Progesterone and forskolin dose response experiments were performed on preterm non-
labouring primary myometrial cells, and progesterone and forskolin stimulation increases 
11βHSD1, MKP-1 and IκBα mRNA expression in dose dependent manner (Appendix 5). The 
results showed that progesterone treatment resulted in the increase of FKBP51 mRNA 
expression with the highest response was noted with stimulation of 10µM progesterone. As 
in the term samples, forskolin reduced FKBP51 mRNA expression (Appendix 5). These results 
showed that progesterone and forskolin have similar effects on progesterone responsive 
genes in myometrial cells derived from both preterm and term myometrial biopsies. 
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5.2.2. The effect of cAMP effector knockdown and cAMP effectors antagonists on the 
ability of cAMP to enhance the expression of progesterone responsive genes  
 
cAMP effectors knockdown  
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Figure 5-5. The effect of cAMP effectors knockdown on the mechanisms of how cAMP enhances 
progesterone modulation of gene expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. PKAC-α, EPAC1 and AMPK were knocked down using siRNA (siPKAC-α, siEPAC1 and siAMPK, 
controlled with non-targeted siRNA [siNT]). Representative western blots to demonstrate transfection is 
shown above (A-C). After transfection, cells were incubated for 96 hours before being treated with 
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progesterone (10μM) and or forskolin (100µM) for 6 hours either alone or in combination. mRNA and proteins 
were extracted, and the levels of 11βHSD1 (D), MKP-1 (E), IκBα (F) mRNA and proteins were measured using 
rt-PCR and western blotting respectively. Data are shown as the mean, and SEM, and were compared using 
Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that were 
normally distributed. #P<0.05 ##P<0.01, ###P<0.001 when compared between the corresponding forskolin 
treated cells F in siNT, siPKA, siEPAC1, and siAMPK cells to the corresponding combination of progesterone and 
forskolin P4 + F in siNT, siPKA, siEPAC1, siAMPK knocked-down cells (n=6) NS=not significant.  
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cAMP effectors antagonists 
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Figure 5-6. The effect of cAMP effectors antagonists on the mechanisms of how cAMP enhances 
progesterone modulation of gene expression.   
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated and after the cells were approximately 80% confluent, 
the cells were pre-incubated with KT5720 (PKA antagonist) (10μM), or Brefeldin A (Epac antagonist) (100µM), 
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or Compound C (AMPK antagonist) (100µM) for 30 minutes before being exposed to different stimuli. 
Depending on the experimental conditions, the cells were stimulated with progesterone (10μM) and or 
forskolin (100µM) for 6 hours. mRNA and proteins were extracted, and the levels of 11βHSD1 (A), MKP-1 (B), 
IκBα (C) mRNA and proteins were measured using rt-PCR and western blotting. Data are shown as the mean, 
and SEM, and were compared using Wilcoxon matched pairs test for data that were not normally distributed 
and paired t test for data that were normally distributed. #P<0.05 ##P<0.01, ###P<0.001 when compared 
between the corresponding forskolin treated cells (F) in cells treated with and without cAMP effectors 
antagonists to the corresponding combination of progesterone and forskolin (P4 + F) in cells treated with and 
without cAMP effectors antagonists (n=5-6) NS=not significant.  
 
In order to investigate the interactions of progesterone and forskolin, and the molecular 
mechanisms involved in cAMP-induced enhancement of progesterone responsive genes 
expression, cAMP effectors were knocked down, using siRNA to PKACα, Epac1 and AMPK. 
The results above showed that knockdown of PKA-Cα blocked the forskolin-induced 
enhancement of 11βHSD1 mRNA expression (Fig 5-5 Di). On the contrary, knockdown of 
PKA-Cα had minimal effect on MKP-1 mRNA expression (Fig 5-5 Ei). Intriguingly, although 
the combination of progesterone and forskolin enhanced the level of IκBα mRNA gene 
expression on PKA-Cα knockdown cells, this enhancement is much smaller compared to siNT 
treated cells (Fig 5-5 Fi), similar trend is observed with regards to Epac1 and AMPK knocked 
down cells on level of IκBα mRNA gene expression, suggesting that the cAMP effectors are 
essential for the increase of IκBα mRNA gene expression. Epac1 knockdown had minimal 
effects on 11βHSD1 and MKP-1 mRNA gene expression (Figs 5-5 Di&Ei). Knockdown of 
AMPK had minimal effect on 11βHSD1, and MKP-1 mRNA gene expression compared to siNT 
cells (Figs 5-5 Di&Ei).  
Similar experiments were repeated to explore the effect of the cAMP effectors knockdown 
on the protein levels. In general, the knock down of Epac1 and AMPK has minimal effects on 
11βHSD1, MKP-1, and IκBα protein expression (Figs 5-5 Dii,Eii,Fii). However it is clearly 
demonstrated that with the PKA knockdown, the combination of progesterone and forskolin 
can no longer able to enhance progesterone in driving the protein expression of 11βHSD1, 
MKP-1, and IκBα (Figs 5-5 Dii,Eii,Fii).  
The mRNA data with the siRNA against the cAMP effectors indicated that the transfection 
process may alter the basal responses of 11βHSD1, MKP-1, and IκBα mRNA gene expression. 
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Consequently, chemical antagonists of the cAMP effectors were used to investigate and 
confirm the mechanisms involved in cAMP-induced enhancement of progesterone 
responsive genes expression. The results above showed that the addition of PKA antagonist 
has minimal effect on 11βHSD1 mRNA gene expression, and that the combination of 
progesterone and forskolin in the presence of PKA antagonist still able to enhance 11βHSD1 
mRNA gene expression, a pattern which was not observed in the PKA knocked down cells 
(Figs 5-6 Ai,Bi,Ci). Intriguingly, the addition of AMPK antagonist has affected the ability of 
progesterone and forskolin in enhancing 11βHSD1 and IκBα RNA mRNA expression (Figs 5-6 
Ai&Ci). Similar pattern was also noted with the addition of Epac1 antagonist on IκBα mRNA 
gene expression (Figs 5-6 Ci). The addition of cAMP effectors had minimal effect on MKP1 
mRNA gene expression (Figs 5-6 Bi).  Overall the pattern of mRNA changes was not as 
expected, but with regards to the effects at the protein level, the results were more 
consistent with the knockdown protein data (Figs 5-5). The addition of the PKA antagonist in 
the above experiments has impaired the ability of progesterone and forskolin to increase 
11βHSD1, MKP-1, and IκBα protein expression, suggesting that PKA is a key cAMP effector 
mediating cAMP effect in enhancing progesterone responsive genes (Figs 5-6 Aii, Bii, Cii).  
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5.2.3. The effect of nuclear receptors knockdown and nuclear receptors antagonists on the 
ability of cAMP in enhancing mRNA expression of progesterone responsive genes  
Nuclear receptors knockdown 
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Figure 5-7. The effect of nuclear receptors knockdown on cAMP enhancement of progesterone driven genes 
expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. PR and GR were knocked down using siRNA (siPR and siGR, controlled with non-targeted 
siRNA [siNT]). Representative western blots to demonstrate transfection is shown above (A-B). After 
transfection, cells were incubated for 96 hours before being treated with progesterone (10μM) and or 
forskolin (100µM) for 6 hours either alone or in combination. C-E mRNA were extracted, and the levels of 
11βHSD1, MKP-1, IκBα mRNA were measured using rt-PCR. Data were shown as the mean, and SEM, and were 
compared using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for 
data that were normally distributed. #P<0.05 ##P<0.01, ###P<0.001 when compared between the 
corresponding forskolin treated cells (F) in siNT, siPR, and siGR cells to the corresponding combination of 
progesterone and forskolin (P4 + F) in siNT, siPR, and siGR knocked-down cells (n=6) NS=not significant.  
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Nuclear receptors antagonists 
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Figure 5-8. The effect of nuclear receptors antagonists on the ability of cAMP in enhancing mRNA expression 
of progesterone responsive genes.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated and after the cells were approximately 80% confluent, 
the cells were pre-incubated with mirepristone (RU486 1 μM) (PR/GR antagonist) for 30 minutes before being 
exposed to different stimuli. Depending on the experimental conditions cells were stimulated with 
progesterone (10μM) and or forskolin (100µM) for 6 hours either alone or in combination. mRNA and proteins 
were extracted, and the levels of 11βHSD1 (A), MKP-1 (B), IκBα (C) were measured using rt-PCR and western 
blotting. The representative blots shown on figure Aii, Bii, Cii, are blots that were taken on the same western 
blots. Data are shown as the mean, and SEM, and were compared using Wilcoxon matched pairs test for data 
that were not normally distributed and paired t test for data that were normally distributed. #P<0.05 ##P<0.01, 
###P<0.001 when compared between the corresponding forkolin treated cells (F) in cells treated with and 
without nuclear receptors antagonists to the corresponding combination of progesterone and forskolin (P4 + F) 
in cells treated with and without nuclear receptors antagonists (n=5-6).  
 
 
The role of nuclear receptors such as PR and GR in mediating the ability of cAMP to enhance 
progesterone responsive genes was studied. It was observed that knockdown of PR and GR 
has minimal effect in the ability of forskolin to enhance progesterone in driving 11βHSD1 
and MKP-1 mRNA gene expression (Figs 5-7 C-D). On the other hand, the knockdown of PR 
and GR has impaired the ability of forskolin to enhance IKBα mRNA gene expression (Fig 5-7 
E). It is possible that in the absence of PR, progesterone may signal via GR and vice versa, 
perhaps explaining the lack of effect on both siPR and siGR on the expression of MKP-1 and 
11βHSD1. However, it is intriguing that in the case of IκBα, knock down of either appears to 
block the effect of the combination of progesterone and forskolin (Fig 5-7 E). 
To confirm these findings, a combined PR and GR antagonist, mifepristone, was added to 
investigate whether the same effects were achieved. Mifepristone appeared to have very 
little effect on 11βHSD1 and IκBα mRNA and protein expressions (Figs.5-8 Ai&ii, Ci&ii). With 
regards to MKP-1 expression, the addition of mifepristone had minimal effect on mRNA 
expression. However, the addition of mifepristone seemed to repress MKP-1 at protein level 
although this was not statistically significant (Fig.5-8 Bi&ii) 
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Figure 5-9. The effect of MKP-1 antagonist on the ability of cAMP in enhancing mRNA expression of 
progesterone responsive genes at mRNA level.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated and after the cells were approximately 80% confluent, 
the cells were pre-incubated with sanguinarine (Sang, 0.5 μM) (MKP-1 antagonist) for 30 minutes before being 
exposed to different stimuli. Depending on the experimental conditions cells were stimulated with 
progesterone (10μM) and or forskolin (100µM) for 6 hours either alone or in combination. mRNA were 
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extracted, and the levels of 11βHSD1 (A) and IκBα (B) were measured using qPCR. Data are shown as the 
mean, and SEM, and were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed. #P<0.05 ##P<0.01, ###P<0.001 when 
compared between the corresponding forskolin treated cells (F) in cells treated with and without MKP-1 
antagonist to the corresponding combination of progesterone and forskolin (P4 + F) in cells treated with and 
without MKP-1 antagonist (n=5-6).  
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Figure 5-10. The effect of MKP-1 antagonist on the ability of cAMP in enhancing mRNA expression of 
progesterone responsive genes at protein level.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated and after the cells were approximately 80% confluent, 
the cells were pre-incubated with sanguinarine (Sang, 0.5 μM) (MKP-1 antagonist) for 30 minutes before being 
exposed to different stimuli. Depending on the experimental conditions cells were stimulated with 
progesterone (10μM) and or forskolin (100µM) for 6 hours either alone or in combination. mRNA and Proteins 
were extracted, and the levels of 11βHSD1 (A) and IκBα (B) were measured using rt-PCR and western blotting. 
The representative blots shown on figure Aii, Bii, Cii, are blots that were taken on the same western blots. Data 
are shown as the mean, and SEM, and were compared using Wilcoxon matched pairs test for data that were 
not normally distributed and paired t test for data that were normally distributed. #P<0.05 ##P<0.01, 
###P<0.001 when compared between the corresponding forkolin treated cells (F) in cells treated with and 
without MKP-1 antagonist to the corresponding combination of progesterone and forskolin (P4 + F) in cells 
treated with and without MKP-1 antagonist (n=5-6).  
 
Recently, Lei et al. reported that progesterone acts via GR-induced increase in MKP-1 
activity to repress IL-1β-driven COX-2 mRNA expression (191). For this part of the study, the 
effect of MKP-1 knockdown to investigate whether the additive effects of forskolin and 
progesterone on progesterone responsive genes were also mediated via MKP-1 was studied. 
The data showed that MKP-1 knocked down had minimal effect in the ability of forskolin to 
enhance progesterone in driving 11βHSD1 and IκBα mRNA gene expressions (Figs. 5-9 B&C). 
The MKP-1 inhibitor, sanguinarine, repressed 11βHSD1 mRNA expression, but had no effect 
on its protein levels (Figs. 5-10 Ai&ii). Intriguingly, it did not affect MKP-1 mRNA, but 
appeared to reduced MKP-1 protein levels (results not shown). In the case of IκBα 
expression, sanguinarine had no effect at both mRNA and protein expression (Figs. 5-10 
Bi&ii). 
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5.2.4. The effect of cAMP effector knockdown and cAMP effector antagonists on the 
ability of cAMP to enhancing protein expression of progesterone receptor. 
 
 
 
Figure 5-11. Cyclic AMP enhances progesterone in driving the protein expression of progesterone receptor 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section. Cells were cultured and incubated with progesterone (at 0.1, 1, and 10μM) and forskolin 
(100µM) either alone or in combination for 24 hours. The levels of PRA/PRB (A, B) proteins were measured 
using western blotting. Data are shown as the mean, and SEM and, were compared using Wilcoxon matched 
pairs test for data that were not normally distributed and paired t test for data that were normally distributed. 
(A) *P<0.05 when PRA was compared to PRA control, and #P<0.05, when PRB was compared to PRB control.  
(B) *P<0.05 (n=8-9). 
 
The impact of progesterone and forskolin on PR-B and PR-A protein levels was also assessed. 
Forskolin alone, and in combination with progesterone, increased PRB protein levels at 24 
hours (Figs. 5-11 A-B). Progesterone reduced PRA protein levels expression and forskolin 
increased its expression significantly compared to control, however, the combination of 
progesterone and forskolin did not alter its expression compared to control (Figs. 5-11 A-B).  
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Figure 5-12. The effect of cAMP effector knockdown and cAMP effectors antagonists on the ability of cAMP 
in enhancing protein expression of progesterone receptor B. 
(A) Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour 
term Caesarean section. PKAC-α, EPAC1 and AMPK were knocked down using siRNA (siPKAC-α, siEPAC1 and 
siAMPK, controlled with non-targeted siRNA [siNT]). After transfection, cells were incubated for 96 hours 
before being treated with treated with progesterone (10μM) and or forskolin (100µM) for 6 hours either alone 
or in combination and the levels of PRB protein levels were measured using western blotting. The 
representative knock down blots were shown on Figure 5-5. (B) On a separate experiment, myometrial cells 
were isolated from myometrial biopsies obtained from women at the time of pre-labour term Caesarean 
section. Cells were cultured and incubated and after the cells were approximately 80% confluent, the cells 
were pre-incubated with KT5720 (PKA antagonist) (10μM), or Brefeldin A (Epac antagonist) (100µM), or 
Compound C (AMPK antagonist) (100µM) for 30 minutes before being exposed to different stimuli. Depending 
on the experimental conditions, the cells were stimulated with progesterone (10μM) and or forskolin (100µM) 
for 6 hours either alone or in combination. Proteins were extracted, and the levels of PRB were measured 
using western blotting. Data are shown as the mean, and SEM, and were compared using Wilcoxon matched 
pairs test for data that were not normally distributed and paired t test for data that were normally distributed. 
(A) #P<0.05 ##P<0.01, ###P<0.001 when compared between the corresponding forkolin treated cells (F) in 
siNT, siPKA, siEPAC1, and siAMPK cells to the corresponding combination of progesterone and forskolin (P4 + F) 
in siNT, siPKA, siEPAC1, siAMPK knocked-down cells (n=6). (B) #P<0.05 ##P<0.01, ###P<0.001 when compared 
between the corresponding forskolin treated cells (F) in cells treated with and without cAMP effectors 
antagonists to the corresponding combination of progesterone and forskolin (P4 + F) in cells treated with and 
without cAMP effectors antagonists (n=5-6).  
 
With regards to the increase in PRB levels induced by the combination of progesterone and 
forskolin, these seemed to be mediated via PKA as both PKA knockdown and PKA antagonist 
inhibited the increase, while EPAC and AMPK knockdown and antagonists had no effect (Figs. 
5-12 A&B). Although it was not statistically significant, the additional of PR/GR antagonist 
and MKP-1 antagonist on the other hand reduced the ability of combination of progesterone 
and forskolin to enhance the protein expression of PRB (Appendix 6).  Statistically, there was 
no significant difference observed in PRA and PRB to PRA ratios across the different 
treatment conditions (results not shown).  
 
Intriguingly, the western blots in Figure 5-12 demonstrated that there was a change in 
molecular weight of the PRB with the addition of progesterone and/or forskolin. From the 
blots, the addition of forskolin appeared to reduce the molecular weight of PRB, while the 
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combination of forskolin and progesterone seemed to increase it (Figs. 5-12 A&B). Changes 
in phosphorylation status might be responsible, but PRB might also be subjected to other 
forms of post-translational modification, which could affect its function and metabolism.  
 
5.3. Summary and Discussion 
Currently, it is clinically challenging to achieve effective tocolysis in preterm labour. This may 
be because once the process of labour is initiated it is difficult to stop or may be because 
there are several different causes of preterm labour and the use of one treatment is not 
necessarily going to be effective in all cases. In this chapter, the ability of cAMP to enhance 
progesterone driven gene expression were explored with the view of using the combination 
of progesterone and cAMP prophylactically in women at high-risk of preterm labour. The 
results showed that the combination of progesterone and cAMP significantly enhance the 
level of some progesterone responsive genes compared to progesterone or cAMP alone 
(Figs. 5-2, 5-4).  
In terms of the mechanism underpinning the enhancement of progesterone responsive 
genes expression with the additional of forskolin to progesterone treatment, the results from 
this chapter showed that PKA is a key component that mediates cAMP action in causing the 
cells to be more responsive to progesterone treatment (Figs. 5-5, 5-6,). The data were pretty 
clear at protein level. However, at mRNA level, the evidence was inconsistent, suggesting 
that these effects may not be mediated through the changes in the mRNA expression. One 
possible explanation includes the presence of miRNA, which could inhibit the translation of 
the mRNA, and thus altering the rates of translation of the mRNA. Nevertheless, the exact 
mechanism(s) on how PKA enhance progesterone responsive genes is still remains unclear.   
With regards to the effect of nuclear receptors, knock down of PR/GR has minimal effect on 
the ability of forskolin to enhance progesterone in driving the mRNA levels of progesterone 
responsive genes (Fig. 5-7). Similar observation was also noted with regards to the effect of 
MKP-1 knock down (Fig. 5-9).  However although it is not statistically significant, the 
addition of PR/GR antagonists reduced the ability of progesterone and forskolin to drive 
MKP-1 protein expression (Fig 5-8.). Previous studies from our group by Lei et al. showed 
that progesterone acts via GR and MKP-1 to repress IL-1β-driven COX-2 activation (191), and 
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although more studies are needed to explore the interaction between nuclear receptors and 
progesterone and forskolin, it is possible that this pathway may explain the results.  
Interestingly, with regards to the effect of progesterone and forskolin and the combination 
of the two agents on PR levels, treatment with forskolin alone increased PRB and PRA 
protein levels, whereas treatment with progesterone reduced both, and the combination of 
progesterone and cAMP reversed the inhibition of PRB but not PRA (Fig. 5-11). Thus, in this 
context, cAMP would be predicted to enhance progesterone action by increasing the PRB to 
PRA ratio, and thus the combination of forskolin and progesterone would be expected to 
enhance PR-B mediated gene expression (Fig. 5-12). The effect of forskolin in this context 
was clearly mediated through PKA, consistent with the earlier observations in the chapter. 
In an attempt to understand the mechanism(s) mediating cAMP enhancement of 
progesterone, earlier studies performed in our group demonstrated not only that forskolin 
enhanced progesterone-induced gene expression and PRE activation, but forskolin also 
enhanced progesterone/PR-B transcriptional activity by increasing progesterone/PR-B DNA 
binding and PRE activation in association with a reduction in both the PR-A to PR-B ratio and 
the association of PR with its co-repressor, NCoR (392). Similarly, others have suggested 
that, another cAMP-elevating agent, 8-bromo-cAMP decreases the association of NCoR and 
PR (390). These findings suggest that drugs that reduce myometrial PR co-repressor 
expression, such as cAMP agonists, may be able to maintain progesterone-induced 
myometrial quiescence. 
In summary, the data presented in this chapter strongly suggest that cAMP has the ability to 
enhance progesterone activity via PKA and may be of potential benefit to be used in 
combination with progesterone to drive the expression of progesterone responsive genes 
and to reduce labour-associated gene expression. 
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Chapter 6: 
The Combination of cAMP and Progesterone 
Represses IL-1β-induced COX-2 mRNA 
expression via PKA 
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6. The Combination of cAMP and Progesterone Represses IL-1β-induced COX-
2 mRNA expression via PKA 
 
6.1. Introduction 
To date, it is well defined that progesterone maintains pregnancy in all animal models 
studied. Earlier studies of Csapo and Frydman suggest that progesterone is also essential for 
the maintenance of human pregnancy. Csapo clearly demonstrated that in early human 
pregnancy, declining circulating progesterone levels increased the sensitivity of the uterus 
to exogenous oxytocin and prostaglandins (12, 247, 248) while Frydman, showed that the 
administration of the anti-progestin, mifepristone, successfully induced labour (249). 
The majority of spontaneous preterm labour involves inflammation (75). Progesterone is 
currently the only drug available that is associated with 40% reduction of the risk of 
spontaneous preterm labour in high-risk singleton pregnancies (65) and has no effect on the 
risk in multiple (twins and triplet) pregnancies (27). Although progesterone has been 
suggested to maintain pregnancy by acting primarily as an anti-inflammatory agent in the 
human (162, 284, 467), it is not clear that this is the mechanism through which it reduces 
the risk of spontaneous preterm labour.  
The anti-inflammatory effect of progesterone is suggested to be through the repression of 
NFB via a direct interaction with its receptor, PR-B, and the principle NFB subunit, p65 
(162, 284, 467) and by increasing IB, which binds p65 maintaining it in an inactive state 
(284). With the onset of human labour, it is proposed that the effect of progesterone is 
reversed by a combination of increased expression of PR-A (267, 275), which inhibits PR-B, a 
reduction in the level of the PR co-activator, SRC1 (266) and by increased activity of NFB, 
which consequently represses PR activity through a direct interaction (160, 162, 467). 
As progesterone may only be 40% effective in preventing preterm labour (65, 66), there is 
continuous and extensive laboratory research being performed in order to find ways to 
enhance the response to progesterone. As well as functioning as an anti-inflammatory in its 
own right, cAMP acting via PKA, has been shown to promote myometrial quiescence (220, 
308). Besides enhancing agonist bound PR activity activity (386-388), several studies have 
established that cAMP can also convert the PR antagonist, RU486, into a partial agonist 
(386, 388). Moreover, the combination of cAMP and progesterone has also been shown to 
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be better than cAMP or progesterone alone in promoting decidualisation in endometrial 
stromal cells (385).  
Data from chapter 4 show that cAMP represses IL-1β-induced inflammation in human 
myometrial cells. Data from chapter 5 demonstrate that cAMP enhanced progesterone 
driven gene expression. Together, these data suggest that the combination of progesterone 
and a cAMP agonist may be more effective for the prevention of preterm labour than either 
progesterone or cAMP alone. The aim of this chapter is firstly, to investigate whether cAMP 
enhances the ability of progesterone to repress IL-1β-induced gene expression, including 
COX-2 in human myometrial cells and secondly, to define the mechanism(s) involved in this 
repression. The effect of inflammation on progesterone’s ability to stimulate gene 
expression will also be explored. 
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6.2. Results  
6.2.1. The combination cAMP and progesterone enhances the anti-inflammatory effect of 
progesterone. 
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Figure 6-1. The effect of cAMP and progesterone in repressing IL-1β-driven IL-8 gene expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. A-E. mRNA were 
extracted and the levels of IL-8 mRNA were measured using quantitative rt-PCR. F. Myometrial cells were 
isolated as described in Materials and Methods, and treated with progesterone (1μM), forskolin (100µM) or IL-
1β (1ng/mL) either alone or in combination for 24 hours. Cells Supernatants were collected and the levels of IL-
8 proteins were measured using ELISA assay. A,B. Data are shown as the mean and SEM, and were compared 
using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that 
were normally distributed, P<0.05, **P<0.01, ***P<0.001. C,D,F. Data were compared using Friedman’s Test, 
with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using 
ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. E. Data were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed when comparing data between IL-1β and 
100F + IL-1β, and between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, ***P<0.001. Data were compared using 
Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, 
and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed, #P<0.05, 
when compared to IL-1β, $ P<0.05 when compared with 100F + IL-1β (n=8-9). 
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Figure 6-2. The effect of cAMP and progesterone in repressing IL-1β-driven IL-1β gene expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. A-E. mRNA were 
extracted and the levels of IL-1β mRNA were measured using quantitative rt-PCR. F. Myometrial cells were 
isolated as described in Materials and Methods, and treated with progesterone (1μM), forskolin (100µM) or IL-
1β (1ng/mL) either alone or in combination for 24 hours. Cells Supernatants were collected and the levels of IL-
1β proteins were measured using ELISA assay. A,B. Data are shown as the mean and SEM, and were compared 
using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that 
were normally distributed, P<0.05, **P<0.01, ***P<0.001. C,D,F. Data were compared using Friedman’s Test, 
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with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using 
ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. E. Data were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed when comparing data between IL-1β and 
100F + IL-1β, and between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, ***P<0.001. Data were compared using 
Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, 
and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed, #P<0.05, 
when P4 + IL-1β compared to IL-1β, $ P<0.05 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=8-9). 
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Figure 6-3. The effect of cAMP and progesterone in repressing IL-1β-driven COX-2 gene expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. A-E. mRNA were 
extracted and the levels of COX-2 mRNA were measured using quantitative rt-PCR. F-J. In a separate 
experiment, myometrial cells were isolated as described in Materials and Methods, and treated with 
progesterone (0.1, 1, and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 
hours. Proteins were extracted and COX-2 proteins were measured using western blotting. K. A representative 
of the western blots is shown above. A,B,F,G. Data are shown as the mean and SEM, and were compared using 
Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that were 
normally distributed, P<0.05, **P<0.01, ***P<0.001. C,D,H,I. Data were compared using Friedman’s Test, with 
a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using ANOVA, 
with Dunnett and Bonferroni’s post-test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. E,J. Data were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed when comparing data between IL-1β and 
100F + IL-1β, and between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, ***P<0.001. Data were compared using 
Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, 
and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed, #P<0.05, 
##P<0.01 when P4 + IL-1β compared to IL-1β, $P<0.05, $$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β 
compared with 100F + IL-1β (n=8-9). 
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Figure 6-4. The effect of cAMP and progesterone in repressing IL-1β-driven OTR gene expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. A-E. mRNA were 
extracted and the levels of OTR mRNA were measured using quantitative rt-PCR. F. In a separate experiment, 
myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (1μM), 
forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. Proteins were extracted and 
OTR proteins were measured using western blotting. A representative of the western blot is shown above. A,B. 
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Data are shown as the mean and SEM, and were compared using Wilcoxon matched pairs test for data that 
were not normally distributed and paired t test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. C,D,F. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc 
test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed, P<0.05, **P<0.01, ***P<0.001. E. Data were compared using Wilcoxon 
matched pairs test for data that were not normally distributed and paired t test for data that were normally 
distributed when comparing data between IL-1β and 100F + IL-1β, and between IL-1β and P4 + IL-1β, P<0.05, 
**P<0.01, ***P<0.001. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post 
hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-
test for data that were normally distributed, #P<0.05, ##P<0.01, ###P<0.001 when P4 + IL-1β compared to IL-
1β, $P<0.05, $$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=8-9). 
 
Since infection and inflammation are strongly implicated in the pathology of spontaneous 
preterm labour (468), IL-1β was used in the experiments to mimic the inflammatory 
environment in primary human myometrial cells. The effect of combination of progesterone 
and forskolin in repressing pro-inflammatory cytokines IL-8, and IL1β, and pro-labour genes 
such as COX-2 and OTR was explored.  
Figure 6-1 showed the effect of progesterone, forskolin, and the combination of 
progesterone and forskolin in repressing IL-1β-induced IL-8 expression. IL-1β stimulation to 
primary myometrial cells resulted in the significant increase in IL-8 mRNA and protein 
expression (Figs. 6-1 A,F). Forskolin treatment alone was able to reduce the basal level of IL-
8 mRNA expression compared to control vehicle (Fig. 6-1 B).  Forskolin treatment on its own 
was also associated with significant reduction IL-1β-mediated increase in IL-8 mRNA and 
protein expression (Fig. 6-1 A,F); whereas progesterone alone did not (Fig. 6-1 D,F). In 
addition, progesterone treatment alone was not associated with a reduction in the basal 
level of IL-8 mRNA when compared to control vehicle (Fig. 6-1 C). IL-1β-induced increase of 
IL-8 mRNA and protein levels were reduced by the combination of progesterone and 
forskolin (Figs. 6-1 E, 6-1 F), however this reduction was not greater when compared to 
forskolin treatment alone, suggesting that forskolin on its own was capable of acting as a 
potent anti-inflammatory agent and that this effect was not enhanced by progesterone (Fig 
6-1 E). In Figure 6-2, the effects of the combination of progesterone and forskolin in 
repressing IL-1β induced IL-1β expression was explored. Similar to IL-8, IL-1β stimulation to 
primary myometrial cells resulted in the significant increase in IL-1β mRNA and protein 
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expression (Figs. 6-2 A,F). Forskolin treatment alone however, was associated with a 
significant increase in basal IL-1β mRNA expression when compared to control vehicle (Fig. 
6-2 B).  Progesterone at dose of 10μM was able to repress basal level of IL-1β mRNA 
expression (Fig. 6-2 C), and was also able to repress IL-1β-induced IL-1β at both mRNA and 
protein level (Fig. 6-2 F).  Forskolin treatment alone was associated with significant reduction 
of IL-1β protein expression, but not at mRNA level (Fig. 6-2 E,F).  The combination of 
progesterone and forskolin enhanced progesterone in repressing IL-1β-induced IL-1β mRNA 
expression (Fig. 6-2 E), and was associated with a significant reduction of IL-1β-induced IL-1β 
at mRNA and protein level (Fig. 6-2 E,F).  
Figure 6-3 showed the effect of progesterone treatment in the absence and presence of 
forskolin on IL-1β stimulated cells on COX-2 mRNA expression and protein levels. IL-1β 
stimulation to the myometrial cells resulted in the up-regulation of COX-2 mRNA and 
protein expression (Figs. 6-3 A&F). Cyclic AMP stimulation using forskolin was associated 
with the increase of COX-2 mRNA expression (Fig. 6-1 B), but not protein expression (Fig. 6-3 
G). Progesterone treatment at 10 μM was able to reduce basal level of COX-2 mRNA 
expression (Fig. 6-3 C) but not protein level (Fig. 6-1 H). Although progesterone treatment 
alone was able to repress IL-1β-induced COX-2 mRNA and protein expression (Figs. 6-3 D&I), 
the combination of progesterone and forskolin resulted in a further reduction of COX-2 gene 
expression (Figs. 6-3 E&J), even at a low dose of 0.1μM progesterone.  
Similar to IL-8 expression, IL-1β stimulation to primary myometrial cells was associated in 
the significant increase in OTR mRNA expression and protein levels (Figs. 6-4 A,F). Forskolin 
treatment alone was able to reduce the basal level of OTR mRNA expression compared to 
control vehicle (Fig. 6-4 B).  Progesterone treatment significantly reduced basal OTR mRNA 
expression (Fig. 6-4 C) and there was a trend towards a decrease in OTR protein expression 
compared to vehicle control (Fig. 6-4 F).  Both progesterone and forskolin when tested 
separately siginifcantly reduced IL-1β-induced OTR mRNA expression and protein levels, and 
the reduction was further enhanced with the combination of the two agents (Fig. 6-4 D-F).   
In Appendix 7, the effects of the combination of progesterone and forskolin in repressing IL-
1β-induced inflammation on IL-1β responsive genes at mRNA level was explored further. The 
combination of progesterone (at 10µM) and forskolin was associated with more significant 
reduction in CCL8 mRNA expression compared to forskolin or progesterone treatment alone 
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(Appendix 7). Progesterone treatment has significantly reduced IL-1β-induced IL-24 mRNA 
expression, and this reduction was noted to be greater with the additional of forskolin. In 
terms of IRAK3, progesterone treatment at 10µM to IL-1β stimulated myometrial cells is 
associated with significant increase of IRAK3 mRNA expression compared to those without 
progesterone treatment. IRAK3 functions as a negative regulator of Toll-like receptor 
signalling, which is also negative regulator of the IL-1β induced signalling pathway. Forskolin 
treatment however reduced IL-1β-induced IRAK3 mRNA expression, the combination of 
progesterone and forskolin reduced IRAK3 mRNA expression, however this reduction was 
not greater when compared to forskolin treatment alone (Appendix 7). Thus in terms of 
IRAK3, progesterone has a more potent anti-inflammatory effect in comparison to forskolin.  
In addition to the above results, the anti-inflammatory effect of forskolin was further 
demonstrated when treatment with forskolin was associated with a significant reduction in 
IL-1β-induced increase of pro-inflammatory cytokines and chemokines, such as  LIF, IL-6, 
CXCL1, CXCL2, ICAM-1, CCL11, CCL2, and CCL20 (Appendix 8). Progesterone treatment on its 
own had no effect in repressing IL-1β-induced increase of pro-inflammatory cytokines and 
chemokines. The additional of forskolin enhanced the effect of progesterone but only the 
expressions of LIF and CCL20 were significantly reduced with this combination of treatment 
when compared with forskolin treatment alone (Appendix 8).  
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6.2.2. The effect of combination cAMP and progesterone on IL-1β-driven MKP-1 and IκBα 
mRNA expression. 
 
 
 
 
 
Figure 6-5. The combination of cAMP and progesterone increases IL-1β-induced MKP-1 expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. The levels of 
MKP-1 mRNA were measured using quantitative rt-PCR. Data were compared using Wilcoxon matched pairs 
test for data that were not normally distributed and paired t test for data that were normally distributed when 
comparing data between IL-1β and 100F + IL-1β, and between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, 
***P<0.001. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for 
data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data 
that were normally distributed, #P<0.05, ##P<0.01, ###P<0.001 when P4 + IL-1β compared to IL-1β, $P<0.05, 
$$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=8-9). 
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Figure 6-6. The effect of cAMP in enhancing progesterone in increasing IL-1β-induced IκBα expression. 
Myometrial cells were isolated as described above in Materials and Methods, and treated with progesterone 
(10µM), IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in combination for 24 hours. mRNA were 
extracted, and the levels of IκBα mRNA expression were measured using rt-PCR. Data were compared using 
Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that were 
normally distributed when comparing data between IL-1β and 100F + IL-1β, and between IL-1β and P4 + IL-1β, 
P<0.05, **P<0.01, ***P<0.001. Data were compared using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and 
Bonferroni’s post-test for data that were normally distributed, #P<0.05, ##P<0.01, ###P<0.001 when P4 + IL-1β 
compared to IL-1β, $P<0.05, $$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=8-9). 
 
The ability of progesterone and cAMP to increase IL-1β-induced MKP-1 and IκBα gene 
expression was investigated. Figure 6-5 showed that treatment with forskolin increased IL-
1β-induced MKP-1 mRNA expression where treatment with progesterone alone did not. The 
combination of forskolin and progesterone significantly enhanced the effect of forskolin at 
10µM progesterone in driving MKP-1 mRNA expression. With regards to IκBα gene 
expression, as previously shown in chapter 4, the combination of forskolin and IL-1β 
compared to IL-1β alone was associated with a significant increase in IκBα mRNA expression 
(Figs. 6-6). However, this was not observed with progesterone treatment. The combination 
of progesterone and forskolin did not result in a significant increase of IL-1β-induced IκBα at 
mRNA at 24 hour time point, when compared to IL-1β treatment alone, combination of IL-
1β with forskolin or combination of IL-1β and progesterone.  
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6.2.3. The combination cAMP and progesterone represses IL-1β-induced c-jun and c-fos 
protein synthesis. 
 
Figure 6-7. Cyclic AMP enhances progesterone in repressing IL-1β driven c-jun at protein levels. 
Figure 6-7. Cyclic AMP enhances progesterone in repressing IL-1β- driven c-jun at protein levels. 
Myometrial cells were isolated as described above in Materials and Methods, and treated with progesterone 
(0.1, 1, and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. The levels 
of c-jun (A-G) were measured using western blotting. Figure G is a representative blot for total c-jun. A-C. Data 
are shown as the mean and SEM, and were compared using Wilcoxon matched pairs test for data that were 
not normally distributed and paired t test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. D,E. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc 
test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed, P<0.05, **P<0.01, ***P<0.001. F. Data were compared using Wilcoxon 
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matched pairs test for data that were not normally distributed and paired t test for data that were normally 
distributed when comparing data between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, ***P<0.001. Data were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
distributed, $P<0.05, $$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=6-7). 
 
 
 
Figure 6-8. Cyclic AMP enhances progesterone in repressing IL-1β- driven c-fos at protein levels. 
Myometrial cells were isolated as described above in Materials and Methods, and treated with progesterone 
(0.1, 1, and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. The levels 
of c-fos (A-G) were measured using western blotting. Figure G is a representative blot for total c-fos. A-C. Data 
are shown as the mean and SEM, and were compared using Wilcoxon matched pairs test for data that were 
219 
 
not normally distributed and paired t test for data that were normally distributed, P<0.05, **P<0.01, 
***P<0.001. D,E. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc 
test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed, P<0.05, **P<0.01, ***P<0.001. F. Data were compared using Wilcoxon 
matched pairs test for data that were not normally distributed and paired t test for data that were normally 
distributed when comparing data between IL-1β and P4 + IL-1β, P<0.05, **P<0.01, ***P<0.001. Data were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
distributed, $P<0.05, $$P<0.01, $$$P<0.001 when P4 + 100F+ IL-1β compared with 100F + IL-1β (n=6-7). 
 
The impact of the combination of progesterone and cAMP on AP-1 protein levels was 
assessed (Figs. 6-7, 6-8). IL-1β stimulation to primary myometrial cells resulted in the up-
regulation of total c-jun and c-fos (Figs. 6-7 A, 6-8 A). Forskolin treatment reduced the basal 
level of total c-fos and total c-jun compared to control (Figs. 6-7 B, 6-8 B). Similarly, 
progesterone treatment (10 μM) results in the reduced level of total c-fos and total c-jun 
compared to control (Figs. 6-7 D, 6-8 D). Forskolin treatment alone was able to reduce IL-1β-
induced increased in c-jun and c-fos (Figs. 6-7 C, 6-8 C). Similar results were also noted in 
cells treated with progesterone (Figs. 6-7 E, 6-8 E). The combination of progesterone and 
forskolin compared to progesterone alone reduced c-fos and c-jun proteins gene expression, 
however, this reduction was not greater when compared with the cells treated with forskolin 
and IL-1β (Figs. 6-7 F, 6-8 F).  
The effect of progesterone and forskolin treatment on cells treated with IL-1β on total p65 
protein levels was also studied. Progesterone (0.1, 1, and 10μM) and forskolin (100μM) 
when tested separately was able to reduce IL-1β induced total p-65 at 6 hour. Although there 
was a trend that the combination of progesterone and forskolin enhanced both agents in 
repressing IL-1β induced total p-65 at 6 hour, this was not statistically significant. The effect 
of progesterone and forskolin in repressing IL-1β induced total p-65 was lost at 24 and 48 
hour (data not shown).  
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6.2.4. The combination cAMP and progesterone delays the IL-1β-induced nuclear transfer of phospho p65 and IL-1β-induced degradation of 
IκBα. 
 
 
 
 
Figure 6-9.  The combination of progesterone and cAMP delays the IL-1β-induced nuclear transfer of phospho p65 and IL-1β-induced degradation of IκBα. 
Myometrial cells were isolated as described above in Materials and Methods and treated with P4 (10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in 
combination for for 0 minute, 30 minutes, 1 hour, 2 hours and 6 hours. Cells were lysed and samples purified for cytoplasmic or nuclear protein. Western blotting was 
performed using antibodies directed against phospho-p65 (Ser536), phospho c-jun, and IκBα. TATA-bind protein (TBP) and α-tubulin were used as the internal controls for 
cytosolic and nuclear fraction, respectively (n=6).  
221 
 
The impact of the combination of progesterone and cAMP on NFκB and AP-1 activity was 
further assessed in the nucleo-cytoplasmic study. The combination of progesterone and 
cAMP was associated with a delay in the nuclear translocation of phospho-p65 and the 
degradation of IκBα although forskolin alone appeared to have a similar effect. There was no 
delay in the nuclear translocation of phospho-cjun observed (Fig 6-9).  
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6.2.5. The combination of cAMP and progesterone represses IL-1β-induced nuclear 
transfer of phospho p65 and phospho-cjun and increases IL-1β-induced IκBα. The 
combination cAMP and progesterone represses IL-1β-induced activation of JNK and p-38.  
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Figure 6-10. The combination of cAMP with progesterone represses IL-1β-induced nuclear transfer of 
phospho p65 and phospho c-jun and increases IL-1β-induced IκBα.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods, and treated with progesterone (10μM), 
forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for for 0 minute, 30 minutes, 1 hour, 2 
hours and 6 hours. Cells were lysed and samples purified for cytoplasmic or nuclear protein. Western blotting 
was performed using antibodies directed against phospho-p65 (Ser536), IκBα, and phospho c-jun. α-tubulin 
and TATA-bind protein (TBP) were used as the internal controls for cytosolic and nuclear fraction, respectively. 
Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that 
were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were 
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normally distributed, P<0.05, **P<0.01, ***P<0.001. (n=6 and only 30 minutes, 1 hour and 2 hours time points 
were shown in the figure above). 
 
 
Figure 6-11. The combination of cAMP with progesterone represses IL-1β activation of JNK and p38.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods, and treated with progesterone (10μM), 
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forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for for 30 min. Cells were lysed and 
samples purified for cytoplasmic or nuclear protein. Western blotting was performed using antibodies directed 
against phospho-JNK, and phospho p38. α-tubulin was used as the internal controls for cytosolic fraction. Data 
were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were 
not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were 
normally distributed, P<0.05, **P<0.01, ***P<0.001. (n=6 and only 30 minutes time point were shown in the 
figure above).  
 
The impact of the combination of progesterone and cAMP on NFκB, AP-1, and MAPK activity 
was further assessed in this study. In terms of NFκB, the nucleo-cytosolic study showed that 
at 30 minutes and 1 hour, forskolin reduced IL-1β induced nuclear phospho p-65 (Fig. 6-10 A). 
The combination of progesterone and forskolin did not enhance this reduction at 30 minutes. 
At 1 hour, progesterone alone was observed to repress IL-1β induced nuclear phospho p-65, 
and the addition of forskolin had a greater effect in the repression of IL-1β-stimulated 
nuclear transport of phospho p65 (Fig. 6-10 A). In the cytosolic, forskolin reduced IL-1β 
induced phospho p-65 at 1 hour. The combination of progesterone and forskolin was 
associated with significant reduction of IL-1β induced phospho p-65 at 30 minutes and 1 
hour, however this effect was not greater when compared to forskolin treatment alone at 1 
hour (Fig. 6-10 B). Given that progesterone had previously been shown to increase IκBα 
levels (chapter 5), the impact of progesterone and forskolin on IL-1β-induced IκBα protein 
synthesis was also investigated. It was noted in figure 6-6 that at 24 hour treatment point, 
progesterone, and the combination of progesterone and forskolin was not associated with an 
increase in IL-1β-induced IκBα mRNA expression. On the other hand, it was observed that at 
1 hour, progesterone, and the combination of progesterone and forskolin was able to 
increase IL-1β-induced cytoplasmic IκBα protein level. At 2 hour, the combination of 
progesterone and forskolin was able to increase IL-1β-induced IκBα protein levels maximally 
(Fig. 6-10 C). These results showed that the effect of forskolin was greater than that of 
progesterone and that the combination of progesterone and forskolin in repressing nuclear 
p65 translocation or increasing IkB levels was no greater than forskolin alone.  
With regards to AP-1, both forskolin and progesterone acting individually was able to reduce 
nuclear transfer of phospho c-jun at 1 hour, however the combination did not further 
enhance this reduction (Fig. 6-10 D). In the cytoplasm, progesterone alone did not reduce IL-
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1β-induced increase of phospho-c-jun, but forskolin alone and in combination with 
progesterone did (Fig. 6-10 E).  
The impact of the combination of progesterone and cAMP on MAPK activity was also 
explored in this study. Figure 6-11 A&B showed that progesterone had no effect on the IL-
1β-induced activation of JNK or p38, but that forskolin alone, and in combination with 
progesterone, reduced their activation. In the case of JNK, the addition of progesterone 
seemed to enhance the repressive effect of forskolin. There were minimal changes observed 
in the phospho-JNK and phospho p38 at nuclear protein level among the treatment 
conditions across the three time points (results not shown). 
 
6.2.6. The combination of cAMP and progesterone enhances IL-1β driven MKP-1 gene 
expression at cytoplasmic protein level.  
 
 
 
Figure 6-12. The combination cAMP with progesterone enhances MKP-1 cytosolic protein expression.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods, and treated with progesterone (10μM), 
forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for for 0 min, 30 min, 1 h, 2 h and 6 h. Cells 
were lysed and samples purified for cytoplasmic protein. Western blotting was performed using antibodies 
directed against MKP-1. α-tubulin was used as the internal controls for cytosolic fraction. Data were compared 
using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally 
distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
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distributed, P<0.05, **P<0.01, ***P<0.001 when compared to control, #P<0.05, ##P<0.01, ###P<0.001 (n=6 
and only 30 minutes, 1 hour and 2 hours time points were shown in the figure above). 
 
The ability of progesterone and forskolin to modulate MKP-1 protein levels after IL-1β 
stimulation was investigated in this study (Fig. 6-12). Forskolin treatment alone and in 
combination with progesterone and/or IL-1β increased MKP-1 cytoplasmic protein levels at 
all the three time points, but neither progesterone nor IL-1β treatments had any effect on 
MKP-1 levels. MKP-1 protein was not found in the nucleus.  
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6.2.7. The effects of AKIP1 and cAMP effector knockdown on the ability of progesterone 
and cAMP alone and in combination to reduce IL-1β-induced COX-2. 
 
 
Figure 6-13. The effects of cAMP effectors and AKIP1 knock down on the ability of cAMP in enhancing 
progesterone as an anti-inflammatory.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
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cAMP effectors such as PKAC-α, Epac1, and AMPK, and AKIP1 were knocked down using siRNA (siPKAC-α, 
siEpac1, siAMPK, and siAKIP1 controlled with non-targeted siRNA [siNT]). A. Cells were knocked down using 
siNT. Representative western blots to demonstrate transfection is shown above (B-E). After transfection, cells 
were incubated for 96 hours before being treated with progesterone (10µM), IL-1β (1ng/mL) and/or forskolin 
(100µM) either alone or in combination for 6 hours. The mRNA was extracted, and the levels of COX-2 mRNA 
were measured using rt-PCR. Data were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed, P<0.05, **P<0.01, ***P<0.001 (n=6-7).  
 
In order to investigate the mechanism(s) responsible on how forksolin enhance the action of 
progesterone in repressing inflammation, the effects of AKIP1 and cAMP effectors 
knockdown on the ability of the combination of progesterone and cAMP to reduce IL-1β-
induced COX-2 was explored. Results in Figure 6-13 showed that compared to the siNT 
knockdown cells (Fig. 6-13 A), the effects of forskolin in synergistically enhancing 
progesterone as an anti-inflammatory was lost in cells with PKA knockdown. Interestingly, in 
the absence of PKA activity, the combination of cAMP and progesterone was pro-
inflammatory (Fig. 6-13 B), suggesting that PKA is a key cAMP effector which mediates the 
anti-inflammatory action when cAMP is combined with progesterone in human myometrial 
cells. The combination of progesterone and forskolin was associated with the reduction in IL-
1β-induced increase in COX-2 mRNA expression in Epac1 and AMPK knocked down cells, 
suggesting that Epac1 and AMPK knockdown had minimal effect in the ability of cAMP in 
enhancing progesterone to repress IL-1β-induced increase in COX-2 mRNA expression (Figs. 
6-13 C&D). 
Like others (365, 411, 412) who demonstrated cAMP’s anti inflammatory effect in various 
cell types, the results taken from chapter 4, highly support of the effectiveness of cAMP’s 
anti-inflammatory actions in myometrial cells, and this inflammatory effect of cAMP is 
further enhanced with AKIP1 knockdown (Fig. 4-8). Results in Figure 6-13 E showed that 
there was no significant difference on the ability of progesterone alone in reducing IL-1β-
induced COX-2 mRNA expression when compared from siNT and siAKIP1 knockdown cells. 
Similarly, there was no significant difference on the ability of forskolin to enhance 
progesterone anti-inflammatory action when compared from siNT with siAKIP1 knockdown 
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cells (Fig. 6-13 E), suggesting that the ability of cAMP in enhancing progesterone’s anti-
inflammatory action on myometrial cells was not dependent on AKIP1.  
 
6.3. Summary and Discussion 
 
In this chapter, the ability of cAMP to enhance progesterone repression of IL-1β-induced 
gene expression in myometrial cells was studied and the potential mechanisms were 
investigated. Since spontaneous preterm labour is an inflammatory event (73, 75), 
characterised by elevated IL-1β levels, IL-1β was used to mimic this inflammatory 
environment in primary human myometrial cell cultures. Progesterone treatment alone did 
not repress IL-1β-induced IL-8 gene expression (Fig. 6-1), and only in the case of OTR and 
COX-2, 2 key pro-labour genes, was the effect of the combination of progesterone and 
forskolin greater than forskolin alone (Figs. 6-3, 6-4). The combination of progesterone and 
forskolin increased MKP-1 and IκBα gene expression helping to reduce IL-1β-induced 
activation of both AP-1 and NFκB pathways (Figs. 6-5, 6-6).  
Others have suggested that progesterone represses inflammation primarily through an 
effect on NFκB activity via increased levels of IκBα (467) while data from our group suggest 
that progesterone suppresses AP-1 activity (191). Previously, data from our group provided 
strong evidence that cAMP enhances progesterone action in human primary myometrial 
cells. Chen et al. demonstrated that forskolin enhanced the ability of progesterone to 
repress IL-1β-driven COX-2 expression, p65 nuclear transfer and DNA binding in human 
myometrial cells (392).  
The impact of the combination of progesterone and forskolin on AP-1 activity was assessed. 
Forskolin and progesterone treatment on its own was able to reduce the IL-1β-induced 
increased in c-jun and c-fos (Figs. 6-7, 6-8). The combination of progesterone and forskolin 
treatment compared to progesterone treatment alone further reduced IL-1β induced c-fos 
and c-jun protein levels (Fig. 6-7). Although forskolin and progesterone alone were observed 
to reduce nuclear levels of phospho c-jun at 1 hour, this reduction was not further enhanced 
with the combination of the two agents (Fig. 6-10). On the other hand, in the cytoplasm, 
progesterone treatment alone did not inhibit IL-1β-induced increase of phospho c-jun, 
whereas the combination of the two agents reduced its level significantly (Fig. 6-10). 
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However, the combination of progesterone and forskolin was not associated with a delay in 
the nuclear translocation of phospho c-jun (Fig. 6-9).  
Cyclic AMP, acting via PKA, has been suggested to reduce NFκB activity by reducing its ability 
to bind DNA altering the p65 transactivation domain and inhibiting IκBα degradation (151). 
However, progesterone has been shown to increase IκBα levels and to repress NFκB 
transcriptional activity (158). The impact of the combination of progesterone and cAMP on 
NFκB activity was further assessed in this chapter. The nucleo-cytoplasmic study showed 
that the combination of progesterone and cAMP reduced IL-1β induced nuclear and 
cytosolic phospho p-65 (Fig. 6-10). Morevover, the treatment combination of progesterone 
and cAMP is also associated with a delay in the nuclear translocation of phospho-p65 and 
the degradation of IκBα although forskolin alone appeared to have a similar effect (Fig. 6-9). 
However, the effect of forskolin was greater than that of progesterone and the combination 
of forskolin and progesterone was no greater than progesterone alone. 
In an attempt to examine the distribution of NFκB expression in human myometrium, 
Chapman et al. (159) found that the principal NFκB dimers at term myometrium are 
p65:p50, and intriguingly, there is a decrease in the overall expression of both p65 and p50 
in the lower but not the upper segment in association with onset of labour. Subsequently, 
Condon and colleagues (160) explored NFκB p65 nuclear localisation in both lower and 
upper segment myometrium of women before and after the onset of labour. They observed 
that p65 was primarily cytoplasmic in tissues collected before the onset of labour, but was 
nuclear in upper but not lower segment myometrium after the onset of labour. These 
studies suggest that the activation of NFκB within the human myometrium at the time of 
the onset of labour is region-dependent. However, like many others, most of the studies in 
this thesis have been performed on myometrium obtained from lower segment of the 
uterus; others have shown upregulation of NFκB associated genes such as COX-2, IL-8 and 
chemokines with the onset labour (125, 234). These data suggest that activation of NFκB 
occurs in both upper and lower segment of the uterus at the time of the onset of labour. 
Both progesterone, and the combination of progesterone and forskolin, increased IL-1β-
induced reduction in IκBα levels, which may explain the repressive effect of progesterone 
and cAMP on IL-1β-induced NFκB nuclear translocation (Fig. 6-10). One possible explanation 
for the observed results is it could be that cAMP and progesterone treatment reduces IκK 
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activity, which prevents the phosphorylation IκBα or interrupt the ubiquitination of IκBα and 
so the degradation of IκBα, as has been observed previously (151, 158). Furthermore, 
previous findings in our group showed that both progesterone and forskolin individually 
reduced NFκB binding to the COX-2 promoter, but the combination of progesterone and 
forskolin had a greater and potentially synergistic effect (392). Other findings in this study 
suggest that forskolin treatment alone enhanced the IL-1β-stimulated COX-2 mRNA gene 
expression, but when it was combined with progesterone, it enhanced the repressive effect 
of progesterone on IL-1β-driven COX-2 expression (Fig. 6-13).  
In view of the fact that the combination of progesterone and forskolin increased IL-1β-
induced MKP-1 and IκBα gene expression, the impact of combination of progesterone and 
forskolin on MAPK activity was explored. Similar to the findings of Lei et al., who showed 
that progesterone treatment decreased LPS-mediated phosphorylation of p38 and 
extracellular regulated kinase MAPKs in microglial cells (469), the anti-inflammatory effects 
of progesterone and forskolin in this chapter were shown to be associated with a reduction 
in cytoplasmic levels of phospho JNK and phospho p38 (Fig. 6-11). 
The knockdown studies showed that the ability of forskolin in enhancing progesterone as an 
anti-inflammatory is not only lost in cells with PKA knockdown but reversed. The results in 
Figure 6-13 demonstrate that in the absence of PKA, the combination of cAMP and 
progesterone becomes pro-inflammatory. This is reminiscent of the effects on OTR 
expression explored in chapter 3 and may further supports the theory that PKA is a key 
component in the anti-inflammatory action of cAMP, particularly when it is combined with 
progesterone.  
Collectively, these data show in this chapter promising results regarding the effect of cAMP 
on progesterone action in myometrials cells studied. These findings suggest that the 
combination of progesterone and a PKA agonist would be more effective than progesterone 
or cAMP alone in the suppression of inflammation-induced preterm labour. 
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Chapter 7: 
Combined phosphodiesterase inhibition and 
progesterone supplementation inhibits 
inflammation-induced preterm labour in 
mice 
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7. Combined phosphodiesterase inhibition and progesterone 
supplementation inhibits inflammation-induced preterm labour in mice  
 
7.1. Introduction 
Progesterone supplementation is the most widely used therapy for the prevention of 
preterm labour, however it may only effective in about 40 % of high-risk singleton 
pregnancies (65, 66) and is ineffective in twins (27). Improving the response to progesterone 
is a major research goal for the prevention of prematurity. 
Previous work done in our group involved investigating the use of cAMP-specific PDE 
inhibitors as a potential therapy for the prevention of preterm labour. With that work, our 
group showed that in the lipopolysaccharide (LPS)-based mouse model of preterm labour, 
administration of rolipram, a PDE4-specific inhibitor, alone doubled the time it took for 
labour onset to occur after LPS treatment compared to control mice (24.7 ± 1.1 (n = 13) 
versus 12.6 ± 3.4 (n = 15) hours; P ≤ 0.001). However rolipram was associated with marked 
maternal side effects, as has been reported with PDE4 inhibitor use in humans (470).  
Aminophylline, another cAMP-PDE inhibitor, is a xanthine derivative and is known for its use 
in the treatment of asthma in both pregnant and non-pregnant women. Previously in vitro 
studies have shown that aminophylline and theophylline promote relaxation in human 
myometrial tissue after the onset of contractions and in the absence of progesterone 
supplementation (356, 471, 472). In addition, aminophylline also reduces the contractility of 
human myometrial strips (471). It  has been used widely to promote fetal lung maturation 
and to reduce the risk of apnoea in newborns (473) and bronchopulmonary dysplasia in 
extremely preterm infants (474), aiming to improve neonatal outcomes in a similar way to 
caffeine, another cAMP-PDE inhibitor (475).  
In the previous chapters, cAMP alone was shown to act as an anti-inflammatory and the 
combination of cAMP and progesterone to be more effective than progesterone alone in 
repressing inflammation in human myometrial cells. In this chapter, the aim was to 
investigate the effects of the combination of aminophylline, a cAMP-elevating agent which 
works by inhibiting PDE, and progesterone treatment in a mouse model of inflammation 
induced preterm labour. This work has been extended to examine the effects of the 
combination of aminophylline and progesterone in human myometrial cells and myometrial 
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tissue explants, exploring whether the combination enhances the anti-inflammatory action 
of progesterone alone.  
 
7.2. Results 
 
Sample preparation - Animal study 
The animal study described in this chapter was performed in collaboration with Dr Bronwen 
Herbert. Preterm labour was induced in pregnant CD1 mice at E16, by intrauterine injection 
of 10ug 0111:B4 LPS. Mice were pre-treated with either vehicle or 10mg/kg aminophylline 
via intraperitoneal injection 2 hours prior to LPS administration, followed by either vehicle or 
5mg of progesterone via subcutaneous injection 30 minutes prior to LPS. Latency to labour 
was monitored by infra-red CCTV imaging.  
Plasma, placental and uterine tissue samples were collected from a second group of animals 
at the time of labour or 7 hours post LPS administration (whichever was the later time). Total 
mRNA was isolated from myometrial samples, converted to cDNA, and the expression levels 
of progesterone and cAMP-regulated genes were analysed by rt-PCR. Myometrial 
cytokine/chemokine levels were measured on a Bioplex Pro Cytokine Multiplex Assay (Bio-
Rad Laboratories Ltd), using 500μg protein lysate produced according to the manufacturer's 
instructions as described in the Materials and Methods section.  
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7.2.1. Combined phosphodiesterase inhibition and progesterone supplementation 
inhibits LPS-induced preterm labour in mice. 
 
 
 
 
 
 
 
Figure 7-1. Latency to labour post LPS injection.  
Pregnant females were treated with either vehicle or aminophylline and/or progesterone, administered IP 2 
hours and 30 minutes respectively, prior to intrauterine injection of either PBS or LPS. The time taken to labour 
post LPS injection was noted. Data are shown as the mean, and SEM, and were compared using Wilcoxon 
matched pairs test for data that were not normally distributed and paired t test for data that were normally 
distributed  P<0.001; n=10/14 for each LPS group and n=5 for each PBS group. 
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Figure 7-2. Pup survival score 7 hours post LPS injection. 
Individual pups were examined at the time of tissue collection, from a second group of dams for each of the 
treatment groups at 7 hours post-LPS injection when previous studies have shown that pups from LPS-treated 
dams will start to die. Pups were scored (0-3) according to their ability to spontaneously move and in response 
to painful stimuli (0=dead 3=alive, spontaneously moving, full body movement in response to stimuli) (n=6 
litters per group). 
 
All PBS treated dams gave birth at similar times (~day 19-20) to live pups. LPS and vehicle 
treatment in mice resulted in preterm labour (~day 16) and approximately only 20% of pups 
were seen alive at labour and these died soon after birth due to prematurity. Single 
treatments did not significantly delay labour, although there was a positive trend with 
progesterone treatment (V+V+LPS=9.3h±1.5; A+V+LPS=11.3h±1.7; V+P+LPS=30.5h±9.3). Yet 
combining both drugs delayed labour to 57.6h±7.9 (p<0.001) (Fig. 7-1). Aminophylline and 
progesterone treatment, whether alone or in combination, did not improve pup survival 
rates at either 7 hours post LPS or at labour (Fig. 7-2). 
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7.2.2. Combined phosphodiesterase inhibition and progesterone supplementation 
downregulates IL-1β responsive genes mRNA expression and upregulates progesterone 
sensitive gene. 
 
 
 
 
 
 
239 
 
Figure 7-3. Effects of aminophylline and progesterone on IL-1β responsive genes mRNA expression levels. 
Myometrial mRNA expression levels of several IL-1β responsive genes thought to be important in labour, 
including (A) IL-24, (B) IL-11, (C) COX-2, (D) OTR, (E) CXCL-2, and (F) IRAK-3 were analysed by rt-PCR from 
samples collected 7 hours post-LPS administration. mRNA levels are shown here as a ratio of expression level 
relative to a normalisation factor calculated from 3 housekeeping genes. Data are shown as the mean, and 
SEM, and were compared using Wilcoxon matched pairs test for data that were not normally distributed and 
paired t test for data that were normally distributed *P<0.05, **P<0.01 *** P<0.001 (n=6-8 per group).  
 
 
 
 
 
Figure 7-4. Effects of aminophylline and progesterone on progesterone responsive genes mRNA expression 
levels.  
Myometrial mRNA expression levels of several progesterone responsive genes thought to be important in 
labour, including (A) FKBP51, (B) 11βHSD1, and (C) MKP-1, were analysed by rt-PCR from samples collected 7 
hours post-LPS administration. The mRNA levels shown here as a ratio of expression level relative to a 
240 
 
normalisation factor calculated from 3 housekeeping genes. Data are shown as the mean, and SEM, and were 
compared using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for 
data that were normally distributed *P<0.05, when non LPS arm is compared to control (DMSO +OIL, PBS), 
#
P<0.05,  
###
 P<0.001 (n=6-8 per group).  
 
 
Treatment with progesterone alone reduced the LPS-induced increased in COX-2 and OTR 
mRNA expression (Figs. 7-3 C&D), treatment with aminophylline alone did not produce this 
effect. The combination of aminophylline and progesterone results in the reduction of LPS-
induced increased of COX-2 and OTR mRNA expression, but the reduction was not greater 
compared to the progesterone action alone (Figs. 7-3 C, D). Both progesterone and 
aminophylline alone and in combination down-regulated the LPS induced increase of IL-11 
mRNA expression but the combination was not greater than progesterone or aminophylline 
alone (Fig. 7-3 B). With regards to IL-24, only the combination of progesterone and 
aminophylline reduced the LPS-induced increase in IL-24 mRNA expression (Fig. 7-3 A). In 
the case of CXCL-2, progesterone alone failed to reduce its expression, but aminophylline 
alone and the combination did (Fig. 7-3 E). 
The combination of aminophylline and progesterone enhanced the response of IRAK-3 
mRNA expression compared to aminophylline alone. Thus, this suggests that the 
combination therapy of aminophylline and progesterone plays an anti-inflammatory role not 
only by inhibiting pro-inflammatory genes expression, but also by enhancing IL-1β’s effect on 
certain genes expression, such as IRAK3, which is a negative regulator of the IL-1β induced 
signalling pathway (Fig. 7-3 F). 
With regards to progesterone sensitive genes, progesterone, and the combination of 
progesterone and aminophylline treatment significantly up-regulated the expression of 
FKBP51 mRNA in the non-LPS arm (Fig. 7-4 A) when compared to control. The combination 
of aminophylline and progesterone increased FKBP51 mRNA expression compared to either 
agent alone. In the LPS arm, the combination of progesterone and aminophylline was 
associated with a significant increase in FKBP51 mRNA expression levels, aminophylline was 
also observed to enhance progesterone effect (Fig. 7-4 A). On the other hand, the effect of 
progesterone, aminophylline or the combination of aminophylline and progesterone to LPS-
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induced MKP-1 and 11βHSD1 mRNA expression was not statistically significant (Figs. 7-4 
B&C).  
 
7.2.3. Combined phosphodiesterase inhibition and progesterone supplementation reduces 
myometrial protein levels of pro-inflammatory cytokine. 
 
 
 
 
 
Figure 7-5. Effects of aminophylline and progesterone on myometrial pro-inflammatory cytokine levels.  
Myometrial protein lysates were analysed on a Bioplex Pro-Cytokine assay to look at the effect of the different 
treatment groups on LPS-induced inflammatory markers. Treatment groups at 7 hours post-LPS were further 
compared to pregnant dams (E16 group) which had not undergone any manipulation to identify any effects of 
surgery separately from that of LPS. Cytokines examined include: (A) IL-1β, (B) IL-4, (C) CXCL-1, (D) IL-12p70, (E) 
CXCL2, (F) TNFα [n=6-8 per group; * p<0.05; ** p<0.01]. 
 
 
Surgery raised the levels of myometrial cytokines compared to untreated pregnant dams and 
this increase was further magnified in the presence of LPS in all cytokines explored in this 
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experiment (Figs. 7-5 and Appendix 9). Treatment with progesterone significantly lowered 
the levels of CXCL1, TNFα, IL-12p70, TNFα, IL-4, and IFNγ (Figs. 7-5 A, D-F, and Appendix 9 A) 
levels compared to LPS treated animals alone, and this trend continued with the addition of 
aminophylline but did not quite reach significance. The combination of aminophylline and 
progesterone was associated with a greater reduction of LPS-induced increase in TNFα and 
IL-4 levels compared to treatment with progesterone alone (Figs. 7-5 D&F). 
Both aminophylline and progesterone were necessary to reduce the LPS-induced increase of 
CXCL-2 and IL-1β cytokine levels (Figs. 7-5 B&C). In contrast, CCL2 and G-CSF levels remained 
raised post-LPS in all treatment groups (Appendix 9. F&G). With regards to other cytokines 
such as RANTES, IL-1α, IL-12p40, IL-10 and IL-6, although treatment with progesterone alone 
(RANTES, IL-1α, IL-12p40, IL-10 and IL-6) or aminophylline alone (IL-1α, IL-12p40 and IL-6) or 
the combination of the two (RANTES, IL-1α, IL-12p40, IL-10 and IL-6) reduced LPS-induced 
increase of the cytokines levels, the reduction was not significant (Appendix 9). 
There was no significant difference in the phospho small heat shock-related protein 20 
(HSP20) and total HSP20 protein levels between the treatment groups (results not shown). 
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7.2.4. Combined phosphodiesterase inhibition and progesterone supplementation 
enhances progesterone inflammatory action in human myometrial cells and tissue 
explants. 
 
 
 
Figure 7-6. Effects of aminophylline and progesterone treatment on IL-1β stimulated human myometrial 
cells on COX-2 and IL-8 mRNA expression. 
Human myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-
labour Caesarean section. Cells were cultured and incubated with progesterone (10 µM) and/or aminophylline 
(10µM) either alone or in combination before adding IL-1β (10ng/mL) 24 hours. The levels COX-2 mRNA were 
measured using rt-PCR. Data are shown as the mean and SEM, and were compared using Friedman’s Test, with 
a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, and using ANOVA, 
with Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01 (n=7-9 in 
each experiment).  
 
In human myometrial cells, progesterone treatment was associated with a reduction in IL-1β 
induced COX-2 mRNA expression (Fig. 7-6 A). The combination of progesterone and 
aminophylline on IL-1β stimulated cells was associated with lower COX-2 mRNA expression 
compared to progesterone treatment alone, and this was statistically significant at the 24 
hour time point (Figs. 7-6 A).  The combination of aminophylline and progesterone reduced 
IL-1β-induced increase of IL-8 mRNA expression at 24 hour time point (Fig. 7-6 B). Although 
progesterone alone repressed IL-1β-induced increase of IL-8 mRNA expression at 48 hour 
time point, the additional of aminophylline did not enhance this reduction further (data not 
shown).  
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Figure 7-7. Effects of aminophylline and progesterone treatment on IL-1β stimulated human myometrial 
cells cytokines levels. 
Human myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-
labour Caesarean section. Cells were cultured and incubated with progesterone (10 µM) and/or aminophylline 
(10µM) either alone or in combination before adding IL-1β (10ng/mL) for 24 hours. The levels proinflammatory 
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cytokines were measured using Multiplex assay as described in Materials and Methods. Data are shown as the 
mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test 
for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 (n=7-9 in each experiment).  
 
Although progesterone or aminophylline treatment alone repressed IL-1β induced increase 
TNFα and IL-1β cytokine levels, the combination of progesterone and aminophylline is 
associated with a greater repression of the IL-1β induced increase TNFα and IL-1β cytokine 
levels (Figs. 7-7 C&F). On the other hand, the combination of progesterone and 
aminophylline is necessary for the reduction of IL-1β induced increase of CXCL1, CXCL2, INFγ, 
and IL-6 cytokine levels (Figs. 7-7 A, B, D, E). 
 
7.2.5. Combined phosphodiesterase inhibition and progesterone supplementation 
enhances progesterone inflammatory action in human myometrial tissue explants. 
 
Sample preparation 
 
The explants study described below was done in collaboration with Dr Ektoras Georgiou.  
 
 
 
Figure 7-8. Effects of aminophylline and progesterone treatment on IL-1β stimulated human myometrial 
tissue explants on COX-2 mRNA expression.  
Human myometrium obtained from non-labouring women was finely dissected into 3x3x3mm
3
 explants. 
Explants were immediately pre-treated for 6 hours with ethanol vehicle, 1µM P4, 10µM aminophylline either 
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alone or in combination followed by a 24 hour treatment with IL-1β (10ng/mL).  Explants were subsequently 
snap frozen in liquid nitrogen. Protein was extracted and quantified, and Western blotting for COX-2 was 
performed as described in Materials and Methods. The data are expressed as mean + SEM. Normality was 
tested using a Kolmogorov-Smirnov test followed by comparison of control versus IL-1β by paired t testing, 
*P<0.05 (n=6-8). 
 
The effect of the combination of aminophylline and progesterone on COX-2 protein levels on 
IL-1β stimulated human myometrial tissue explants was studied. The results demonstrated 
that, similar to the human myometrial cell, progesterone alone is able to repress IL-1β-
induced increase of COX-2 expression. However, unlike in human myometrial cells, 
aminophylline treatment alone in human myometrial tissue explants is also associated with 
the reduction IL-1β-induced increase of COX-2 expression. The combination of progesterone 
and aminophylline did not enhance the reduction IL-1β-induced increase of COX-2 
expression further (Fig. 7-8).  
 
7.3. Summary and Discussion 
 
In this chapter, the combined effect of aminophylline and progesterone treatment in 
preventing the onset of labour and improving neonatal survival rates in a mouse model of 
inflammation-induced preterm labour were studied. The combination of aminophylline and 
progesterone significantly delayed the onset of labour in the mouse model of inflammation-
induced preterm labour without adverse maternal side effects (Fig. 7-1). The delay in the 
onset of labour could be mediated through the reduction in contractile associated genes 
such as OTR, and the down-regulation of proinflammatory cytokines such as IL-1β, INFγ, 
TNFα and the neutrophil chemoattractants CXCL1 and CXCL2, resulting in altered leukocyte 
behaviour (Figs. 7-3, 7-5, Appendix 9). Although aminophylline and progesterone treatment 
delayed the onset of labour in the mouse, it did not increase pup survival rates at either 7 
hours post LPS administration or at labour (Fig. 7-2). This may be due to the fact that as 
labour onset is delayed, the pups were kept in an inflammatory environment that caused 
their death.  
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Aminophylline enhanced the anti-inflammatory effects of progesterone in both mice and 
human myometrial cells (Figs. 7-3, 7-4, 7-6, 7-7). These results supported the earlier study 
published in our group by Chen et al. where, in series of in vitro experiments with human 
myometrial cells, the combination of a cAMP agonist and progesterone enhanced the ability 
of progesterone to repress IL-1ß-driven COX-2 expression, p65 nuclear transfer and DNA 
binding (392). In addition, cAMP enhanced progesterone transcriptional activity by 
increasing progesterone/PR-B DNA binding and PRE activation, while at the same time 
increasing PR-B levels, so reducing the PR-A:PR-B ratio and reducing  the association 
between PR and NCoR, a negative co-regulator of PR-action (392).  
The effect of treatment with progesterone, aminophylline either alone or in combination on 
the level of phospho-HSP20 and total HSP20 protein level was also explored. The small heat 
shock proteins (sHSPs) are a family of proteins and are expressed in all tissues, but reaches a 
maximal level of 1.3% of total proteins in skeletal and smooth muscle (476). This 20 kDa 
protein can be phosphorylated by both cAMP- and cGMP-dependent protein kinases 
(PKA/PKG) and the increase in phosphorylation was associated with smooth muscle 
relaxation (477). A previous study demonstrated that HSP20 mRNA and protein were highly 
expressed during early and mid-pregnancy in rat myometrium and that the expression was 
markedly decreased during late pregnancy and labour. These results were consistent with a 
potential role for HSP20 in facilitating myometrium quiescence during pregnancy (478). 
Intriguingly, there was no significant difference in the expression of both phospho and total 
level of HSP20 among the treatment groups, suggesting that the mechanism through which 
progesterone, aminophylline or the combination delayed the onset of preterm labour may 
not involve HSP20.  
Recently, our group sought to establish a model that reflects the in vivo situation more 
accurately than myometrial cell cultures and to use this model to study cAMP and 
progesterone signaling in the myometrium. Georgiou et al. (unpublished data) 
demonstrated that nuclear receptor levels more closely resemble those in vivo in 
myometrial explants than in myometrial cell cultures and that treatment with a 
physiological dose of progesterone (1µM) significantly reduced inflammation in explants, 
whereas in myometrial cells it did not. Although others have shown that cultured myocyte 
passage number did not affect the myometrial phenotype (479), results from Georgiou et al. 
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(unpublished data) suggested that there were marked functional differences between 
explants and myometrial cell cultures. Using this explant model, the combination of 
aminophylline and progesterone successfully repressed IL-1β-induced increased in COX-2.  
To date, no human in vivo studies have investigated the efficacy of aminophylline and 
progesterone combination therapy in the prevention of preterm labour. The data 
demonstrated in this chapter provide strong and promising evidence that the addition of 
aminophylline might enhance progesterone’s therapeutic effect in delaying preterm labour. 
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Chapter 8: 
The Role of EP2 Receptor In Mediating PGE2-
induced Reduction of OTR gene expression in 
Term Pregnant Human Myometrium 
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8. The Role of EP2 Receptor In Mediating PGE2-induced Reduction of OTR 
gene expression   in Term Pregnant human Myometrium 
 
8.1. Introduction 
Prostaglandins (PGs) are members of the eicosanoid family and are produced by nearly all 
the cells in the body (480). They are synthesised from arachidonic acid via the actions of 
COX and then via specific synthase enzymes, for example PG E synthase (PGES) and PG F 
synthase for PGF2α, either constitutively or in response to specific stimuli, or signalling 
molecules (120, 480). PGE2 is the most abundant prostanoid in the human body, and 
depending upon the situations, PGE2 can exerts homeostatic (480, 481), inflammatory (482), 
or in some cases anti-inflammatory (483) effects. For decades, the inhibition of PGE2 
synthesis has been an important anti-inflammatory strategy in clinical settings (484).  
PGE2 has also been shown to play a central and essential role in human labour (52, 143).  
PGE2 synthesis and expression by intrauterine tissues, in particular, the fetal membranes 
(485) and myometrium (125), is increased throughout the third trimester labour, and during 
labour. This increase is accompanied by the elevation of the metabolites in amniotic fluid 
and maternal plasma (486). PGE2 predominantly mediates its cellular effects through 
members of the G protein-coupled receptor (GPCR) superfamily, mainly EP1, EP2, EP3, and 
EP4, which are encoded by distinct genes. Each receptor is associated with activation of 
specific heterotrimeric G proteins, thus allowing PGE2 to activate a diverse array of 
responses and pathways in a given cell. All EP receptors are expressed in the pregnant 
human myometrium (487). The EP2 and EP4 are linked to Gαs (488), and activation 
increases intracellular cAMP, maintaining uterine quiescence. EP1 and EP3 are linked to 
Gαq/11 and Gαi, the former activates the phospholipase C/inositol trisphosphate 
(IP3)/calcium pathway and the latter decreases cAMP levels, increasing myometrial 
contractility (147, 489). This is consistent with previous studies performed in our group, 
which showed that EP3 mediates PGE2-induced contractility in human pregnant 
myometrium at term (490). Indeed, PGs have been widely used in obstetrics to ripen the 
cervix and to initate uterine contraction as in the case of induction of labour (164). 
However, for some women, induction of labour with PGs can be unsuccessful with 
significant proportion of women ended with Caesarean section because of the failure of the 
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induction process (491). These observations reflect that the role of PGs in pregnancy and 
parturition is complex. 
Given the central role of PGs in the parturition process, COX-2 has become a therapeutic 
target for the prevention of preterm labour, however, this has been associated with many 
adverse side effects. For example, the use of the nonselective PGHS inhibitor Indomethacin 
as a tocolytic (492), is associated with severe fetal cardiovascular and renal side effects and 
with intraventricular hemorrhage and necrotising enterocolitis in the preterm babies (493). 
In addition, Nimesulide, a PGHS-2 selective nonsteroidal antiinflammatory drug, is also 
linked to serious fetal side effects (494). Intriguingly, the use of a specific COX-2 inhibitor, 
Rofecoxib, had to be discontinued as it increases the incidence of preterm labour in high-risk 
women (495). Why specific inhibition of COX-2 increases the risk of preterm labour remains 
unclear. It is possible that inhibition of COX-2 not only prevents the prolabour PG synthesis 
but also the production of other PGs, such as prostacyclin and cyclopentenone-PGs, which 
inhibit contractions and promote relaxation, and/or are anti-inflammatory effects in 
myometrium (496). Another possible reason could be that the inhibition of COX-2 results in 
the inhibition of PGE2 synthesis and this may promote myometrial relaxation by repressing 
labour associated gene such as OTR.  
PGE2 has anti-inflammatory actions in a variety of cells, inhibiting inflammatory chemokine 
release from activated dendritic cells (497), and suppressing cytokine production in human 
macrophages via the EP4 receptor (483). Conversely, deletion of microsomal prostaglandin E 
synthase-1 (mPGES-1), which is responsible for PGE2 production, results in the suppression 
of collagen-induced arthritis (CIA) in mice, suggesting an aetiological role for PGE2 (498). In 
this chapter, the potential mechanism(s) that mediates PGE2-induced reduction of OTR gene 
expression in pregnant human myometrium will be explored; understanding the 
mechanism(s) involved may aid the design of therapies for women at risk of preterm labour.   
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8.2. Results 
8.2.1 PGE2 repressed OTR expression independent of PKA 
 
 
Figure 8-1. PGE2 repressed OTR expression at mRNA and protein level. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Cells were cultured and incubated with PGE2 (10nM) for 6 hours. The levels OTR mRNA 
were measured using quantitative rt-PCR. B. In a separate experiment, myometrial cells were isolated from 
myometrial biopsies obtained from women at the time of term pre-labour Caesarean section. Cells were 
cultured and incubated with PGE2 (10nM) for 6 hours. Proteins were extracted and the levels of OTR protein 
were measured using western blotting.  GAPDH was used as a loading control. Representative western blots 
are shown above. Data are shown as the mean and SEM, and were compared using Wilcoxon matched pairs 
test for data that were not normally distributed and paired t test for data that were normally distributed. 
***P<0.001 when compared to control (n=6-9 in each experiment).  
 
 
 
 
A B 
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Figure 8-2. PKA knockdown and PKA antagonist has minimal effect on the ability of PGE2 in repressing OTR 
gene expression. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. After the cells were approximately 80% confluent, PKAC-α was knocked down using siRNA 
(siPKAC-α) controlled with non-targeted siRNA (siNT). Representative western blots to demonstrate 
transfection are shown above.  After transfection, cells were incubated for 96 hours before being treated with 
PKA antagonist, KT5720 (10μM), PGE2 (10nM) either alone or in combination for 6 hours. For the combination 
treatments, KT5720 was added 30 minutes prior to PGE2 treatment. mRNA were extracted and the levels of 
OTR mRNA were measured using rt-PCR. Data are shown as the mean and SEM and were compared using 
Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not normally distributed, 
and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally distributed *P<0.05, 
**P<0.01, ***P<0.001 when compared to control (n=6-7 in each experiment).  
 
Figure 8-1 demonstrates that PGE2 treatment in myometrial cells represses OTR mRNA and 
protein expression. To establish the mechanism responsible, the PKA antagonist, KT5720, 
and siPKAC-α were used either alone or in combination and shown to have a minimal effect 
on the ability of PGE2 to repress OTR gene expression, suggesting a PKA independent 
mechanism (Fig. 8-2). Since acute stretch of the myometrial cells was shown to increase OTR 
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mRNA expression (chapter 3 Fig. 3-9), the interaction between stretch and PGE2 was 
investigated in the next experiment.  
 
8.2.2 Stretch does not affect the ability of PGE2 to repress OTR expression 
 
 
Figure 8-3. PGE2 treatment is associated an increase in cAMP level. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Myometrial cells were grown up to passage 3 and plated on to the stretched plates. Cells 
were stretched for 30 hours in total. At 24 hour, cells were incubated for an additional 6 hours in the absence 
and presence of PGE2 (10µM). Cell supernatants were collected and cAMP levels (pmol/mL) measured using an 
assay kit (cAMP assay, R&D Systems, UK) following the manufacturer’s instructions. Data are shown as the 
mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test 
for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-9 in each 
experiment).  
 
In the study above, PGE2 treatment to myometrial cell is associated with the increase in 
cAMP levels, in both stretched and non-stretched cells, although the increase appeared to 
be slightly (not significantly) less in stretched cells compared to non-stretched cells. The 
data shown above is consistent with the previous findings in chapter 3, where stretch of 
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myometrial cells in vitro. and in vivo. was associated with the reduction in cAMP levels (Figs. 
3-9, 3-11).  
 
 
 
Figure 8-4. Stretch does not affect the ability of PGE2 to repress OTR. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Myometrial cells were grown up to passage 3 and plated on to the stretched plates. Cells 
were stretched for 30 hours in total. At 24 hour, cells were incubated for an additional 6 hours in the absence 
and presence of PGE2 (10µM). The levels GαS (A), and OTR (B) mRNA were measured using quantitative rt-PCR. 
Data are shown as the mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and 
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Bonferroni’s post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared 
to control (n=6-9 in each experiment).  
 
Next, as stretch was associated with a reduction in cAMP level, the impact of stretch on GαS 
mRNA expression was studied (Fig. 8-4 A). As seen in chapter 3, stretch reduced GαS mRNA 
expression, perhaps explaining the slight reduction in cAMP generation observed. Next, the 
ability of PGE2 to repress OTR expression in stretched cells was investigated in the 
experiment above. The results, illustrated in Figure 8-4 B, revealed that stretch did not 
impair the ability of PGE2 to repress OTR mRNA expression in myometrial cells, suggesting 
that the mechanism mediating PGE2 reduction of OTR is independent of cAMP.  
 
8.2.3 PGE2 repression of OTR gene expression is not via GαI, Gαq/11 or GαS 
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Figure 8-5. Gαq/11 knockdown and Gαi antagonist has minimal effect on the ability of PGE2 in repressing 
OTR gene expression. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. After the cells were approximately 80% confluent, Gαq/11 was knocked down using siRNA 
(siGαq/11) controlled with non-targeted siRNA (siNT). Representative western blots to demonstrate 
transfection are shown above.  After transfection, cells were incubated for 96 hours before being treated with 
PGE2 (10nM), pertussis toxin (Gαi inhibitor) (10μM) either alone or in combination for 6 hours. For the 
combination treatments, pertussis toxin was added 30 minutes prior to PGE2 treatment. mRNA were extracted 
and the levels of OTR mRNA were measured using rt-PCR. Data are shown as the mean and SEM and were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-7 in each experiment).  
 
 
 
Figure 8-6. GαS knockdown has minimal effect on the ability of PGE2 in repressing OTR gene expression. GαS 
knockdown is associated with a reduction in cAMP level. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. After the cells were approximately 80% confluent, GαS was knocked down using siRNA 
(siGαS) controlled with non-targeted siRNA (siNT). Representative western blots to demonstrate transfection 
are shown above.  After transfection, cells were incubated for 96 hours before being treated with PGE2 (10nM) 
for 6 hours. mRNA were extracted and the levels of OTR mRNA (A) were measured using rt-PCR. (B) Cells 
supernatants were collected and cAMP levels (pmol/mL) were measured from the stored supernatants using 
an assay kit (cAMP assay, R&D Systems, UK) following the manufacturer’s instructions. Data are shown as the 
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mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test 
for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for 
data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-7 in each 
experiment).  
 
 
The role of GPCRs in mediating the mechanism responsible for PGE2-induced repression on 
OTR gene expression was explored in this section. In Fig 8-5, the cells were treated with Gαi 
inhibitor and Gαq/11 was knocked down either alone or in combination. Pertussis toxin (Gαi 
inhibitor) has been widely used as a reagent to characterize the involvement of 
heterotrimeric G-proteins in signalling. This toxin catalyses the ADP-ribosylation of specific 
G-protein a subunits of the Gαi family, and this modification impairs G protein heterotrimer 
interaction with receptors, thus blocking receptor coupling. The results above showed that 
Gαi inhibitor and Gαq/11 knocked down either alone or in combination had a minimal effect 
on the ability of PGE2 to reduce OTR mRNA expression. Intriguingly, the treatment 
combination of Gαi inhibitor and PGE2 is associated with a greater reduction in OTR mRNA 
expression compared to cells treated with PGE2 (statistically not significant) or Gαi inhibitor 
(statistically significant) alone in both cells knocked down with non-target siRNA and in 
Gαq/11 knocked down cells. This could be because OTR was being reduced by 2 
independent mechanisms, one via the inhibition of Gαi, which would increase cAMP and 
repress OTR via PKA (chapter 3), and the second via an independent PGE2-driven 
mechanism. 
As activation of GαS is thought to be responsible for the maintenance of uterine quiescence 
during pregnancy via an increase in intracellular cAMP, it seemed likely that the PGE2-
induced reduction of OTR gene expression would be mediated through this pathway. 
However, although PGE2 treatment was associated with an increase in cAMP levels and GαS 
knock down reduced cAMP levels in both control cells and PGE2 treated cells (Fig. 8-6 A), it 
did not affect the ability of PGE2 to repress OTR mRNA expression, supporting the idea that 
the mechanism mediating PGE2 reduction of OTR is independent of the cAMP/PKA pathway 
(Fig. 8-6 B).  
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8.2.4 PGE2 repressed OTR gene expression is via EP2, PLC and PKC 
 
 
Figure 8-7. PGE2 repressed OTR expression via EP2. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Cells were cultured and incubated with PGE2 (10nM) alone and in combination with EP2 
antagonist (20nM, 10μM and 100μM) for 6 hours. For the combination treatments, EP2 antagonist was added 
30 minutes prior to PGE2 treatment. The levels OTR mRNA were measured using quantitative rt-PCR. Data are 
shown as the mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed *P<0.05, ***P<0.001 when compared to control (n=6-9 in 
each experiment).  
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Figure 8-8. PGE2 repressed OTR expression via PLC. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Cells were cultured and incubated with PGE2 (10nM) and PLC inhibitor (5μM and 10μM) 
either alone or in combination for 6 hours. For the combination treatments, PLC inhibitors were added 30 
minutes prior to PGE2 treatment. The levels OTR mRNA were measured using quantitative rt-PCR. Data are 
shown as the mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control, 
##
P<0.01 (n=6-9 in each experiment).  
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Figure 8-9. PGE2 repressed OTR expression via PKC. 
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of term pre-labour 
Caesarean section. Cells were cultured and incubated with PGE2 (10nM) and PKC inhibitor (5μM and 10μM) 
either alone or in combination for 6 hours. For the combination treatments, PKC inhibitors were added 30 
minutes prior to PGE2 treatment. The levels OTR mRNA were measured using quantitative rt-PCR. Data are 
shown as the mean and SEM and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed *P<0.05 when compared to control, 
##
P<0.01 (n=6-9 in each 
experiment).  
 
Previously, it was shown that PGE2 acts via EP2 and EP4 coupled to Gαs (488) to increase 
cAMP and promote myometrial relaxation. EP2 is a GPCR linked typically to Gαs, but which 
can be linked to other Gα proteins such as Gαq (148) In this section, the role of EP2, PLC and 
PKC in PGE2-induced reduction of OTR expression was investigated. The data presented 
above suggest that the PGE2 acts via EP2 and both PLC and PKC to reduce OTR expression. 
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8.3. Summary and Discussion 
 
The data in this chapter demonstrate that in human myometrial cells, PGE2 reduces OTR 
mRNA expression and protein levels (Fig. 8-1). Further, the data suggest that the mechanism 
is cAMP/PKA-independent (Figs. 8-2, 8-3), despite the fact that the PGE2 effect is mediated 
via EP2, which is typically linked to Gαs/adenylate cyclase resulting in increased cAMP 
production (499). Consistent with this, knock down of Gαs (Fig. 8-6), and treatment with Gαi 
inhibitor (Fig. 8-5) had no effect on the ability the PGE2 to repress OTR gene expression. 
However, PLC and PKC antagonists reversed the repressive effect of PGE2 (Figs. 8-8, 8-9), 
although knock down of Gαq/11 also had no impact (Fig.8-5). Overall, these data imply that 
PGE2 reduces OTR mRNA expression via EP-2 in PLC and PKC sensitive manner (Figs. 8-7, 8-8, 
8-9), but the linkage, from EP2 to PLC/PKC is unclear.  
Despite not being involved in the PGE2 repression of OTR mRNA expression, the PKA studies 
did reveal that PKA tonically represses OTR in resting cells as the PKA antagonist caused an 
increase in OTR mRNA expression (Fig. 8-2). Similarly, when pertussis toxin alone was added 
to the cells, the OTR mRNA expression declined, implying that Gαi also exerted an effect in 
resting cells to repress adenylyl cyclase activity and that its inhibition, allowed greater cAMP 
synthesis resulting in repression of OTR mRNA expression (Fig. 8-5). In addition, myometrial 
cell stretch did not impact the ability of PGE2 to reduce OTR mRNA expression (Fig. 8-4). 
In certain cell types, such as smooth muscle, the release of calcium is mainly triggered via 
Gαq protein- or tyrosine kinase-linked receptor-dependent activation of PLC. PLC hydrolyses 
PIP2 to release second messengers, IP3 and DAG. IP3 promotes calcium release from 
intracellular stores via its receptors (IP3Rs), and DAG activates PKC, which consequently 
phosphorylates other target proteins (221). Interestingly, the data shown in this chapter 
suggest that PGE2-induced repression of OTR expression is meditated via PLC and PKC. 
Generally, the release of calcium promotes muscle contraction. However, whether the 
ability of PGE2/PLC inhibition of OTR mRNA expression involves a change in IP3 and calcium 
levels is not known.  
The ability of PGE2 to repress OTR may offer some explanation for the increase in preterm 
labour seen after the administration of the specific COX-2 inhibitor, rofecoxib, which might 
be expected to induce a fall in PGE2 levels (495). However, the regulation of labour-
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associated PGs may be more complex than initially thought as shown by the rofecoxib 
experience. The limitations in the use of the β-adrenergic receptor agonists, which repress 
uterine activity in the short term, have driven the search for effective tocolytic agents with 
out maternal side effects. Some have suggested using specific inhibitors of procontractile PG 
receptors FP, EP1, and EP3 (490, 500, 501), and/or specific agonists for EP2 and EP4 (148). 
However, a recent study in our group have shown that activation of EP2, but not EP4, 
stimulates PGHS-2 in human myometrial cells (183), which might triggers a prolabour, rather 
than a pro-relaxation effect, depending on the downstream PG synthetic enzyme profile of 
the myometrium. Also, the latest findings in our group described a previously unreported 
signalling pathway for EP2, Kandola and colleagues showed that EP2 stimulates the PG 
synthetic pathway via a Gαq/11-mediated increase of intracellular calcium (148). They have 
elegantly demonstrated that EP2 switches between two contrasting roles in the human 
myometrium at term by two distinct signalling pathways. Before labour, EP2 mediates both 
myometrial quiescence via cAMP and increases COX-2 expression via Gαq/11-calcium. With 
the onset of labour, EP2 loses its ability to increase cAMP and functions predominantly via 
the Gαq/11-calcium pathway to increase PG synthesis and hence becomes a prolabour 
receptor (148). 
Considering the complexity of GPCRs signalling, more research needs to be done to 
understand the interaction between PGE2 and EP2 and the relations with PLC and PKC. By 
understanding the mechanism(s), we may be able to design therapies can prevent preterm 
labour.  
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Chapter 9: 
Final Discussion and Summary 
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9.1. Final Discussion and Summary 
 
Throughout most pregnancy, progesterone and other signalling pathways help to promote 
myometrial quiescence. The activation of inflammatory pathways and the removal of factors 
that contribute to myometrial quiescence trigger the onset of parturition (17, 290). 
Untimely initiation of these pathways can result in preterm labour, a major cause of 
neonatal morbidity and mortality and of long-term disability worldwide (54). Regulatory 
factors such as, cAMP, are increasingly recognised to be up-regulated in the human 
myometrium during pregnancy and is believed to contribute to the maintenance of uterine 
quiescence until term (220). The molecular mechanisms of the interactions involving cAMP 
in the myometrium during pregnancy have been investigated in this project. 
 
Chapter 3 
In chapter 3, the effect of pregnancy and different stages of labour on the mRNA expression 
and protein synthesis of the cAMP associated genes was studied. The data suggest that 
myometrial quiescence in pregnancy is characterised by high cAMP tone and this may be 
associated with the reduction of OTR gene expression via PKA dependent pathway (Figs. 3-
5, 3-8). In addition, I have also shown that based on the experiments performed, as the 
activity of the cAMP/PKA pathway declined, an increase in Epac1 levels occurred, and this 
coincides with the increase in OTR expression leading to increased uterine contractility (Figs. 
3-5, 3-8, 3-12). These findings may contribute to the design of treatment strategies for the 
prevention of preterm labour and suggests that the cAMP/PKA pathway may be a novel 
therapeutic target. 
 
Chapter 4 
In order to design an effective therapy to prevent or treat preterm labour, it is essential to 
understand the underlying pathophysiology of term and preterm labour. Given the key role 
played by cAMP in the respiratory and cardiovascular systems, it seems highly likely that it 
would play a similar critical role in the reproductive system. Elucidating the molecular 
mechanisms of how cAMP promotes myometrial quiescence during pregnancy needs to be 
explored. Further, although it is well accepted that intrauterine infection and inflammation 
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are a major contributing factor to the onset of preterm labour (73), the interaction between 
cAMP and inflammation in the myometrium is unclear. Consequently, in chapter 4, the role 
played by cAMP in repressing inflammation in human myometrial cells was investigated. The 
results of the studies showed that, with the exception of COX-2, cAMP repressed the IL-1β-
induced increase in inflammation related gene expression in human myometrial cells (Figs. 
4-1, 4-2). These results strongly suggest that high cAMP tone (which was previously 
suggested in chapter 3) in pregnancy may exert an anti-inflammatory effect in the uterus 
which may then help to prevent premature labour, and that the reduction of cAMP/PKA 
tone which may be associated with labour process may perhaps be associated with the 
reduction of cAMP anti-inflammatory action in repressing inflammation. 
 
Others have demonstrated the anti-inflammatory properties of cAMP in various cell types 
(364-367). Recently, in breast cancer cell lines, AKIP1 has been identified to act as a key 
molecular switch, determining whether cAMP/PKA positively or negatively affects NFκB 
activity (369). Gao et al. demonstrated that PKA positively affects p65 transactivation in cells 
expressing high levels of AKIP1, whereas PKA oppositely inhibited NFκB activity in cells 
containing low levels of AKIP1 (369). To date, no study was done to investigate the role 
played by AKIP1 in human uterine smooth myometrial cells. In the second part of chapter 4, 
the effect of AKIP1 expression knock down was explored in myometrial cells, where cAMP is 
observed to enhance the IL-1β-induced increase in COX-2 mRNA expression (Fig. 4-8). 
Intriguingly, the ability of cAMP to increase IL-1β-induced COX-2 mRNA and protein 
expression is lost with AKIP1 knockdown (Fig. 4-8). In fact, with AKIP1 knockdown, cAMP 
strongly repressed IL-1β-induced COX-2 mRNA and protein expression (Figs. 4-8, 4-9). 
Interestingly, the results also showed that AKIP1 expression is down-regulated in pregnancy 
and increased with the onset of labour (Fig. 4-12). Further research is needed to identify 
whether AKIP interacts with PKA/NFκB, as has been shown in other systems, since it is 
observed from this study that, in the myometrium, the increase in AKIP1 coincides with a 
reduction in the activity of the PKA system. However, it seems probable that the increase in 
AKIP1 levels is related to the increase in COX-2 levels with the onset of labour. In addition, it 
was noted that AKIP1 expression is up-regulated in the sample taken from women who 
267 
 
were affected by preterm labour caused by chorioamnionitis (Fig. 4-13), which suggest that 
AKIP1 may contribute to the inflammatory process and the onset of preterm labour.  
 
Chapter 5 
As progesterone may reduce the risk of preterm labour by 40% in women at high-risk 
singleton pregnancies (65, 66), the ability of cAMP to enhance progesterone driven gene 
expression in myometrial cells was explored. The results from chapter 5 showed that cAMP 
enhanced the progesterone-induced expression of 11βHSD1, IKBα, and MKP-1 when 
myometrial cells were treated with forskolin combined with progesterone (Figs. 5-2, 5-4). In 
addition, forskolin significantly increased the levels of PR-B protein level (Fig. 5-11), thus 
enhancing PR-B mediated effects. The effects of cAMP in enhancing progesterone driven 
gene expression in this chapter were shown to be mediated primarily through the activity of 
PKA.  
 
Chapter 6 
Results form chapter 6 showed that cAMP enhanced the ability of progesterone to repress 
IL-1β-induced expression of COX-2 and IL-1β associated genes possibly by delaying the 
nuclear translocation of phospho-p65 and the degradation of IκBα and the reduction in cJun 
activation through increased MKP-1 levels (Figs. 6-5, 6-7, 6-9, 6-12).  The combination of 
cAMP and progesterone reduced the level of nuclear phospho-p65 and phospho c-jun at 1 
hour in association with an increase in IκBα synthesis (Fig. 6-10). Again, the siRNA 
knockdown studies showed synergistic anti-inflammatory effect of the combination of 
progesterone and cAMP are mediated by PKA (Fig. 6-13). In the absence of PKA activity, the 
combination of cAMP and progesterone is strongly pro-inflammatory, at least in terms of 
COX-2 expression. These data strongly suggest that PKA is a key effector of cAMP, not only 
does it contributes to the regulation of myometrial OTR expression, it also plays an essential 
role in enhancing progesterone responsive gene and enhancing the ability of progresterone 
to repress inflammation. Collectively, the data taken from chapter 3 to chapter 5 strongly 
suggest that the decline in PKA levels in early labour is critically important, especially when 
they are coupled with increases in Epac1 and AKIP1. Together, these changes may convert 
cAMP from a potent pro-gestational, anti-inflammatory molecule to a key pro-labour factor, 
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thus promoting the expression of OTR and COX-2 and driving the onset of labour. The 
summary of the molecular mechanisms of the interactions involving cAMP in the 
myometrium during pregnancy and labour is summarised in Figure 9-1.  
 
Chapter 7 
Having previously demonstrated the anti-inflammatory action of cAMP and showed that the 
combination of cAMP and progesterone is better than progesterone or cAMP alone in 
repressing inflammation in human myometrial cells, the next step was to investigate the in 
vivo effects of the combination of aminophylline, another cAMP elevating agent, which 
works by inhibiting PDE, and progesterone in preventing the onset of labour and improving 
neonatal survival rates in a mouse model of inflammation-induced preterm labour. In 
addition, the effects of this combination were studied in human myometrial cells and 
myometrial tissue explants. The results in chapter 7 showed that the combination of 
aminophylline and progesterone prolonged the pregnancy in mouse, but had no benefit on 
neonatal survival (Figs. 7-1, 7-2). The effect seemed to be primarily mediated through a 
reduction in the LPS-induced inflammation and to a lesser extent on a reduction in the 
prolabour COX-2 and OTR (Fig. 7-3). The enhancement of anti-inflammatory action of 
progesterone by aminophylline was also observed in human myometrial cells and 
myometrial tissue explants (Figs. 7-6, 7-7, 7-8).  
 
Chapter 8 
In chapter 8, the mechanisms behind the PGE2-induced reduction of OTR gene expression 
were studied as this may explain to some extent why specific inhibition of COX-2 increases 
the risk of preterm labour (495). Knockdown of Gαs and Gαq/11, and treatment with Gαi 
antagonist had minimal effect on the ability of PGE2 to decrease OTR mRNA expression (Figs. 
8-5, 8-6). The addition of EP2, PLC, and PKC antagonists all blocked PGE2-induced repression 
of OTR mRNA expression (Figs. 8-7, 8-8, 8-9). These results shown in this chapter strongly 
suggest that PGE2 represses OTR mRNA expression via EP2, and PLC and PKC. Further 
studies need to be performed to investigate the interaction between PGE2 and EP2 and the 
relationship with PLC and PKC.  
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Limitations: 
 
There are a few limitations of the above studies. Firstly, the expression and functional 
studies have been performed only in tissues and cells taken from the lower segment of the 
uterus, because it was not possible to obtain adequate tissue and cell numbers from the 
smaller upper segment myometrial biopsies for in vitro studies. The data shown in chapter 3 
demonstrated that in lower segment of myometrium, cAMP acting via PKA downregulates 
OTR gene expression. Macdougall et al. have established that comparison of pregnant 
myometrium obtained from the upper and lower uterine segment showed uniform levels of 
cellular RIα, RIIα, Cα, and Cβ proteins, indicating no topographical differences for these PKA 
subunits (220). Therefore, it is highly unlikely that the regulation of OTR differs significantly 
within the uterus. 
 
Secondly, although the myometrial biopsies were categorically grouped and taken according 
to the clinical conditions and stages of labour, there are genetic and ethnic variations 
between the samples, which may influence some of the findings.  
 
Another possible limitation is that almost all the experiments involving treatment with 
chemicals were performed on primary myometrial cells. Although Mosher et al. showed 
that primary cultured human myometrial cells are able to retain molecular memory of their 
origin and thus, able to maintain their ability to respond to the inflammatory stimulus IL-1β 
for at least ten passages (479), data from our group by Georgiou et al. (unpublished 
observation) revealed that direct comparison of paired explants and primary myometrial 
cells showed the former maintained  both  PR and GR levels (versus untreated tissue) 
whereas cells only maintained GR levels. As one of the known progesterone most sensitive 
genes work via PR alone (11βHSD1), and most of the experiments in our laboratory are 
carried out with cells from passage 3, consistent PR expression is necessary for analysis of 
genes mediated by PR. These results are supported by the findings of Zaitseva et al. Their 
findings indicate that although primary cultured human myometrial cells provide an 
important tool to study the expression and regulation of pregnancy and labour-associated 
genes within the human uterus, in vitro studies must be carefully planned and evaluated in 
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order to provide meaningful results (502). It has also been suggested that due to the 
reasons stated above, myometrial explants is a better model for studying progesterone 
action in the human myometrium, when compared to primary cell culture, thus this 
approach should be considered for future experiments. In addition to the above, all in vitro 
experiments demonstrated in this thesis are limited to the myometrium and therefore the 
conclusions cannot be extended to other tissues. In vivo, it is possible that the fetal 
membranes and the placenta may influence the ultimate effect of any intervention.  
 
 
 
Figure 9-1. Summary of the molecular mechanisms of the interactions involving cAMP in the myometrium 
during pregnancy and labour. 
In pregnancy, high levels of cAMP act via a PKA-dependent pathway to suppress OTR mRNA expression and 
calcium release. In the presence of low AKIP1 level, cAMP acts as an anti-inflammatory, repressing 
inflammation induced COX-2 expression. Progesterone also exerts its anti-inflammatory action, and in the 
presence of abundant PKA, both progesterone and cAMP work synergistically together to suppress 
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inflammation and promote myometrial quiescence. While circulating progesterone levels do not decline with 
the onset of labour, a reduction in the activity of the cAMP/PKA pathway correlated with an increase in OTR 
mRNA expression and protein levels. If PKA is reduced or absent, then cAMP, working via Epac1, increases OTR 
mRNA expression. The increase in OTR results in an increase in myometrial contractility. The increase in AKIP1 
converts cAMP to a pro-inflammatory factor, increasing the pro-inflammatory genes and cytokines associated 
with labour. Furthermore, the decline in PKA, means that the combination of progesterone and cAMP 
becomes pro-inflammatory. The net effect of these changes is to increase uterine contractility, and drive the 
the process of labour.  
 
In conclusion, the data presented in this thesis may help to explain how shifts in cAMP 
effector pathways change cAMP from being a major pro-gestational factor to driving the 
onset and progression of labour. While the combination of progesterone and a cAMP 
agonist may be an ideal approach to the reduction of preterm labour in a high-risk 
population, changes in the molecular environment may dramatically alter the response to 
this combination. We need to understand how the cAMP effector pathways are regulated in 
order to be able to design an effective treatment for the prevention of preterm labour. 
 
9.2. Future work 
 
Based on the findings in this thesis, a list of my future potential work is as follows: 
 
Cyclic AMP regulates myometrial oxytocin receptor during gestation 
 
 To further investigate the mechanism of how of cAMP (via PKA) reduces OTR 
expression level, I will perform chromatin immunoprecipitation (ChIP) studies to 
define whether the addition of cAMP enhances the binding of phospho-CREB to OTR 
promoter.  
 To investigate whether a fall in cAMP levels affects myometrial response to 
progesterone and whether this may be another mechanism responsible for the 
functional withdrawal of progesterone, I will look at the effect of stretch in the 
presence and absence of cAMP (either alone or in the combination with 
progesterone) in repressing IL-1β-driven gene expression. 
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Cyclic AMP enhances progesterone action in human myometrial cells 
 
 Since cAMP enhanced progesterone-driven gene expressions, I will assess the effect 
of cAMP on the activity of transfected PRE reporter construct. I will investigate the 
effects of cAMP on progesterone/PR-B PRE activation. In addition I will perform ChIP 
studies to investigate whether the addition of cAMP to progesterone enhances the 
binding of PRB to PRE.  
 I will use 11βHSD1 promoter construct to define whether the addition of cAMP to 
progesterone compared to progesterone alone increase the luciferase activity. I will 
create mutations/deletions of the segments of the 11βHSD1 promoter construct to 
investigate which segment(s) is essential for the increase in the luciferase activity.  
 To further investigate the mechanism of how of cAMP (via PKA) enhances 
progesterone-induced expression of 11βHSD1, I will perform ChIP studies to define 
whether the addition of cAMP to progesterone enhances the binding of phospho-
CREB to 11βHSD1 promoter.  
 
The role of cAMP as an anti-inflammatory 
 
 To further investigate the mechanism of how of cAMP reduces phospho p65 level and 
phospho c-jun, I will perform CoIP studies to define whether the addition of cAMP ± 
progesterone enhances the binding of phospho-CREB to p65 and c-jun. 
 Previously it was shown that AKIP1 functions as a molecular switch determining 
whether cAMP positively or negatively affects NFκB activity (369). The siRNA 
knockdown studies in chapter 4 showed that in the absence of AKIP1, cAMP reduces 
IL-1β induced COX-2. Earlier, it was hypothesised that in cells expressing AKIP1, cAMP-
activated PKA is targeted to NFκB-dependent promoters, where it phosphorylates 
p65, leading to recruitment of CBP and enhanced transcriptional activation. In cells 
that do not express AKIP1 or have low expression of AKIP1, PKA preferentially 
phosphorylates CREB and consequently reduced NFκB-dependent gene expression 
(151). I will perform TF:TF array on siAKIP-1 knockdown cells to explore which TFs are 
activated by the knockdown compared to siNT. I will use ChIP to study the 
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interactions of the TFs with COX-2 promoter. In addition, ChIP-sequencing may be 
able to demonstrate how the effects of cAMP on the NFκB-dependent gene 
expression relate to the recruitment of CREB and/or NFκB to gene promoters, and 
may identify gene networks and promoter sequences prone to cAMP/NFκB 
coregulation. Then I would also explore which transcription factor that is increased by 
forskolin in the presence of AKIP1 and which is also reduced in AKIP1 absence. I will 
then perform ChIP to see how the transcriptional complex is altered.  
 
The role of cAMP in enhancing progesterone as an anti-inflammatory 
 
 The effect of PKA knockdown in the ability of cAMP to enhance progesterone in 
repressing other IL-1β responsive genes will be assessed.  
 To further investigate the mechanism of how the combination of progesterone and 
cAMP (via PKA) reduces COX-2 level, I will perform ChIP studies to define whether 
the addition of cAMP ± progesterone enhances the binding of phospho-CREB to COX-
2 promoter. 
 I will perform CoIP studies to investigate whether the addition of cAMP ± 
progesterone induces the exchange of transactivating NFκB complexes (i.e p50-p65) 
for repressive complexes (i.e p50-p50). 
 
The role of EP2 receptor in mediating PGE2-induced reduction of OTR gene expression 
 
 The interaction between PGE2 and EP2 and the relations with PLC and PKC will be 
investigated further. I will investigate whether the inhibition of EP2 and PLC, thus 
PKC is associated with PGE2-induced reduction of OTR expression at protein level.  I 
will also explore the effect of Gαs, Gαi, and Gαq/11 knockdown on the ability of PGE2 
to decrease OTR expression at protein level. 
 To asess the effects of inhibition of EP2 and PLC on intracellular calcium activation, I 
will perform fluorescence microscopy experiments on primary myometrial cells 
treated with PGE2 and compare this with cells treated with PGE2 in the presence of 
EP2 and PLC antagonists.  
274 
 
To investigate the efficacy of the combination of aminophylline and progesterone in 
reducing preterm labour in humans 
 
 As previously demonstrated in Chapter 7 that the combination of aminophylline and 
progesterone enhanced anti-inflammatory effect of progesterone and prevented 
LPS-induced preterm labour in our mouse model, I plan to investigate the efficacy of 
aminophylline and progesterone combination therapy in preterm labour prevention 
in humans. I will carry out a feasibility study of aminophylline and progesterone 
combination therapy effects on women identified as at risk of preterm labour. 
Although it was shown that the combination of aminophylline and progesterone can 
reduce myometrial inflammation in LPS-treated mice, it is possible that the 
combination also exerts effects on cervical and systemic immune function to prolong 
labour. Consequently, this trial will involve routine collection of clinical parameters, 
including cervical length, cervico-vaginal fluids and maternal blood, in which I will 
measure inflammatory mediators to continually monitor the treatment’s ability to 
delay pro-labour changes in the cervix and maternal blood. At the same time, we will 
investigate the mechanisms through which the combination of aminophylline and 
progesterone repress pro-labour gene expression in our in vitro models of labour. 
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Appendix 1. The effects of different agents which capable of raising intracellular cAMP levels on cAMP 
associated genes in primary human primary myometrial cells.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour 
Caesarean section. Cells were cultured and incubated with forskolin (100µM) (Appendix 1i), 8 bromo cAMP 
(250µM) (Appendix 1ii), dibutyrylc-AMP (50µM) (Appendix 1iii), and rolipram (10µM) (Appendix 1iv), for 48 
hours. The mRNA levels of cAMP associated genes were measured using quantitative rt-PCR. A-F. Genes up-
regulated by cAMP. G-K. Genes down-regulated by cAMP. Data are shown as the mean, and SEM, and were 
compared using Wilcoxon matched pairs test for data that were not normally distributed and paired t test for 
data that were normally distributed. *P<0.05, **P<0.01, ***P<0.001 when compared to control (n=6-9).  
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Appendix 2 
 
 
Appendix 2. Cyclic AMP represses IL-1β driven pro-inflammatory cytokines. 
Myometrial cells were isolated as described above, and treated with IL-1β (1ng/mL) and/or forskolin (100µM) 
either alone or in combination for 24 hours. The levels of ICAM, IL-6, IL-1α, CXCL1, CXCL2, CCL2, CCL11, CCL20, 
and LIF (A-I) protein were measured from supernatants using ELISA assay. Data are shown as the mean and 
SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data 
that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that 
were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. Data are shown as the 
mean, and SEM, and were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed #P<0.05, ##P<0.01, ###P<0.001 when IL-
1β is compared to 100F + IL-1β (n=8-9 in each experiment). 
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Appendix 3. The effects of AKIP1 knock down on the ability of cAMP in repressing IL-8, IL-1β, and OTR.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour term 
Caesarean section as described above in Materials and Methods. After the cells were about 80% confluent, 
AKIP1 was knocked down using siAKIP1, controlled with non-targeted siRNA [siNT]). A, C, E. Myometrial cells 
were knocked down using siNT. (B, D, F). Myometrial cells were knocked down using siAKIP. Representative 
western blot to demonstrate transfection is shown above. After transfection, cells were incubated for 96 hours 
before being treated with IL-1β (1ng/mL) and/or forskolin (100µM) either alone or in combination for 6 hours. 
The mRNA were extracted, and the levels of IL-8, IL-1β, and OTR mRNA were measured using rt-PCR. Data are 
shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed *P<0.05, **P<0.01, ***P<0.001 when compared to control. 
Data are shown as the mean, and SEM, and were compared using Wilcoxon matched pairs test for data that 
were not normally distributed and paired t test for data that were normally distributed #P<0.05, ##P<0.01, 
###P<0.001 when IL-1β is compared to 100F + IL-1β (n=6). 
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Appendix 4. Expression of ICER and CBP in myometrial tissue obtained from pregnancy complicated by 
chorioamnionitis and preterm twin labour. 
Human myometrial tissue samples were collected from different groups of non-labouring and labouring 
women at the time of Caesarean section. Women were recruited in two defined groups: preterm not in labour 
(PTNL) (24-36 weeks), preterm in labour with evidence of chorioamnionitis as stated in Materials and 
Methods. Samples were snap frozen at -80
o
C for mRNA and protein extraction. The levels of ICER (A,C), CBP 
(E,G) mRNA and ICER (B,D), CBP (F,H) proteins were measured using rt-PCR and western blotting respectively. 
A representative western blot is shown next each protein graph displaying the densitometry of the protein 
levels. Blots were probed with ICER, and CBP antibody, and GAPDH was used as a loading control. Data are 
shown as the mean, and SEM, and were compared using Wilcoxon matched pairs test for data that were not 
normally distributed and paired t test for data that were normally distributed. *P<0.05, **P<0.01 (n=11-17 in 
each group).  
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Appendix 5. The effect of progesterone and cAMP on mRNA expression of progesterone responsive genes in 
preterm and term myometrial cells.  
Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour 
preterm (24-37 weeks) and term (<37 weeks) Caesarean section. Cells were cultured and incubated with 
progesterone (at 0.1, 0.5, 1, 5 and 10μM) (A, C, E, G) or forskolin (1, 10 and 100µM) (B, D, F, H) for 24 hours. 
The levels of 11βHSD1, MKP-1, IκBα, and FKBP51 mRNA were measured using quantitative rt-PCR. Data are 
shown as the mean and SEM, and were compared using Friedman’s Test, with a Dunn's Multiple Comparisons 
post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and Bonferroni’s 
post-test for data that were normally distributed. *P<0.05, **P<0.01, ***P<0.001 when compared to control 
(n=5 for preterm samples, n=7-8 for term samples). 
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Appendix 6. The effect of cAMP effectors and nuclear receptors antagonists on the ability of cAMP in 
enhancing protein expression of progesterone receptor B. 
(A) Myometrial cells were isolated from myometrial biopsies obtained from women at the time of pre-labour 
term Caesarean section. Cells were cultured and incubated and after the cells were approximately 80% 
confluent, the cells were pre-incubated with KT5720 (PKA antagonist) (10μM), or Brefeldin A (Epac antagonist) 
(100µM), or Compound C (AMPK antagonist) (100µM), Mirepristone (RU486 1 μM) (PR/GR antagonist), 
Sanguinarine (Sang, 0.5 μM) (MKP-1 antagonist) for 30 minutes before being exposed to different stimuli. 
Depending on the experimental conditions, the cells were stimulated with progesterone (10μM) and or 
forskolin (100µM) for 6 hours either alone or in combination. Proteins were extracted, and the levels of PRB 
were measured using western blotting. Data are shown as the mean, and SEM, and were compared using 
Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that were 
normally distributed. #P<0.05 ##P<0.01, ###P<0.001 when compared between the corresponding forskolin 
treated cells (F) in cells treated with and without cAMP effectors and nuclear receptors antagonists to the 
corresponding combination of progesterone and forskolin (P4 + F) in cells treated with and without cAMP 
effectors and nuclear receptors antagonists (n=5-6).  
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Appendix 7. The effect of combination of cAMP and progesterone on IL-1β-driven inflammation associated 
genes expression. 
Myometrial cells were isolated as described in Materials and Methods, and treated with progesterone (0.1, 1, 
and 10μM), forskolin (100µM) or IL-1β (1ng/mL) either alone or in combination for 24 hours. mRNA were 
extracted and the levels of CCL8 (A), IL-24 (B), and IRAK3 (C) mRNA were measured using quantitative rt-PCR. 
Data are shown as the mean and SEM, and were compared using Wilcoxon matched pairs test for data that 
were not normally distributed and paired t test for data that were normally distributed,  P<0.05, **P<0.01, 
***P<0.001, when compared between IL-1β and 100F + IL-1β, and between IL-1β and P4 + IL-1β. Data were 
compared using Friedman’s Test, with a Dunn's Multiple Comparisons post hoc test for data that were not 
normally distributed, and using ANOVA, with Dunnett and Bonferroni’s post-test for data that were normally 
distributed, #P<0.05, when compared to IL-1β, $ P<0.05 when compared with 100F + IL-1β (n=8-9). 
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Appendix 8. The effect of combination of cAMP and progesterone on IL-1β-driven inflammation associated 
genes expression at protein level. 
Myometrial cells were isolated as described above, and treated with progesterone (1µM), IL-1β (1ng/mL) 
and/or forskolin (100µM) either alone or in combination for 24 hours. The levels of LIF, IL-6, CXCL1, CXCL2, IL-
1α, ICAM-1, CCL11, CCL2, and CCL20 (A-I) protein were measured from supernatants using ELISA assay. Data 
are shown as the mean and SEM, and were compared using using Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test for data that were not normally distributed, and using ANOVA, with Dunnett and 
Bonferroni’s post-test for data that were normally distributed, P<0.05, **P<0.01, ***P<0.001 (n=8-9). 
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Appendix 9 
 
 
Appendix 9. Effects of aminophylline and progesterone on myometrial cytokine levels. 
Myometrial protein lysates were analysed on a Bioplex Pro-Cytokine assay to look at the effect of the different 
treatment groups on LPS-induced inflammatory markers. Treatment groups at 7 hours post-LPS were further 
compared to pregnant dams (E16 group) which had not undergone any manipulation to identify any effects of 
surgery separately from that of LPS. Cytokines examined include: (A) IFNγ, (B) IL-12p40 (C) RANTES, (D) IL-6, (E) 
IL-1α, (F) CCL2, (G) G-CSF, (H) IL-10. Data are shown as the mean, and SEM, and were compared using 
Wilcoxon matched pairs test for data that were not normally distributed and paired t test for data that were 
normally distributed. *P<0.05 (n=6-8 per group). 
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